Dialing Compuserve at 0070670476888

CONNECT 48000

Connecting through CompuServe

ODIATEM

Host Name: STNT

Connected to 0006 CAA D

Welcome to STN International! Enter x:x LOGINID:TKYBAJ74 PASSWORD: TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2

Welcome to STN International \* \* \* \* \* \* \* \* \* Headline Item Date

Headline

STN, CAS FILES Workshop Schedule in Japan

KOREAPAT now available on STN

CUrrent-awareness elects, saved answer sets, and

current search transcripts to be affected by CERAB,

COMPUAB, ELCOM, and SOLIDSTATE reloads

November 22, 2004 LISA new on STN

PHAR reloaded with additional data
12 databases to be removed from STN on 31,Dec.,2004

MEDLINE update schedule for December 2004

ELCOM reloaded; updating to resume; current-awareness

alerts(SDIs) affected

COMPUAB reloaded; updating to resume;

Current-awareness alerts(SDIs) affected

SOLIDSTATE reloaded; updating to resume;

Current-awareness alerts(SDIs) affected

CERAB reloaded; updating to resume;

Current-awareness alerts(SDIs) affected

ERAB reloaded; updating to resume;

CURRENT-awareness alerts(SDIs) affected

Three new fields added to IFIPAT/IFIODB/IFICDB

EFFOLL:New patent full text database to be available

on STN

CAPLUS - PATENT COVERAGE EXPANDED

4 Nov 22 5 Dec 1 6 Dec 15 7 Dec 17 8 Dec 20

NEWS 9 Dec 20

NEWS 10 Dec 20 NEWS 11 Dec 20

NEWS 16 Jan 5

EPFULL: New patent full text database to be available on STN
CAPLUS - PATENT COVERAGE EXPANDED
No connect-hour charges in EPFULL during January and February 2005
Urgent announcement to STN customers accessing via phone line WorldCom access points were changed
CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT) NEWS 17 Jan 12

NEWS HOURS NEWS WORLDCOM NEWS INTER

STN operating Hours STN High Speed Access via Worldcom INTERNET ACCSESS to STNT(STN-Tokyo)

Page 1

JP2004 018717.trn

-----

ring/chain nodes : chain bonds : 1-2 1-5 2-3 2-4 15-16 15-17 ring/chain bonds : 3-14 14-15 3-14 14-15 ring bonds -7 7-8 8-9 9-10 exact/norm bonds : 1-2 1-5. 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17 isolated ring systems : containing 5 :

Match level : 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 10:Atom 14:CLASS 15:CLASS 16:Atom 17:Cl 17:CLASS

Ll STRUCTURE UPLOADED

Uploading A:\018717A.str

chain nodes: 1 2 4 16 17 20 21 ring nodes: 5 7 8 9 10 ring/chain nodes: 3 14 15 3 14 15 nodes;

Chain bonds:

1-2 1-5 2-3 2-4 15-16 15-17 16-20 20-21 ring/chain bonds:

3-14 14-15 ring bonds:

5-6 5-10 6-7 7-8 8-9 9-10 exact/norm bonds:

1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17 16-20 20-21 16-20 20-21 16-20 20-21 16-20 39stems:

containing 5:

G1:C.N

Match level: 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS 21:Atom B:Atom 9:Atom JP2004\_018717.trn

NEWS EXPRESS STN Express 7.0 with Discover! (Windows) Now available! STN Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:44:23 ON 08 FEB 2005

SINCE FILE

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:44:34 ON 08 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS) CHARGED TO COST-4PRD

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7 DICTIONARY FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting  ${\tt SmartSELECT}$  searches.

Crossover limits have been increased. See HELP CROSSOVER for details

Experimental and calculated property data are now available. For mor information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

Uploading A:\018717.str

chain nodes 1 2 4 17 ring nodes: 5 6 7 8 9 10 16

Page 2

16:
Saturation : Saturated
Number of Carbon Atoms : less than
Type of Ring System : Monocycli

Element Count : Node 21: Limited N,N1

L2 STRUCTURE UPLOADED

-> S L1 AND L2 SAM > S L1 AND LZ SAM SAMPLE SEARCH INITIATED 13:45:30 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 2819 TO ITERATE

35.5% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01 35.5% PROCESSED

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*
PROJECTED ITERATIONS: 53196 TO 59564
PROJECTED ANSWERS: 205 TO 809

9 SEA SSS SAM L1 AND L2

-> D SCAN

9 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-bentoxazoly1)-1-[3-[[[(2,3-dichlorophenyl)amino]carbonyl]
(1-methylethyl)amino]-1-oxopropyl]- (9CI)
C25 B28 C12 N 03

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

HOW MANY MORE AMSWERS DO YOU WISH TO SCAN? (1):0

-> S L1 AND L2 FUL FULL SEARCH IMITIATED 13:45:58 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 56823 TO ITERATE

100.0% PROCESSED 56823 ITERATIONS SEARCE TIME: 00.00.04

349 AMSWERS

# 

Uploading A:\018717B.str

chain nodes:
1 2 3 4 14 15 17
ring nodes:
5 6 7 8 9 10 16
chain bonds:
1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17
ring bonds:
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds:
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
isolated ring systems:
containing 5:

Match level: 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS

### L5 STRUCTURE UPLOADED

Uploading A:\018717C.atr

chain nodes: 1 2 3 4 14 15 16 17 20 21 ring nodes: 5 6 7 8 9 10 5 6 7 8 9 10 chain bonds : 1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17 16-20 20-21 ring bonds : 5-6 5-10 6-7 7-8 8-9 9-10

------

## Page 5

## JP2004\_018717.trn

ring bonds :  $5-6 \quad 5-10 \quad 6-7 \quad 7-8 \quad 8-9 \quad 9-10$  exact/nore bonds :  $1-2 \quad 1-5 \quad 2-3 \quad 2-4 \quad 3-14 \quad 5-6 \quad 5-10 \quad 6-7 \quad 7-8 \quad 8-9 \quad 9-10 \quad 14-15 \quad 15-16 \quad 15-17$  containing 5 : containing 5 :

## G1:C.N

Match level: 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS

### LB STRUCTURE UPLOADED

Uploading A:\018717CC.str

Chain nodes:
1 2 3 4 14 15 16 17 20 21
ring nodes:
5 6 7 8 9 10
chain bonds:
1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17 16-20 20-21
ring bonds:
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds:
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
16-20 20-21
isolated ring systems:
containing 5:

# G1:C,N

Match level:
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS 21:Atom
Generic attributes:
16:
Saturation : Saturated
Mumber of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count : Node 21: Limited N,N1

## . JP2004\_018717.trn

exact/norm bonds : 1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17 16-20 20-21 isolated ring systems : containing 5

### G1:C.N

Match level:
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS 21:Atom
Generic attributes:
16:
Saturation : Saturated Saturation : Saturated Number of Carbon Atoms : less than 7 Type of Ring System : Monocyclic

Element Count : Node 21: Limited N,N1

### L6 STRUCTURE UPLOADED

=> S L5 AND L6 SAM SAMPLE SEARCH INITIATED 13:47:02 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 47198 TO ITERATE

2.14 PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*
PROJECTED ITERATIONS: 931002 TO 955618
PROJECTED ANSWERS: 0 10

L.7 O SEA SSS SAM LS AND L6

Uploading A:\01871788.str

chain nodes: 1 2 3 4 14 15 17 ring nodes: 5 6 7 8 9 10 16 chain bonds: 1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17

------

## Page 6

## JP2004\_018717.trn

### L9 STRUCTURE UPLOADED

-> S L8 AND L9 SAM SAMPLE SEARCH INITIATED 13:50:31 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 165 TO ITERATE

100.04 PROCESSED 165 ITERATIONS SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
PROJECTED TERRATIONS: 2530 TO 4070
PROJECTED ANSWERS: 0 TO 0

0 SEA SSS SAM L8 AND L9

-> S L8 AND L9 FUL FULL SEARCH INITIATED 13:50:38 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 3239 TO ITERATE

0 SEA SSS FUL L8 AND L9

100.0% PROCESSED 3239 ITERATIONS SEARCH TIME: 00.00.01

0 ANSWERS

Uploading A:\018717D.str

$$G_1 \qquad G_1 \qquad P \qquad G_1 \qquad G_1 \qquad P \qquad G_1 \qquad G_$$

M=-0-

Chain nodes:
1 2 3 13 14 16
ring nodes:
4 5 6 7 8 9 15
chain bonds:
1-2 1-4 2-3 2-13 13-14 14-15 14-16
ring bonds:
4-5 4-9 5-6 6-7 7-8 8-9
exact/norm bonds:
1-2 1-4 2-3 2-13 4-5 4-9 5-6 6-7 7-8 8-9 13-14 14-15 14-16
isolated ring systems:
containing 4:

Match level: 1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 13:CLASS 14:CLASS 15:Atom 16:CLASS

chain nodes:
1 2 3 13 14 15 16 19 20
ring nodes:
4 5 6 7 8 9
chain bonds:
1-2 1-4 2-3 2-13 13-14 14-15 14-16 15-19 19-20
ring bonds:
4-5 4-9 5-6 6-7 7-8 8-9
exect/open bonds: exact/norm bonds: 1-2 1-4 2-3 2-13 4-5 4-9 5-6 6-7 7-8 8-9 13-14 14-15 14-16 15-19 19-20 isolated ring systems : containing 4 :

G1:C.N

Match level:
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
13:CLASS 14:CLASS 15:Atom 16:CLASS 19:CLASS 20:Atom
Generic attributes:

Saturation : Saturated Number of Carbon Atoms : less than 7 Type of Ring System : Monocyclic

Element Count : Node 20: Limited N,N1

L13 STRUCTURE UPLOADED

-> S L12 AND L13 SAM SAMPLE SEARCH INITIATED 13:52:21 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 1798 TO ITERATE

-----

55.6% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

Page 9

JP2004\_018717.trn

held by the publishers listed in the FUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2005 VOL 142 ISS 7 FILE LAST UPDATED: 6 Feb 2005 (20050206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

-> S L15 9 L15 -> S L18 AND P/DT 4628444 P/DT 8 L18 AND P/DT L19

-> D BIB ABS HITSTR 1-8

ANSMER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN 2004:964811 CAPLUS 141:395810

141:395810
Preparation of heterocyclic dipeptides as hepatitis C inhibitors
Bailey, Murray D.; Llinas-Brunet, Montse
Boehringer Ingelheim International GmbH, Germany
'U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO

DT

Patent English

LA Eng-FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. 20040302 20040302 BZ, CA, CH, FI, GB, GD, KR, KZ, LC, MZ, NA, NI, SK, SL, SY, ZA, ZM, ZW, ZM, AM, AZ, OE, DK, EE, RO, SE, SI, MR, NE, SN, US'2004224900 WO 2004101602 AE, AG, CN, CO, GE, GH, LK, LR, LK, LR, NO, NZ, TJ, TM, BW, GH, BY, KG, ES, FI, SK, TR,

PRAI US 2003-452187P P 20030305 MARPAT 141:395810

Dags 11

BATCH \*\*COMPLETE\* PROJECTED ITERATIONS: PROJECTED ANSWERS:

33417 TO 0 TO 38503

0 SEA SSS SAM L12 AND L13

-> S L12 AND L13 FUL FULL SEARCH INITIATED 13:52:30 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 35773 TO ITERATE

100.0% PROCESSED 35773 ITERATIONS SEARCH TIME: 00.00.02

31 ANSWERS

31 SEA SSS FUL L12 AND L13

=> SAV TEMP L4 RD018717/A

-> FILE CAOLD COST IN JAPANESE YEN FULL ESTIMATED COST

SINCE FILE ENTRY 63220

FILE 'CAOLD' ENTERED AT 13:53:00 ON 08 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS) CHARGED TO COST-4PRD

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

-> S L4 L16 0 1.4

=> S L15 L17 0 1.15

-> FILE CAPLUS COST IN JAPANESE YEN

SINCE FILE ENTRY

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:53:14 ON 08 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "BELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS) CHARGED TO COST-4PRD

Copyright of the articles to which records in this database refer is

Page 10

JP2004\_018717.trn

Peptides I [B is (un)substituted alkyl, cycloalkyl, Ph or heteroaryl; Y is B or alkyl; R3 is alkyl or (un)substituted cycloalkyl; R2 is (un)substituted alkyl or cycloalkyl, an amino or acylamino group; R24 is alkozy, mono- or dealkylamino; R1 is alkyl or alkenyl; RC is OH or MHSO2RS, where RS is (cyclo)alkyl, alkylcycloalkyl, Ph, naphthyl or pyridinyl which are optionally substituted) or their racemates, diastereoisomers, optical isomers or pharmaceutically-acceptable salts were prepared as inhibitors of the hepatitis C virus (RCV) MS3 protease. Thus, I [B = R3 = t-Bu, Y = H, R2 = NHAC, R24 = OHe, R1 = CB:CH2, RC = OH) was prepared as inhom to how ICSO < 0.1 µM in the NS3-NS4A protease assasy and ECSO ≤ 0.5 µM in the cell-based HCV RNA replication

assay, 784178-97-8P 784179-01-7P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of heterocyclic dipeptides as hepatitis C inhibitors) 784178-97-8 CAPLUS

784178-97-8 CAPLUS
Cyclopropanecarboxylic acid, 1-[[[(25,4R)-4-[[2-[2-(acetylamino)-4-tiazoly])-7-methoxy-4-quinolinyl]oxy]-1-[(25)-3,3-dimethyl-1-oxo-2-2-[phenylamino)=thyl]buyl]-2-pyrrolidinyl]carbonyl]amino]-2-ethenyl(R.25)-(9C1) (CA INDEX MAME)

784179-01-7 CAPLUS 7841/7-UL-/ CAPLUS

(Cyclopropanecarboxylic acid, 1-[[[2S.4R]-4-[[7-(dimethylamino]-2-[2-[(3,3-dimethyl-1-oxobutyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-1-[(2S)-3,3-dimethyl-1-oxo-2-[2-2-oxo-2-(phenylamino] ethyl]butyl]-2
pyrrolidinyl]carbonyl]amino]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

## olute stereochemistry.

ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
2004:819908 CAPLUS
141:307555
1-(1-Substituted-4-piperidinylmethyl)piperidine derivatives as 5-TH4
receptor agonists, pharmaceutical compositions containing them, and their
use
Kato, Shiro; Yamazaki, Hiroshi; Hirokawa, Yoshimi; Suga, Yoko; Yoshida,
Naoyuki; Morikage, Yukiko; Morikage, Kazuo; Oku, Seiko
Dainippon Pharmaceutical Co., Ltd., Japan
Japan Kokai Tokkyo Koho, 37 pp.
CODEN: JAXXAF
Patemt
Japanese
CNT 1
PATENT NO. KIND DATE

IN

DT LA

NT 1 PATENT NO.

DATE

APPLICATION NO

Page 13

JP2004\_018717.trn

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

\_\_\_\_E\_\_CO28 HO2C

ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN 2004:566599 CAPLUS 141:123613 L19

AN DN TI

ON 141:123613
TI Preparation of piperidinyl thiazole carboxamide derivatives for altering vascular tone
IN Enox, Pater; Pappa, Helen; Lam, Winnie
PA Hetris Therapeutics Limited, UK
SO PCT Int. Appl., 54 pp.
COODE: PIXXD2
DT Patent
LA English
FAN.CHT 2
DATEST NO. PATENT NO. DATE APPLICATION NO. A1 20040715 AA, AT, AU, AZ, BA, CC, CZ, DE, DK, DM, BR, BU, ID, IL, IM, LT, LU, LV, MA, MD, PH, PL, PT, SD, RU, TT, TZ, UA, UG, US, ELS, NM, MZ, SD, MD, RU, TJ, TM, AT, GB, GR, HU, IE, IT, CF, CG, CI, CM, A 20021224 20031224 BZ, CA, CH, FI, GB, GD, KR, KZ, LC, MZ, NI, MO, SL, SY, TJ, ZM, ZW ZM, AM, AZ, DE, DK, EE, SE, SI, SK, NE, SN, TD, WO 2004058751 PI WO 2004058751

W: AE, AG, AL,
CN, CO, CR,
GE, GH, GH,
LK, LK, LS,
NZ, OM, PG,
TM, NN, TR,
RM: BW, GE, GM,
BY, KG, FZ,
ES, FI, FR,
TR, BF, BJ,
PRAI GB 2002-30162
OS MARRAT 141:123613 WO 2003-GB5654 MO 2003-GB5654
BB, BG, BR, BW, BY,
DZ, EC. EE, EG. ES.
IS, JP, KE, KG, ES,
NG, MX, MN, MM, MX,
SC. SD, SE, SG, SK,
UZ, VC, VN, YU, ZA,
SL, SZ, TZ, UG, ZM,
BE, BG, CE, CY, CT,
LU, MC, NL, PT, RO,
GM, GG, MR, MR, MR,

MARPAT 141:123613

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

The title compds. I and II [Q = (substituted)alkyl, (substituted)alkenyl,

JP2004 018717.trn

PI JP 2004277318 PRAI JP 2003-69326 OS MARPAT 141:307555 20041007 20030314 JP 2003-69326

The derivs. are represented by I [Ar = Q, Q1; R1 = halo; R2 = H, lower alkyl; R3 = H, lower alkyl, lower alkyl, R6 = H, lower alkyl; R5, R6 = H, lower alkyl; h = 1, 2, 3; x = lower alkenyl, cycloalkenyl, lower alkyl, CH: CHA; A = halo, lower alkoxycarbonyl, cycloalkyl, (un) substituted Ph, carbamoyl in which N may be substituted yellowlyl, (un) substituted Ph, carbamoyl in which N may be substituted with lower alkyl or (un) substituted Ph, lower alkanoyl, lower alkoxy, unsatd. mono or dicyclic heterocyclyl, saturated monocyclic heterocyclyl;

20030314

unsatd. mono or dicyclic heterocyclyl, saturated monocyclic heterocyclyl;

0. 1; if m = 0, then X = lower alkenyll or their physiol. acceptable acid salts. Also claimed are pharmaceutical compns. 5-H74 receptor agonists, and digestive tract motility promoters or digestive tract function improvers containing I or their salts. Thus,

1-anino-5-chloro-N-[1
(1-(3-cyclohexene-1-carbonyl)-4-piperidinylmethyl)-4-piperidinyl]-2-methoxybenzamide funarate, prepared from

4-amino-5-chloro-2-methoxy-N-[1-(4
piperidinylmethyl)-4-piperidinyl)benzamide and 3-cyclohexene-1-carboxylic acid, inhibited binding of GR113808 to a guinea pig 5-H74 receptor preparation

at IC50 8.71 nM, vs. 23.0 nM of cisapride. Pharmaceutical prepns.

I over also given.

768372-01-69

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(1-substituted-4-piperidinylmethyl)piperidine derivs.

5-TH4 receptor agonists)
768372-01-6 CAPLUS
Benzamide, 4-amino-5-chloro-N-[1-[[1-{(2E)-1,4-dioxo-4-(phenylamino)-2-butenyl]-4-piperidinyl]-4-piperidinyl]-2-methoxy-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 768372-00-5 CMF C29 H36 C1 N5 O4

Double bond geometry as shown.

# JP2004\_018717.trn

(substituted)cycloalkyl, (substituted)aryl, (substituted)aralkyl, (substituted)alkoxy, (substituted)aryloxy, etc.; A = a single bond or alkylene; X = 0 or S; Z = 0, S, NR3; R1-R3 = H or alkyl; p = 0 or 1; q = 0 or 1; n = 0-10; m = 0-10] that are specific to the EP3 receptor and useful in altering vascular tone, in particularly uterine vascular tone (including myometrial and endometrial vascular tone) were prepared The invention is particularly useful in the treatment of menstrual disorders, cardiovascular conditions and hypertension. For example, compound III was prepared in a multi-step synthesis. The latter showed an EC50 = 5.7 µM in the EP3 receptor binding assay. 721970-55-49 721970-56-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)
(preparation of piperidinyl thiasole carboxamide derivs. for altering vascular tone)
721970-55-4 CAPLUS
2-Butenamide, 4-14-[4-(4-bromophenyl)-5-methyl-2-thiasolyl]-1-piperidinyl]-N-(4,5-dimethyl-2-nitrophenyl)-4-oxo-, (2E)- (9CI) (CA INDEX NAME)

721970-56-5 CAPLUS
2-Butenamide, 4-[4-[4-[4-(diethylamino)phenyl]-2-thiazolyl]-1-piperidinyl]-N-(4,5-dimethyl-2-nitrophenyl)-4-oxo-, (2E)- (9CI) (CA IMDEX NAME)

Double bond geometry as shown.

ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STM 2003:221465 CAPLUS 138:255249 Preparation of piperazine and homopiperazine compounds useful in the

```
treatment of thrombosis and to inhibit ADP-mediated platelet aggregation Levy, Daniel E.; Smyth, Mark S.; Scarborough, Robert M. Millennium Pharmaceuticals, Inc., USA PCT Int. Appl., 260 pp. CODEN: PIXXO2
IN
PA
50
DT Patent
LA English
FAN.CNT 1
PATENT NO.
                                                                KIND
                                                                                  DATE
```

PI WO 2003022214 A2 20030320 NO 2002-US28618 20020906 WO 200302214 A3 20040325 WI AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GM, HR, HU, ID, IL, IN, IS, JF, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, HA, HD, NG, MK, NN, HM, MX, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SO, SE, GS, SI, SK, SL, TJ, TM, TN, TT, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZM RN: GR, GM, KE, LS, HM, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SC, TR, BF, BJ, CF, US 2003153556 A1 20030906 US MAPPAT 18E: 25249						
PI WO 2003022214 A2 20030320 M0 2002-US28618 20020906  W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CC, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GH, RH, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, NN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SO, SE, GS, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZM, ZM, ZM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GG, GW, ML, MR, NE, SN, TD, TG  US 2003153555 A1 20030814  PRAI US 2001-317192P P 20010906						
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, BR, HU, 1D, IL, IN, IS, JF, KE, KG, KF, KR, KZ, LC, LK, LR, LS, LT, LU, LV, HA, MD, MG, MK, HN, HM, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SO, SE, GS, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, CM, US, US, UZ, VC, VN, YU, ZA, ZH, ZM RN: GR, GM, KE, LS, HM, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, HC, NL, PT, SE, SK, TR, BF, BJ, CF, CC, CI, CH, GA, GN, GO, GN, HL, MR, NE, SN, TD, TG US 20013151555 A1 20030814 US 2002-237153 20020906	PI				WO 2002-US28618	20020906
	PRAI	W: AE, AG, AL, CO, CR, CU, GM, HR, HU, LS, LT, LU, PL, PT, RO, UA, UG, US, RN: GR, GN, ER, GG, EZ, MD, FI, FR, GB, CG, CI, CM, US 2003153556 US 2001-317192P	AM. AT. C2. DE. ID. IL. LV. MA. RU. SD. U2. VC. LS. MW. RU. TJ. GR. IE. GA, GN.	AU, AZ, DK, DM, IN, IS, MD, MG, SE, SG, VN, YU, MZ, SD, TM, AT, IT, LU, GQ, GW, 20030814	DZ, EC, EE, ES, FI, GE JP, KE, KG, KP, KR, KZ MK, NN, MM, MD, MZ, NC SI, SK, SL, TJ, TM, TN ZA, ZM, ZW SL, SZ, TZ, UG, ZM, ZG BE, BG, CH, CY, CZ, DE MC, NL, PT, SE, SK, TR ML, MR, NE, SN, TD, TG	G. GD. GE. GH. LC. LK. LR. NZ. OM. PH. TR. TT. TZ. AM. AZ. BY. DK. EE. ES. BF. BJ. CF.

Piperaxine and homopiperazine compds. I, wherein Q is (CH2)n; n is 1, 2; m is 0-4; W is N, CR5; X is S, O, NR6; Y is N, CR7; Z is N, CR8; J is CO, CS, CNR9, SO, SO2; A is O, S, NR10, CO, CH(OH); L is a direct link or a divalent linker; R1 is H, halo, CN, NO2, NJ, alkyl, cycloalkyl, alkene, alkyne; R2 is H, halo, CN, NO2, NJ, alkyl, cycloalkyl, alkene, alkyne, acyl; R3 is alkyl, cycloalkyl, acyl; R4 is H, F, CF3, CM, NJ, NO2, alkyl, amino, alkylamino, cycloalkyl, acyl; R4 is H, F, CF3, CM, NJ, NO2, alkyl, amino, alkylamino, cycloalkyl, betaroalkyl, fused bicycloalkyl, fused bicycloalkyl, fused bicycloalkyl, ED, R5 are independently H, alkyl, cycloalkyl, EB is H, CN, NO2, alkyl; R10 is H, alkyl, acyl; are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis. Thus piperazine II was prepared and tested in vitro to inhibit ADP-mediated platelet aggregation (activity ranges are: > 20 mmol; 10-20 µmol; and < 10 µmol). AB

Page 17

JP2004\_018717.trn

2. CM CRN 76-05-1 CMF C2 H F3 02

ANSWER 5 OF 8 CAPLUS - COPYRIGHT 2005 ACS ON STN 2000:548723 CAPLUS 133:150561 133:150561
Preparation of imidazolylalkylazacycloalkanes as H3 receptor antagonists Vaccarb, Mayne D.; Molin, Ronald L.; Solomon, Daniel M.; Aslanian, Robert Vaccarb, Mayne D.; Molin, Stuart B. Schering Corporation, USA
U.S., 33 pp.
CODEM: USXXAM DT Path. LA English FAN CHT 1 PATENT NO. DATE PI US 6100279
PRAI US 1997-64958P
OS MARPAT 133:1504 KIND APPLICATION NO. DATE 20000808 US 1998-185973 19981105 MARPAT 133:150561

```
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of piperazine and homopiperazine compds. useful in treatment of
          ment of
thrombosis and to inhibit ADP-mediated platelet aggregation)
502648-44-4 CAPLUS
1-Piperazinepropanamide, 4-{6-ethylthieno[2,3-d]pyrimidin-4-yl}-β-σxο-
N-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)
                   502648-43-3
C21 H23 N5 O2 S
```

502648-56-8 CAPLUS 1-Piperazinepropanamide, 4-(6-ethylthieno[2,3-d]pyrimidin-4-yl}-β-oxo-N-3-pyridinyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CRN 502648-55-7 CMF C20 H22 N6 02 S

JP2004 018717.trn

AB RIZIZ(CH2)mZ2(CH2)pR6 [I: R1 = (un)substituted 1H-imidazol-4-yl: R6 = (un)substituted heterocyclyl or -(heterolaryl: Z = (un)substituted pyrrolidine-, -piperidine-, or -hexahydrocaepine-n, 1-diyl: Z1 = (un)substituted al(ten)ylene-, -alkynylene: Z2 = 0. CO. CONH. SOZ. etc.; m.p = 0-t, n = 2-6 as approprisel were prepared Thus.

1-tritylimidazole-4propanel was oxidized and the product condensed with (MeO) ZP(0) CH2CO2Ne to diverse the description of the descrip

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT RE.CNT 17

L19 ANSMER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STW
AR 1999:325925 CAPLUS
DN 130:338115
T Preparation of 4-[(azacycloalkyl)alkyl)imidazoles as histamine H3 receptorantagonists
N Vaccaro, Mayne D.; Wolin, Ronald L.; Solomon, Daniel H.; Aslanian, Robert G.; Piwinski, John J.; Rosenblum, Stuart B.
Schering Corporation, USA
PA Schering Corporation, USA
PCT Int. Appl., 68 pp.
CODEM: PIXXO2
P Patent

Patent English

PATENT NO. DATE KIND DATE APPLICATION NO.

```
AA 19990520 CA 1998-2309609 19981105
2967 A1 19990531 AU 1999-12967 19981105
8956 A1 20000823 EP 1998-956443 19981105
AT. BE. CR. DE. DK. ES. FR. GB. CR. IT. LI. LU. NL. SE. PT. IE.
LT. LV. FI. RO
1522845 T2 20011120 JP 2000-520435
186 A 19990506 2
LT, LV, FI, RO

JF 2001522845 T2 20011120 JF 2000-520435 19981105
ZA 9810186 A 19990506 ZA 1998-10186 19981106
PRAI US 1997-955754 A2 19971107
WO 1998-US23224 W 19981105

SMARRAT 130:338115

AB RIXZ(CR2)mY(CH2)pR6 [I; RI = (un)substituted 4-imidazolyl; R6 = (un)substituted heterocyclyl or -(heterolaryl; X = (un)substituted alk(en)ylame or alkynyleme; I = 0, C0, C02, S02, C0NH, etc.; Z = pyrrolidine-, piperidine-, or hexamethyleneimine-n, 1-diyl; m,p = 0-4] were prepared Thus, 1-tritylimidazole-a-propionaldehyde was condensed with (NeO) 2F(0) CR2CO2Ne and the product condensed with NeNO2 to give, after reduction and cyclization and an addnl. reduction step, 1-trityl-4-{12-(3)-pyrrolidinyl)ethyllimidazole which was emidated by 4-ClC6H4SO2C1 to give, after deprotection, RICH2CR2TSO2CSH4C1-4 (R1 = 4-imidazolyl, Z = pyrrolidine-3,1-diyl). Data for biol. activity of I were given.

IT 224168-43-89
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TMU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-[(azacycloslkyl)alkyl)imidazoles as histamine H3
                                                                                                                                                                      20011120
19990506
19971107
19981105
                              JP 2001522845
                           antagonists)
224168-43-8 CAPLUS
1-Piperidinepropanamide, N-(3-chlorophenyl)-4-(1H-imidazol-4-ylmethyl)-
β-oxo- (9CI) (CA INDEX NAME)
```

RE.CNT THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN 1995:995217 CAPLUS 124:117340
Preparation of 4-amino-2-piperarinoquinazolines and analogs as cl-adrenergic antagonists
Leonardi, Amedeo: Motta, Gianni; Boi, Carlo; Testa, Rodolfo Recordati S.A. Chemical and Pharmaceutical Co., Switz.
PCT Int. Appl., 39 pp.
CODEN: PIXXD2
Patent
DT
```

Page 21

JP2004 018717.trn

173059-43-3 CAPLUS 1-Piperazinepropanamide, 4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-β-οxo-N-phenyl- (9CI) (CA INDEX NAME)

```
ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
1993:169119 CAPLUS
118:169119 Preparation of pytrolidinylcarbonyl (heterocyclyl)piperatines and related
compounds as antiesthmatics and respiratory tract antiinflammatories
Long, Glorgio; Gandolff, Carmelo A.; De Cillis, Gianpiero; Di Domenico,
Roberto; Rozzi, Antonella; Gallico, Licia
Boehringer Mannheim Italia S.p.A., Italy
PCT Int. Appl., 65 pp.
CODEN: PIXXO2
Patent
English
CMT 1
PATENT NO. RIND DATE APPLICATION NO. DATE
 PA
50
DT
                         MO 9218478 A1 19921029 MO 1992-E7724 19920401
M: AU, BB, BG, BR, CA, CS, FT, BU, JF, EP, ER, LK, MG, MN, MN, NO, PL, RO, RU, SD, US
RM: AT, BE, BF, BJ, CF, CG, CH, C1, CM, DE, DK, ES, FR, GA, GB, GM, GR, IT, LU, MC, NL, MR, NL, SE, SM, TD, TG
AU 9214475 A1 19921017 AU 1992-14475 19920401
AU 653393 B2 19940929
EP 580633 B1 19940202 EP 1992-907564 19920401
EF 580633 B1 19940210
EF 580633 B1 19940210
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, ML, SE JP 06506450 72 19940721 JP 1992-506863 19920401

FAN.	CNT 1			
	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	WO 9525726	A1 10050020	WO 1995-EP1001	
• •	M. AM ATI DO	BC DD DV 61	WO 1995-EP1001	19950317
	*. AR, AU, DO,	BG. BR. BI, CA.	CN, CZ, EE, FI, GE,	HU, JP, KE, KG,
	RP, RR, RZ,	LK, LK, LT, LV,	MD, MG, MI, MY, MX,	NO, NZ, PL, RO,
	KU, SD, SG,	S1, SK, TJ, TT,	UA, UG, US, UZ, VN	
	KW: KE, RW, SD,	SZ, UG, AT, BE,	CH, DE, DK, ES, FR,	GB. GR. IE, IT,
	LU, MC, NL,	PT, SE, BF, BJ,	CF, CG, CI, CM, GA,	GN, ML, MR, NE,
	SN, TD, TG			
	AU 9518948	A1 19951009	AU 1995-18948	19950317
	ZA 9502208	A 19951228	ZA 1995-2208	19950317
	EP 750614	A1 19970102	EP 1995-911342	19950317
	EP 750614			
	R: AT, BE, CH,	DE, DR, ES, FR,	GB, GR, IE, IT, LI,	LU, NC, NL, PT. 5E
	JP 09511238	T2 19971111	JP 1995-524370	19950317
	IL 113024	A1 20000726	IL 1995-113024	19950317
	ES 2158938	T3 20010916	ES 1995-911342	19950317
	PT 750614	T 20011031	PT 1995-911342	19950317
	TW 416951	B 20010101	TW 1995-84105132	19950523
	US 5798362	A 19980825	US 1996-71616D	19960917
	GR 3036443	T3 20011130	GR 2001-401292	20010823
PRAI	IT 1994-MI506	A 19940318		
	WD 1995-EP1001	₩ 19950317		
os	MARPAT 124:117340			
GI				

Title compds. [I; R6 = Z1Z2(CR1R2)mR, NMeZR7, 4.4-diphenylpiperidino, etc.; R = aryl(oxy), diarylmethyl, aroyl, etc.; R1, R2 = H, alkyl; R7 = Ph, CRPh2, 4.(2-methoxyphenyl)piperazino; Z = alkylene; Z1 = 1.4-piperazinylene; Z2 = bond, O, CO, CONE; n = 0-4; n = 0 or 1] were prepared Thus, I (R6 = piperazino) was amidated by PhCCN2CO2H to give I (R6 = Z1COCH2COPh, Z1 = 1.4-piperazinylene) which had ED25 for blood pressure reduction of 56µg/kg i.v. in normotensed rats and 2.42mg/kg

y
in spontaneously hypertensive rats.
173059-13-7P 173059-43-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-amino-2-piperarinoquinazolines and analogs as
al-adrenergic antagonists)
173059-13-7 CAPLUS
1-Piperazinepropanamide, 4-(4-amino-6.7-dimethoxy-2-quinazolinyl)-βoxo-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Page 22

```
JP2004 018717.trn
```

JP 3218037	B2	20011015		•
HU 69702	A2	19950928	HU 1993-2701	19920401
RU 2108325	C1	19980410	RU 1993-58261	19920401
AT 167470	Е	19980715	AT 1992-907564	19920401
ZA 9202541	A	19931008	ZA 1992-2541	19920408
US 5453423	, A	19950926	US 1993-119202	19930927
ND 9303599	λ	19931112	NO 1993-3599	19931008
NO 180165	В	19961118		
NO 180165	c	19970226		
PRAI IT 1991-MI966	A	19910409		
WO 1992-EP724	A	19920401		
OS MARPAT 118:169	119			

Title compds. I [X = CH2, S; B = CO, CH2, CH2OCO, CH2OCS, CH2NHCO, CH2NHCS; D = (aubstituted) Ph. -CH2Ph. -benthydryl. -5- or 6-membared heterocyclyl, (3-hydroxy-2-pyridyl)mathyl: Y = bond. (CH2)2, (CH2)3, CRaRb; Ra, Rb = H. Cl-3 alkyl, or CRaRb = C3-6 cycloalkyl; A = free or salified carboxy group which may be esterified or smidsted, Cl-3 alkyl, alkanoyl, etc.; A can be cysno when Y = bond) were prepared as antiasthmatics and for the treatment of respiratory tract inflammation. Thus, N-acylation of N-[(pyrolidin-2-yl)carboxyl]-N-[4,6-bis(pyrolidin-1-yl)-1,3,5-triazin-2-yl)piperazine (preparation given) by ClCOCH2CO2Et in

MeCN containing RHCO3 at room temperature gave title compound I [D = 4,6-bis(pyrrolidin-1-y1)-1,3,5-triazin-2-y1; B = CO; X = CH2; Y = CH2; A = CO2Et]. I at 2-50 mg/kg in goinea Þiga are said to show a protective action in a test of forced inspiration of tobacco snoke.

IT 145908-99-2P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antiasthmatic and respiratory tract antiinflammatory)
RN 145908-99-2 CAPLUS
CN 1-Pyrrolidinepropanamide, 2-[{4-(2,6-di-1-pyrrolidiny1-4-pyrinidiny1)-1-piperaziny1]carbony1]-β-oxo-N-2-pyridiny1- [9CI) (CA INDEX NAME)

=> S 118 NOT L19 L20 1 L18 NOT L19

-> D BIB ABS HITSTR

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN 1997:154992 CAPLUS 126:199815 LZO AN DN TI

126:199815
Synthesis of an Amino Acid Analog To Incorporate p-Aminobenzyl-EDTA in Peptides
Song, Anna In.; Rana, Tariq M.
Department of Pharmacology Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, 08854, USA Bioconjugate Chemistry (1971, 8(2), 249-252
CODEN: BCCHES; ISSN: 1043-1802
American Chemical Society
Journal English
CASREACT 126:199815 AU CS

so

PB DT LA OS GI

A convenient and straightforward synthesis of an amino acid analog I (Fmoc - 9-fluorenylmethoxycarbonyl), compatible with Fmoc solid phase peptide synthesis strategy is described. I was used to incorporate p-aminobenyl-EDTA at an internal sequence position in an HIV-1 Tat protein fragment. After cleavage from the resin and standard deprotection, AB

Page 25

JP2004\_018717.trn

PAGE 1-C

JP2004\_018717.trn

the peptide was purified by high-performance liquid chromatog, and characterized by mass spectrometry. Through this methodol., flexible linkers of different lengths and containing various structures can be

between the α-carbon backbone of peptides and metal chelates. These paptides will provide a new class of affinity cleaving reagents that can be directed against protein and nucleic acid targets.

187671-20-1P

187671-20-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of a protected aspartic acid aminobenzyl-EDTA conjugate for incorporation into peptides)
187671-20-1 CAPLUS
L-Glutamine, L-arqinyl-N-(4-{2,3-bis[bis{2-(1,1-dimethylethoxy)-2-oxoethyl] amino]propyl}phenyl]-L-asparaqinyl-L-prolyl-L-prolyl-L-glutaminyldycyl-L-seryl-L-glutaminyl-L-thronyl-L-histidyl-L-glutaminyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-leucyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

Page 26

JP2004\_018717.trn

PAGE 2-A

RE. CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

-> S L4 L21 13 L4 -> 5 L21 AND P/DT 4628444 P/DT L22 13 L21 AND P/DT -> D BIB ABS 1-13

AN DN TI

ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2004:857551 CAPLUS 141:350179
Preparation of arolidinedicarboxamides and related compounds as Factber AES and Factor VIIa (Embrytorsyll)
Taaklakidis. Childing Dorach, Dieter; Mederski, Werner; Ceranne, Bertram; Gleitz, Johannes
Merck Patent GebH, Germany
PCT Int. Appl., 162 pp.
CODEN: PIXXD2
Patent IN

PA SO

DT LA Patent German

FAN.	CNT	5										•						
	PAT	ENT 1	10.				-	DATE				ICAT:					<b>TE</b>	
							-											
PI	WO	20040	8764	16		A2		2004	1014		WO 2	004-6	EP23	50		20	0040	30B
	WO	20040	08764	16		A3		2005	106		•							
		W:	AE,	λG,	AL,	AM,	AT,	AU.	AZ,	BA,	88,	BG,	BR.	B₩,	BY,	BZ,	CA,	CH,
			CN,	co,	CR.	CU,	CZ.	DE,	DK,	Det,	DŹ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HR.	HU,	ID,	IL.	IN,	IS,	JP,	KE.	KG.	KP,	KR,	KZ.	LC.
			LK,	LR.	LS,	LT.	LU,	LV,	MA,	MD,	MG,	MK,	MEN,	HOW,	MX,	MZ,	NA,	NI,
			NO,	MZ.	OM,	PG.	PH,	PL.	Pī,	RO,	RU.	SÇ,	50,	SE,	SG,	SK,	SL,	SY,
			TJ.	TH,	TN.	TR,	TI,	77.	UA,	UG,	US,	UZ,	VC.	VN.	YU,	ZA.	ZM.	ZW
		RM:	BW,	GH,	GM,	KE,	LS.	194 .	MC,	SD,	SL.	52.	TZ.	UG,	ZM.	ZW,	AM,	AZ,
			BY,	KG.	KZ,	MD.	RU,	TJ,	TM,	AT,	BE.	BG.	CH,	CY.	CZ.	DE.	DK.	EE.
			ES,	FI.	FR.	GB,	GR.	EU.	IE,	IT.	w.	HC,	NL.	PL,	PT.	RO.	SE,	51,
			SK,	TR.	Β£,	BJ.	CF,	CG,	CI,	CH.	GA.	GZI.	GQ.	GM .	ML.	MR.	NE.	SN.
			TO,	TG														
	DE	1031	5377			A1		2004	1014		DE 2	003-	1031	5377		2	0030	403
	DE	1032	9295			A1		2005	0203		DE 2	003-	1032	9295		2	0030	630
PRAI	30	2003	-103	1537	7	A		2003	0403									

-- NH2

R1R2(TYX)EMCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, COR3, CON(R3)2, etc.; R3 = H, A, HC.tplbond.CCH2, NeC.tplbond.CCH2, CR2CK(OR)CH2OH, etc.; R4 = H, A; N = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D =

membered (heterocyclic) ring optionally containing a double bond; D =
or
dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3,
[C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nOC(C(R4)2]n,
[C(R4)2]n,NR3[C(R4)2]n, [C(R4)2]nNR3[C(C(R4)2]n, etc.; Y = alkylene,
cycloalkylene, heterocyclylene, arenedly!; T = aubstituted mono- or
dinuclear carbocyclyl, heterocyclyl; A = [fluoro-substituted] alkyl
optionally interrupted by O, S, CH:CH, were prepared Thus, title compoun
(I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and
4-chlorophenyl isocyanate given] bound to Factor Xa receptors with ICSO =
1.8 + 10-8 M.

ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2004:857166 CAPLUS 141:332218
Preparation of distance terocycles as calcitomin gene related peptide

PA SO

DT Patent LA English FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION :				
ΡI	US 2004204397	A1	20041014	US 2003-72915				
	US 2004063735	Al	20040401	US 2003-44552				
	US 6843269	B2	20050118	US 2003-45482				
PRAI	US 2002-386138P	P	20020605					
	US 2002-388617P	₽	20020613					
	US 2002-389870P	P	20020619					
	US 2002-393200P	P	20020701					
	US 2002-413534P	P	20020925					
	US 2003-445523	A2	20030527	•				
os	MARPAT 141:332218							

-----

Page 29

JP2004 018717.trn

US 6843269 PRAI US 2002-386138P US 2002-388617P US 2002-389870P US 2002-393200P

Diazaheterocycles I [m, n = 0-2; m = n = 2; V = (un)substituted NH2, OH; O = (un)substituted alkyl, NH2, NHCOZH, NHCOH2; U = CH2, MH; D = 0, OKN, alkylsubfonylmino; A = C, N, CH; E = (un)substituted heterocyclic) were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, sigrains and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases,

as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 18-indazole-5-carboxaldehyde and had ICSO for calcitonin gene related peptide receptor binding of ≤ 10 nm.

RE.CHT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2003:76556 CAPLUS 138:131125
Fal\_Accumulation-modulating compounds Stevenson, Michael John; Leighton, Harry Jefferson Adipogenix, Inc., USA PCT Int. Appl., 96 pp. CODEN: PIXX02

DT Patent LA English FAM.CNT 1

NT 1 PATENT NO. APPLICATION NO. KIND DATE WO 2003007888 A2 20030130 WO 2002-US23295 20020722

Diaraheterocycles I [m, n = 0-2; V = (un)substituted NH2, OH; Q = (un)substituted alkyl, NH2, NHCOH, NHCOHH2; U = CH2, NH; D = 0, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos) were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headeches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases,

as asthma and chronic obstructive pulmonary disease (COPO). Thus, the indazole II was prepared from lH-indazole-5-carboxaldehyde and had IC50 for calcitonin gene related peptide receptor binding of  $\leq 10$  nM. The (pharmaceutical composition comprising the compound I is claimed.

ANSMER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2003:991516 CAPLUS 140:42208
Preparation of distaheterocycles as calcitonin game related peptide

Preparation of distancerocycles as calcitonin gene related peptide receptor antagonists Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Ban, Xiaojun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Vig, Shikha Bristol-Myers Squibb Company, USA PCT Int. Appl., 309 pp.
CODEN: PIXXD2

DATE 20031205

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003104236		20031218		20030527
	W: AE, A	NG, AL, AM, I	AT, AU, AZ,	BA, BB, BG, BR, BY, BZ,	CA CH CN
	co, c	CR, CU, CZ, I	DE, DK, DM,	DZ, EC, EE, ES, FI, GB	GD. GE. GH.
	GM, 1	IR, HU, ID, :	IL, IN, IS,	JP, KE, KG, KP, KR, KZ,	LC. LK. LR.
	LS, I	LT, LU, LV, E	MA, MD, MG,	MIK, MIN, MON, MIX, MIZ, NI.	NO. NZ. OM.
	PH, 9	?L, PT, RO, I	RU, SC, SD,	SE, SG, SK, SL, TJ, TM,	TN, TR, TT,
	TZ, t	JA, UG, US, (	UZ, VC, VN,	YU, ZA, ZM, ZW	
	RW: GH, G	SM, KE, LS, 1	MW, MZ, SD,	SL, SZ, TZ, UG, ZM, ZW,	AM, AZ, BY,

JP2004 018717.trn


MC 2003007888 A3 20031127

M: AE, AG, AL, AR, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, NN, MM, MX, MZ, NO, NZ, OM, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TM, TR, TT, TZ, UG, UZ, VM, VY, ZA, ZM, ZM

RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, AM, AZ, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CG, CI, CM, GA, GM, GD, GM, MI, MR, ME, SN, TD, TG

US 2003144350 A1 20030731 US 2002-201588 20020

MARPAT 138:131125 WO 2003007888 20031127 20020772



The present invention pertains to compds. effective at modulating fatty acid or triglyceride ("fat") accumulation by cells, such compds. having therapeutic potential as regulators of body mass and for the treatment coverveight individuals, obesity, and metabolic disorders. An example compound is I and protocol for high-throughput screening of compound

acy on human preadipocytes is given. Therapeutic methods and pharmaceutical compns. featuring these compds. are also provided.

ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STM 2002:6377 CAPLUS 136:69635 Preparation of \$\beta\$-lactam compounds as inhibitors of tryptase Bisacchi, Gregory 5.; Slusarchyk, William A.; Treuner, Uwe; Sutton, James C.; Zahler, Robert; Seiler, Steven; Kronenthal, David R.; Randazro, Michael E.; Schwinden, Mark D.; Xu, Zhongain; Shi, Zhongping Bristol-Myers Squibb Co., USA U.S., 171 pp., Cont.-in-part of U. S. Ser. Number 336,253, abandoned. CODEN: USXXXMP

DT Patent LA English FAN.CHT 2 PATENT NO. KIND DATE APPLICATION NO. DATE PI US 6335324 PRAI US 1998-90636P US 1999-336253 В1 20020101 US 1999-458847 19991213 . B2

AB Novel 6-lectam compds., e.g. of formula I [R = CO2H, alkoxycarbonyl, acyl, CC-heterocyclyl, etc.; X = acyl, CC-heterocyclyl, SO2-alkyl, aminoalkylphenyl, etc.; n = 1-6], are prepared These compds. inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinfiammatory agents particularly in the treatment of chronic asthma (no data). Thus, II was prepared from (45)-N-(tert-butyldimethylsilyl)szetidin-2-one-4-carboxylic acid, 1-chloro-3-iodopropane, N,N-bis (benzyloxycarbonyl)-I-guanylpyrazole and benzyl isocyanate.

RE CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2001:507689 CAPLUS COPYRIGHT 2005 ACS on STN 2001:507689 CAPLUS COPYRIGHT 2005 ACS on STN 235:92860 Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander; Muller, Stephan Georg; Doods, Henri; Bauer, Eckhart Boehringer Ingelheim Pharma K.-G., Germany PCT Int. Appl., 153 pp. CODEN: PIXXO2 Patent
IN
 PA
SO
DT Patent
LA German
FAN.CNT 1
```

	PATENT NO.					KIND DATE			APPLICATION NO.						DATE			
PI	WO	2001	0496	76		A1		2001	0712	1	NO 2	000-1	EP13:	236		20	00012	222
		₩:	Æ,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ.	CA,	CH,	CN,
			CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,
			HU,	ID,	IL.	IN.	IS.	JP.	KE.	KG.	KP.	KR,	KZ.	LC.	LK.	LR.	LS.	LT.
												MZ,						
												TT.						
												RU.			•		,	,
		RW:	GH,	GM.	KE.	LS.	MOV .	MZ.	SD.	SL.	SZ.	TZ,	UG.	ZW.	AT.	BE.	CH.	CY.
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT.	SE,	TR.	BF,
			BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD.	TG	-	-
	DE	1996	3868			A1		2001	0712		DE 1	999-	1996	3868		19	99912	230
	CA	2395	541			AA		2001	0712		CA 2	DO0 -:	2395	541		20	00012	222
	BR	2000	0170	63		A		2002	1022	1	BR 2	000-	1706	3		20	30012	222
	EP	1252	153			A1		2002	1030	1	EP 2	000-	9918	96		20	00012	222
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI.	LU.	NL,	SE.	MC.	PT.
								RO,										•
	JΡ	2003	5192	22		<b>T</b> 2		2003	0617		JP 2	001-	5502	16		20	00012	222
	EE	2002	0036	9		λ		2003	1015	1	EE 2	002-	369			20	0001	222

Page 33

# JP2004 018717.trn

PI		2000009543 2000009543			2000										
11	#O	2000009543		12	2000	0224		<b>#</b> O	1999-	LA/3	•		13	990	809
		W: AE, AL,	ма	AT.	AD 47	9A	20	9.0	80	DV	Ch	CU	CM	cti	
		DE, DK,													
		JP, KE,													
		MIN, MIN,													
					UG, US,										
		MD, RU,			,,	,	,		,,	,			,	,	
		RW: GH, GM,			MON. SD.	SL.	SZ.	UG	. ZW.	AT.	BE.	CH.	CY.	DE.	DK.
		ES. FI.	FR.	GB.	GR, IE,	IT.	LU.	MC	NL.	PT.	SE.	BF.	BJ.	CF.	CG.
		CI. CM.	GA.	GN .	GW. ML.	MR.	NE.	SN	TD.	TG					
	บร	6323180		Bì	2001	1127		US	1999-	3688	66		19	990	805
	CA	2338946		AA	2000	0224		CA	1999-	2338	946		19	990	809
		2445938		AA	2000 2000	0224		CA	1999~	2445	938		19	998	809
	UΑ	9952731		A1	2000	0306		λU	1999-	5273	1		1	9990	809
		769738		82	2000 2004 2001	0205									
		9913646		A	2001	0605		BR	1999-	1364	6		1	9990	B09
	EP	1105413			2001										
		R: AT, BE,				FR.	GB,	GR	, IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE, 51,	LT,	LV.	FI, RO										
		200100432		T2	2001 2002 2002	0921		TR	2001-	2001	0043	2		9990	
	TR	200200129		T2	2002	0621		TR	2002~	2002	0012	9	1	9990	B09
	JP	200280129 2002522554 200100081 510396 6268207 6329379		TZ	2002	0723		JP	2000-	5649	93		1	9990	B09
	EE	200100081		À	2002	0815		EE	2001-	81			1	9990	809
	NZ	510396		٠.	2004	0227		NZ	1999-	5103	96		1	9990	809
	US	6268207		81	2001	0731		US	2000-	6600	30		2	0000	912
	110	6323373		B1	2001	1211		05	2000-	2022	98		- 2	0000	929
	80	6329417 105232		P.	2001	1171		05	2000- 2001-	1057	21		_	0010	
	20	2001000102		٠.	2001	11130		55	2001-	1032	32		2	0010	208
	NO	2001000102		W.T	2002	0402		NO.	2001-	102				0010	200
	115	2001000683 2002016442		Ä,	2002	0702		116	2001- 2001-	8276	76		5	0010	406
	115	6420380		82	2002	0716		03	2001-	04/3	,,,		-	0010	406
		2002037998		B2 A1	2002	0328		115	2001-	9491	57		,	0010	504
				B2		0625							-		
	US	6534523		81	2003	0318		US	2002-	9129	3		2	0020	305
PRAI	US	6534523 1998-95931P		P	1996						-		_		
	US	1999-132386P		P	1999	0504									
	US	1999-132386P 1998-132386P 1999-368866 1999-2338946 1999-CA736		P	1998	80810									
	US	1999-368866		A3	1999	0805									
	CA	1999-2338946		A.3	1999	0809									
	WO	1999-CA736		W	1999	0809								-	
	US	2001-849057		A1	2001	10504									
os	MA	RPAT 132:1808	71												
GI															

STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT .

Peptides I [8 = H, (un)substituted aryl, aralkyl, heterocyclyl, or alkylheterocyclyl, acyl R4CO, carboxylate R4O2C, amide R4WRSCO, thioamide R4WRSC(S), or sulfonyl group R4SO2, where R4 = (un)substituted alkyl, cycloalkyl, cycloalkyl, cycloalkyl, exploalkyl, or heterocyclyl, with proviso that R4 = cycloalkoxy for amides or thioamides; R5, T = H, alkyl; R3 = (un)substituted alkyl, cycloalkyl, or alkylcycloalkyl; R2 = (un)substituted alkyl, cycloalkyl, or alkylcycloalkyl; R2 = (un)substituted cycloalkyl-, aryl-, aralkyl-, or heterocyclylmethyl, -amino, -oxy, or -thio; R1 = H; alkyl, cycloalkyl, alkenyl, or alkynyl, all optionally substituted with halogen] or their racemates,

JP2004\_018717.trn

ZA 2002005181 NO 2002003161 US 2003212057 PRAI DE 1999-19963868 WO 2000-EP13236 OS MARPAT 135:92860 20030930 20020628 20031113 19991230 20001222 ZA 2002-5181 NO 2002-3161 US 2002-169009 20020627 20020626 20021107

formulations were given. Preparation of fragments CO2HC(R2)AC(O)R1, and A

Al substituents were given. Thus (R,S)-4-(4-amino-3,5-dibromophenyl)-2[(1,1-dimethylethoxy carbonyl)methylamino]-4-oxo-butanoic acid was react
with 3-(piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one to
give I (R = 1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one; R14-amino-1,5-dibromophenyl; R2 = H; A = (1,1-dimethylethoxy
carbonyl)methylamino; A1 = H). In in vitro tests using SK-M-HC cells as
tests of human CGRP-receptor binding affinity, I had ICS S10000
nM, and acted as CGRP antagoniats at dosages between 10-11 - 10-5 M.
NT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2000:133714 CAPLUS 132:180871
             132:180871
Preparation of hepatitis C inhibitory tripeptides
Llinas-Brunet, Montse; Bailey, Murray D.; Cameron, Dale; Faucher,
Anne-Marie; Chiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Poupart,
Marc-Andre; Rancourt, Jean; Tsantrizos, Youla S.; Wernic, Dominik M.;
             Simoneau, Bruno
Boehringer Ingelheim (Canada) Ltd., Can.
PCT Int. Appl., 168 pp.
CODEN: PIXXD2
PA
So
```

DT Patent LA English FAN.CNT 1 PATENT NO.

APPLICATION NO.

Page 34

## JP2004 018717.trn

diastereoisomers, and optical isomers were prepared as hepatitis C virus (RCV) inhibitory tripeptides. Thus, compound II was prepared via peptide coupling reactions in solution and showed ICSO < 0.5  $\mu$ M in the recombinant RCV NS3 protease/NS4A cofactor peptide radiometric assay.

DATE

```
ANSWER B OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1997:542334 CAPLUS 127:225293
```

Pharmaceutical compositions containing pyrrolidine derivatives for the

Pharmaceutical compositions containing pyrrolidine derivatives for the treatment of drug abuse
Bohme, Andrees; Capet, Marc; Dubroeucq, Marie-Christine; Fratta, Walter;
Guyon, Claude; Imperato, Assunta
Rhone-Poulenc Rorer SA, Fr.; Bohme, Andrees; Capet, Marc; Dubroeucq,
Marie-Christine; Fratta, Walter; Guyon, Claude; Imperato, Assunta
PCT Int. Appl., 34 pp.
CODEN: PIXXD2
PARANT IN

PA

so

DT Pate. LA French FAN.CNT 1 PATENT NO. PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9728799 Al 19970814 WO 1997-FR210 19970203

W: AL, AU, BA, BB, BB, BB, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, RF, KR, LC, LK, LR, LT, LV, MC, MK, NY, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: KE, LS, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, RU, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GM, ML, MR, NE, SN, TD, TG

FR 2744362 B1 19970808 FR 1996-1482 19960207

FR 2744362 B1 19980227

AU 9717273 A1 19970828 AU 1997-17273 19970203

PRAIF R 1996-1482 A 19960207

WO 1997-FR210 W 19970203

OS MARPAT 127:225293

AB Pharmaceutical compos. containing pyrrolidine derivs. (Markush structure given), isomers or selts thereof, are useful for the treatment of abuse of drugs or paychominatics. e.D. nacrotics and hallucthodens. Advanced is ureido)-3-phenylacetic -(4R) acid. A tablet contained a pyrrolidine derivative KIND DATE APPLICATION NO. DATE

vative
50, lactose 104, cellulose 40, polyvidone 10, sodium carboxymethyl starch
22, talc 10, magnesium stearate 2, colloidal silica 2, and a mixture of
hydroxymethyl cellulose, glycerin, titanium oxide q.s. 245 mg.

ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1996:211766 CAPLUS 124:260823

Preparation of pyrrolidine derivatives as cholecystokinin and gastrin receptor ligands

Capet, Marc; Dubroeucq, Marie-Christine Rhone-Poulenc Rorer S.A., Fr.

PCT Int. Appl., 77 pp. CODEN: PIXXD2

DT

Patent French

FAN.CNT 1 APPLICATION NO. PATENT NO. KIND DATE DATE WO 9535310 W: AM. Al 19951228 WD 1995-FR796 19950616 AM, AU, 88, 8G, BR, BY, CA. CH. CZ, EE, FI, GE, HU, IS, JP,

```
RP, RR, KE, LK, LR, LT, LV, MD, MG, MN, MX, NO, NE, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN
RM: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
FR 2721314
B1 19950719
AU 9527966
A1 19950715
AU 1995-27966
B1 19970409 EP 1995-273397
19950616
EP 766695
B1 19980722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LT, LI, NI, PT, CF
                                                                                                                                           19980722,
BES, FR, GB, GR, IE, IT, LI, LU, NL,
19980217 JP 1995-501747 19
19980815 AT 1995-923397 19
199801001 ES 1995-923397 19
19960209 ZA 1995-5052 19
19980210 US 1996-750653 19
                       R: AT, BE, CH, DE, DK,
JP 10501802 T2
AT 168697 E
ES 2119454 T3
                                                                                                                                                                                                                                                                                                   19950616
19950616
19950616
AT 168697
ES 2119454
2A 9505052
US 5716936
PRAI FR 1994-7540
WO 1995-FR796
OS MARPAT 124:260823
                                                                                                                                                                                                                                                                                                    19961218
                                                                                                                                            19950616
```

• STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT •

AB Title compds. [I: R = (cyclo)alk(en)yl, phenylalkyl, heteroaryl, etc.;
R1,R3,R4 = H, alkyl; R2 = carboxyalkyl, alkoxycarbonyloxyalkyl,
(d1)alkylaminoalkyl, etc.; R5 = (un)substituted phenyl (amino), indolyl,
quinolyl; R6 = H, (phenyllalkyl; R7 = alkylsulfonyl, SOZNRRSP, SOZPh,
etc.; R8 = H, alkyl, phenyl(alkyl); R9 = alkyl, phenyl(alkyl)) were
prepared
Thus, 2-FC6H4CH:NCHZCOZCMs3 was cyclocondensed with 4-ClC6H4SOZCH:CH2
(preparation each given) and 1 of the enantiomeric products N-acylated wi
3-(MeOZCCH2)c6H4NHCONICHZCOZH (preparation given) to give title compound
(RS,4SR,5RS)-II. 1 had IC50 of \$2000nM for CCK receptor binding.

(RS, 45R, SRS)-11. I had ICSD of \$2000nM for CCR receptor binding.

ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1994:217658 CAPLUS 120:217658 Preparation and formulation of 2- aryl-3-(ureidoacetyl)thiazolidine-4-carboxylates and analogs as CCR receptor and gastrin receptor ligands Capet, Marc; Cotrel, Claude; Guyon, Claude; Joannic, Michel; Mahfre, Franco; Roussel, Gerard; Dubroeucq, Marie Christine; Cheve, Michel; Dutruc-Rosset, Gilles Rhone-Poulenc Rorer SA, Fr. PCT Int. Appl., 186 pp. CODEN: PIXXD2
Patent French
LCNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	WO 9301167	Al 19930121	WO 1992-FR626	19920703
	W: AU, CA, CS,	FI, HU, JP, KR,	NO, PL, RU, US	
	RW: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LU, MC, NL,	SE
	FR 2678938	A1 19930115	FR 1991-8675	19910710
	FR 2678938	B1 1993100B		
	EP 527069	A1 . 19930210	EP 1992-401904	19920703
	R: PT			
	AU 9223275	A1 19930211	AU 1992-23275	19920703

## JP2004\_018717.trn

LA English FAN.CNT 1 PATENT NO. DATE APPLICATION NO. KIND DATE MS 200295 A1 1920109 MO 1991-U54236 3

M: AU, CA, JP, US
M: AU, CA, JP, US
RW: AT. BE, CH, DE, OR, ES, FR, GB, GR, IT, LU, NL, SE
US 5162316 A1 19921110 US 1990-573514 1
CA 2068887 AA 19911222 CA 1991-2068887 1
AU 9186116 A1 19920123 AU 1991-86116 1
AU 640277 B2 19930819
E7 491943 A1 19920701 EP 1991-916717
R: AT. BE, CH, DE, OK, ES, FR, GB, GR, IT, LI, LU, NL, SE
US 1990-573514 A2 19900824
MO 1991-U54236 A 19910613
MARPAT 116:256054 19910613 19910613 19910613

Title compds. [I; X = aryl; Y = B, slkyl, (substituted) aralkyl, acyl, aroyl, heterocyclylcarbonyl, carbamoyl, alkoxycarbonyl, aryloxycarbonyl aralkoxycarbonyl,  $Z = \{ubstituted\}$  N-containing heterocyclyl, amino, a acid residue, peptide residue, etc.;  $\alpha = 0-3$ ; n = 0-4], were prepared

Thus,

(3R)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-9B-pyrido(3,4-b)indole-3carboxylic acid in THF at -15' was treated with Et3N and
H,N-bis[2-oxo-3-oxarolinyl]phosphorodiamidic chloride followed by stirring
for 20 min. Benzyl N-(L-prolyl)nipecotate was added and the mixture was
stirred overnight at ice temperature to give the amide, which was
deprotected

with CF3CO2H followed by acylation with 3,4-dichlorophenyl isocyanate and
hydrogenolysis to give title compound II. II bound to CCk-A, CCK-B, and
gastrin receptors with ICSO's of 10, 0.111, and 0.026 µM, resp.

ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1988:570130 CAPLUS 109:170130 Preparation and formulation of novel mitomycin derivatives as antitumor agents

	AU 662345	В2	19950831	•	
	EP 593639	A1	19940427	EP 1992-915456 ·	19920703
	EP 593639	B1	19950405		
	R: AT, BE, CH	, DE,	DK, ES, FR,	GB, GR, IT, LI, LU, NL,	. SE
	JP 06509331	T2	19941020	JP 1992-502018	19920703
	JP 3034043	82	20000417		
	AT 120732	Ε	19950415	AT 1992-915456	19920703
	ES 2071510	T3	19950616	ES 1992-915456	19920703
	HU 70403	A2	19951030	HU 1994-61	19920703
	PL 171054	B1	19970228	PL 1992-313380	19920703
	PL 171094	B1	19970328	PL 1992-313379	19920703
	PL 171112	81	19970328	PL 1992-313381	19920703
	PL 171095	B1	19970328	PL 1992-313382	19920703
	PL 171333	. B1	19970430	PL 1992-302029	19920703
	CZ 283602	B6	19980513	CZ 1994-49	19920703
	RU 2118316	C1	19980827	RU 1994-15258	19920703
	CA 2102697	С	20030930	CA 1992-2102697	19920703
	ZA 9205128	Ā	19930428	ZA 1992-5128	19920709
	NO 9304300	A	19931126	NO 1993-4300	19931126
	NO 180166	8	19961118		
	NO 180166	С	19970226		
	FI 105190	B1	20000630	FI 1994-72	19940107
	US 5610144	A	19970311	US 1994-175381	19940627
PRAI	FR 1991-8675	A	19910710		
	WO 1992-FR626	A	19920703		•
OS.	MARPAT 120-217658				

Title compds. [I; Z = CH2, CH2CH2, SOO-2, CHOH and RI = (substituted) (heterojaryl; Z = CH2, RI = H, and R5 = Ph; Z = CHPh and RI = R5 = H; R2 = alkoxycarbonyl, CONH2, Ph, etc.; R3 = (substituted) phenylamino, Ph, etc.; R4 = H, alkyl) were prepared Thus, L-HSCH2CH(NH2)CO2H was cyclocondensed with PhCHO and the esterified product N-acetylated with Me3COZCHNENZCO2H to qive, after silica chromatog, and deprotection, thiazolidinecarboxylate (2R,4R)-II (III; R = H). The latter was condensed with 3-MacCSHANCO to give III (R = CONNCGHAM-3). I had ICSO 2 1 mm for inhibition of binding at CCK receptors. Prepare of a chiral HPLC phase for optical resolution of I is given.

ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1992:256054 CAPLUS 116:256054 Preparation of peptide-linked 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles and related compounds as inhibitors of cholecystokinin and gastrin Molino, Bruce F.; Darkes, Paul R.; Ewing, William R. Roper International (Holdings), Inc., USA PCT Int. Appl., 94 pp. 7 PTXXD2 Patent

рΤ

Page 38

## JP2004 018717.trn

IN PA SO Muto, Kenji; Kuroda, Tokuyuki; Morimoto, Makoto Kyowa Hakko Kogyo Co., Ltd., Japan Japan Kokai Tokkyo Koho, 13 pp. CODEN: JKXXAF

Patent Japanese

LA Japa... FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE PI JP 63035575 PRAI JP 1986-181012 OS MARPAT 109:170130 GI 19880216 A2 JP 1986-181012 19860731

The title compds. I [A = dipeptide, tripeptide residue; R1 = NH2, ONe; on of R2 and R3 is R4CO, R4CO, R4SO2, R4NECO, R5S, the other is H; R4 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl; R5 = substituted aryl, heterocyclyl; or R2R3 = Q; R6 = arylene], useful as antitumor agents, were prepared Condensation of tert-butyloxycarbonyl-L-alenyl-L-proline with mitomycin C in the presence of dicyclonexylcarbondimide gave 93% I [R1 = NH2, R2 = Me3COCO, R3 = H, A = L-alanyl-L-prolyl) (II). II exhibited an ED50 of 7.3 mg/kg against transplanted sercoma 180 tumor in mice, vs. an ED50 of 2.9-3.9 mg/kg for mitomycin C.

ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1986:443340 CAPLUS 105:43340 Tripeptide derivatives for use as antihypertensive agents Eguchi, Chikahiko; Kurauchi, Masahiko; Sakakibara, Shumpei Ajinomoto Co., Inc., Japan Eur. Pat. Appl., 47 pp. CODEN: EFYXDM Patent English CTT 1

FAN.	CNT 1			
	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	EP 173510	A2 19860305	EP 1985-305727	19850813
	EP 173510	A3 19870916		
	R: CH, DE, FR,	GB, IT, LI		
	JP 61053298	A2 19860317	JP 1984-176355	19840824
	JP 0605575B	B4 19940727		
	US 4719200	A 19880112	US 1985-769029	19850826
PRA	JP 1984-176355	A 19840824		
GI				

R1NR2CR3R4CON \_\_\_\_CON

Peptides (I; R1 = H, hydrocarbyl, acyl; R2 = H, hydrocarbyl, acyl, thioacyl, esterified CO2H, carbamoyl, hydrocarbyloxy, NO2, etc.; R3 and R4 = H, alkyl, aryl, aralkyl; R5 = OH, hydrocarbyloxy, hydrocarbylthio, amino, acylamino, etc.), which exhibited antihypertensive activity, were prepared H-Ala-Pro-Pro-OH was treated with C1CO2Et and NaOH to give EtO2C-Ala-Pro-Pro-OH.

-> LOG Y COST IN JAPANESE YEN SINCE FILE ENTRY 11102 TOTAL SESSION 74423 FULL ESTIMATED COST SINCE FILE ENTRY -2068 TOTAL SESSION -2068 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:56:42 ON 08 FEB 2005

OK

CONNECT 46667

Connecting through CompuServe

0076TEW

Host Name: STNT

Connected to 0000 CAA\_0

Welcome to STN International! Enter x:x LOGINID:TRYBAJ14 PASSMORD: TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2

```
Item
                                                                       Readline

STN, CAS FILES Morkshop Schedule in Japan

KOREAPAT now available on STN

CUTTENT-awareness elects, saved answer sets, and

current search transcripts to be affected by CERAB,

COMPURAB, ELCOM, and SOLIDSTATE reloads

November 22, 2004 LISA new on STN

PHAR reloaded with additional data
12 databases to be removed from STN on 31,Dec.,2004

MEDLINE update schedule for December 2004

ELCOM reloaded; updating to resume; current-awareness

alerts[SDIs] affected

COMPURAB reloaded; updating to resume;

CUTTENT-awareness alerts[SDIs] affected

SOLIDSTATE reloaded; updating to resume;

CUTTENT-awareness alerts[SDIs] affected

CERAB reloaded; updating to resume;

CUTTENT-awareness alerts[SDIs] affected

CERAB reloaded; updating to resume;

CUTTENT-awareness alerts[SDIs] affected

Three new fields added to IFIPAT/IFIUDB/IFICDB

EFFULL:New patent full text database to be available

on STN

CAPLIS - PATENT COMPRAGE EYBANDED
 NEWS 1
NEWS 2 Oct 26
NEWS 3 Nov 19
 NEWS 4 Nov 22
NEWS 5 Dec 1
NEWS 6 Dec 15
NEWS 7 Dec 17
                      8 Dec 20
 NEWS
NEWS 9 Dec 20
NEWS 10 Dec 20
NEWS 11 Dec 20
NEWS 12 Dec 20
NEWS 13 Dec 27
                                                                       EPFULL: New patent full text untabase to be constructed on STN
CAPLUS - PATENT COVERAGE EXPANDED
No connect-hour charges in EPFULL during January and February 2005
Urgent announcement to STN customers accessing via phone line WorldCom access points were changed CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS 14 Dec 31
NEWS 15 Jan 1
NEWS 16 Jan 5
NEWS 17 Jan 12
NEWS HOURS
NEWS WORLDCOM
NEWS INTER
                                                                           STN operating Hours
STN High Speed Access via Worldcom
INTERNET ACCSESS to STNT(STN-Tokyo)
```

## JP2004\_018717\_2.trn

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2005 VOL 142 ISS 7 FILE LAST UPDATED: 7 Feb 2005 (20050207/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

-> 5 L3

-> D BIB HITSTR 1-13

IN

DT LA

ANSMER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2004:857551 CAPLUS 141:350179
Preparation of azolidinedicerboxamides and related compounds as Factor Xa and Factor VIIa inhibitors Teaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cexanne, Bertram; Gleitz, Johannes
Merck Patent GmbB, Germany
PCT Int. Appl. 162 pp.
CODEN: PIXXD2
PATENT NO. KIND DATE APPLICATION NO. DATE PARENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004087646 A2 20041014 WO 2004-EP2350 20040308

WO 2004087646 A3 20050106

W: AE, MG, AL, MH, AT, AU, AZ, BA, BB, BG, BR, BM, BY, BZ, CA, CR, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EZ, EG, ES, FI, GB, GD, GG, GH, GH, HR, HU, ID, IL, IH, IS, JF, KE, KG, RF, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, HD, MG, MK, MM, MK, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TM, TT, TZ, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZM, RM, BM, GH, GM, RE, LS, MM, MZ, SD, SL, SI, TZ, UG, ZM, ZM, AX, ES, FI, FR, GB, GR, HD, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, NR, KS, SN, TD, TG

DE 10315377 A1 20041014 DE 2003-10315377 20030403

DE 2003-10329295 A1 20050203 DE 2003-10329295 20030630

PRAIO DE 2003-10329295 A 20030630

US 2003-403897P P 20030702

OS MARPAT 141:350179

R1: PAC (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapoutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

JP2004\_018717\_2.trn

NEWS EXPRESS

STN Express 7.0 with Discover! (Windows) Now available! STR Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:02:50 ON 09 FEB 2005

TOTAL SESSION 36 SINCE FILE ENTRY

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:03:01 ON 09 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPIRIGHT (C) 2005 American Chemical Society (ACS) CHARGED TO COST-4

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0 DICTIONARY FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROF at an arrow prompt in the file or refer to the file aummary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> ACT RD018717/A
L1 STR
L2 STR
L3 349 SEA FILE-REGISTRY SSS FUL L1 AND L2

-> FILE CAPLUS COST IN JAPANESE YEN

SINCE FILE . ENTRY 65

FILE 'CAPLUS' ENTERED AT 11:03:23 ON 09 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR SIN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS) CHARGED TO COST-4PRD

Page 2

## JP2004\_018717\_2.trn

(preparation of azolidinedicarboxamides and related compds. as Factor Xa and

Factor VIIs inhibitors)
774602-65-2 CAPLUS
1-Pyrrolidinecarboxemide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(4-pyridinyl)-1-piperszinyl]carbonyl]-, (2R.4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[(4-(2-pyridinyl)-1-piperaxinyl)carbonyl]-, (2R,4R)- (9Cl) (CA INDEX NAME)

Absolute stereochemistry.

774602-70-9 CAPLUS
1-Pyrrolidinecarboxemide, N-{4-chlorophenyl}-2-[[4-{4-ethyl-1-piperazinyl}-1-piperidinyl]carbonyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

CN

774602-71-0 CAPLUS
1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-2-[[4-(4,6-dimethyl-2-pyrimidinyl)-1-piperazinyl)carbonyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

774602-72-1 CAPLUS
1-Pyrrolidinecarboxamide, N-{4-chlorophenyl}-4-hydroxy-2-{{4-{1-methyl-4-piperidinyl}-1-piperazinyl}carbonyl}-, (2R,4R)- (9CI) (CA INDEX NAME)

L4 AN DN TI

ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
2004:857166 CAPLUS
141:332218
Preparation of diazaheterocycles as calcitonin gene related peptide
receptor antagonists
Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark;
Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun;
Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Greham;
Tora, George; Vig, Shikha
U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. Number 445,523.
CODEN: USXXCO
Patent
English
CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE ' IN

PA SO

### Page 5

## JP2004\_018717\_2.trn

635711-75-0 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-1,4-dioxo-2-[[(2,4,5-trimethylphenyl)amino]carbonyl)amino]butyl|- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

635711-76-1

635711-76-1 CAPLUS
1.4'-Bipiperidine, 1'-[(25)-2-[([(4-chlorophenyl)amino)carbonyl)amino]-4-[4-(1.4-dihydro-2-oxo-3(28)-quinazolinyl)-1-piperidinyl]-1.4-dioxobutyl]-(9CI) (CA INDEX NAME)

## Absolute stereochemistry.

635711-77-2 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinaxoliny1)-1-

## JP2004\_018717\_2.trn

ΡI US 2004204397 US 2004063735 US 6843269 20041014 20040401 20050118 US 2003-729155 US 2003-445523 US 2003-454826 20031205 20030527 20030604 US 2004063797 A1 2004061 US 2003-729155 2003105
US 2004063735 A1 2004061 US 2003-445523 2003065
US 2002-386138P P 20020605
US 2002-38613P P 20020613
US 2002-388617P P 20020613
US 2002-398980P P 20020619
US 2002-393200P P 20020701
US 2002-413534P P 2002095
US 2002-413534P P 2002095
US 2002-413534P P 2002095
US 2003-445523 A2 20030527
HARPAT 141:332218
635711-78-7P 635711-75-0P 635711-76-1P
635711-80-7P 635711-80-9P 635711-91-4P
635711-80-7P 635711-80-9P 635711-90-9P
635711-80-F 635711-80-9P 635711-90-9P
635711-95-4P 635711-93-2P 635711-94-3P
635711-95-4P 635711-96-5P 635711-94-3P
635711-95-4P 635711-96-5P 635711-94-3P
635712-05-9P 635712-06-4P
635712-05-9P 635712-06-2P 635712-00-4P
635712-05-9P 635712-06-2P 635712-09-3P
635712-10-6P 635712-17-1P 635712-10-1P
635712-16-P 635712-10-1P 635712-10-1P
635712-20-PB 635712-20-6P 635712-20-1P
635712-30-PB 635712-31-4-4P 635712-31-3P
635712-31-39 635712-31-4-4P 635712-31-5P
635712-33-3P 635712-31-4P 635712-35-5P
635712-30-6P 635712-30-4P 6 A1 B2 PRAI (Uses)
(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)
65711-72-7 CAPLOS
1.4'-81piperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinexoliny])-1-piperidiny])-1.4-dioxo-2-[[[(2-phenoxyphenyl)amino]carbonyl]amino]butyl)-(9CI) (CA INDEX NAME)

## JP2004 018717 2.trn

piperidiny1]-2-[[[(2-methylphenyl)amino]carbonyl}amino]-1,4-dioxobutyl}(9CI) (CA INDEX NAME)

## Absolute stereochemistry.

635711-78-3 CAPLUS
1.4'-Bipiperidine, 1'-{(25)-4-{4-(1.4-dihydro-2-oxo-3(2H)-quinezolinyl)-1-piperidinyl}-2-[(1(3-ethylphenyl)amino]carbonyl}amino]-1.4-dioxobutyl}-(9CI) (CA INDEX NAME)

635711-79-4 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-{1,4-dihydro-2-oxo-3(2B)-quinazolinyl}-1-piperidinyl}-1,4-dioxo-2-[([phenylamino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

RN 635711-80-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino|4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl|(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-82-9 CAPLUS
CN 1.4'-Bipiperidine, 1'-[{2S}-4-[4-(1.4-dihydro-2-oxo-3[2H]-quinezoliny1)-1piperidiny]-1.4-dioxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]butyl](9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 9

JP2004\_018717\_2.trn

RN 635711-86-3 CAPLUS

N 1.4'-Bipiperidine, 1'-[(25)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinazoliny1)-1piperidiny1]-2-[[(2-methoxypheny1)amino)carbony1)amino]-1.4-dioxobuty1](9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-87-4 CAPLUS
CN 1,4'=Biplperidine, 1'=[(2S)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1piperidiny1)-2-([((3-methoxypheny1)amino]carbony1]amino]-1,4-dioxobuty1)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Pho Pho

N 635711-83-0 CAPLUS
1-{(25}-2-{[(3-acetylphenyl)amino]carbonyl)amino]-4(4-(1,4-dihydro-2-oxo-3(2H)-quinarolinyl)-1-piperidinyl}-1,4-dioxobutyl](9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-84-1 CAPLUS

CN 1.4'-Bipiperidine, 1'-[(25)-2-[[[(2,3-dichlorophenyl)amino]carbonyl]amino}4-[(4-[1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl](9Cl) (CA INDEX NAME)

Absolute stereochemistry.

Page 10

JP2004\_018717\_2.trn

RN 635711-88-5 CAPLUS
RN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1piperidiny1]-2-[[(2,3-dimethylpheny1)amino]carbony1]amino}-1,4dioxobuty1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

N 635711-89-6 CAPLUS

14'-Bipiperidine, l'-|(25)-2-{{[(4-chloro-3-(trifluoromethyl)phenyl]amino | carbonyl|amino|-4-(4-(1,4-dihydro-2-oxo-3(28)-quinatolinyl)-1-piperidinyl]-1,4-dioxobutyl}- (9Cl) (CA INDEX NAME)

635711-90-9 CAPLUS
1,4'-Blpiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-1,4-dioxo-2-[[[[3-(trifluoromethy1)pheny1]amino]carbony1]amin olbuty1]- (9CI) (CA INDEX NAME)

635711-92-1 CAPLUS
1,4-Bipiperidine, 1'-{(25)-4-|4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1}-2-[[[(2,4-dimethoxypheny1)amino]carbony1]amino]-1,4-dioxobuty1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 13

JP2004\_018717\_2.trn

635711-95-4 CAPLUS
1.4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[(3,4-dimethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635711-96-5 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-2-[[(3,5-dichlorophenyl)amino]carbonyl]amino]4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](9C1) (CA INDEX NAME)

Absolute stereochemistry.

JP2004\_018717\_2.trn

635711-93-2 CAPLUS 1.4'-8ipiperidine, 1'-[{2S}-2-[{[(2,4-difluorophenyl)amino}carbonyl]amino}-4-[4-[1,4-dihydro-2-oxo-3{2H})-quinerolinyl}-1-piperidinyl}-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

635711-94-3 CAPLUS
1,4-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-[[(2,5-dimethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Page 14

JP2004\_018717\_2.trn

635711-97-6 CAPLUS
1.4'-Bipiperidine, 1'-[(25)-4-[4-{1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-1,4-dioxo-2-[[[4-{trifluoromethy1)pheny1]amino]carbony1]amino]buty1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635711-98-7 CAPLUS
1.4'-Bipiperidine, 1'-[{25}-2-[[[{2,4-dichlorophenyl]amino}carbonyl]amino}4-[4-(1.4-dihydro-2-oxo-3{2H})-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](SCI) (CA INDEX MAME)

635711-99-8 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1]-2-[([(4-(1-methylethy1)pheny1)amino)carbony1)amino]-1,4-dioxobuty1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-00-4 CAPLUS
1,4'-Bipiperidine, 1'-[{2S}-2-{[[(2,6-difluorophenyl)amino}carbonyl]amino}4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-1,4-dioxobutyl](SCI) (CA INDEX NAME)

Absolute stereochemistry.

Page 17

JP2004\_018717\_2.trn

635712-04-8 CAPLUS
1,4'-Bipiperiddne, 1'-[(2S)-2-{[([2-chloro-5-(trifluoromethyl)phenyl)amino | loarbonyl]amino|-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-05-9 CAPLUS
1.4'-Bipiperidine, 1'-[(2S)-4-[4-(1.4-dihydro-2-oxo-3(ZB)-quinazoliny1)-1-piperidiny]-1.4-dioxo-2-[[((2,3,4-trifluoropheny1)amino)carbony1]amino]buty1]- (9CI) -(CA IMDEX NAME)

Absolute stereochemistry.

635712-01-5 CAPLUS
1.4'-8ipiperidine, l'-{(25)-2-{{[(2,6-dichloro-4-pyridiny]} amino]-4-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-02-6 CAPLUS:
1.4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[(3,5-dimethoxyphenyl)amino]carbonyl]amino]-1.4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 18

JP2004\_018717\_2.trn

635712-08-2 CAPLUS
1.4'-8ipiperidine, 1'-[(2S)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[((2-fluoropheny1)amino]carbony1]amino]-1.4-dioxobuty1]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-09-3 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-2-[[[(2-chloropheny1)amino]carbony1)amino]-4-[4-(1,4-dihydro-2-oxo-3(28)-quinazoliny1)-1-piperidiny1]-1,4-dioxobuty1]-(9CI) (CA INDEX MAME)

635712-10-6 CAPLUS  $1,4'-\text{Bipiperidine}, 1'-[\{2S\}-2-\{[\{(2,5-\text{dichlorophenyl}\}\text{amino}\}-4-\{4-\{1,4-\text{dibydro-}2-\text{oxo-}3\{2H\}-\text{quinazolinyl}\}-1-\text{piperidinyl}]-1,4-\text{dioxobutyl}]-\{9C1\}$  (CA INDEX NAME)

Absolute stereochemistry.

635712-11-7 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinaxolinyl)-1-piperidinyl)-2-[[[(2,5-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 21

JP2004\_018717\_2.trn

635712-14-0 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinezoliny1)-1-piperidiny1]-2-[[(3-f]uoropheny1)amino]carbony1)amino]-1,4-dioxobuty1]-(9CI) (CA INDEX NAME)

635712-15-1 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-2-[[[(3-chlorophenyl)anino]carbonyl]amino]-4[4-(1,4-dihydro-2-oxo-3(2B)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl][9C1] (CA INDEX HAME)

Absolute stereochemistry.

635712-12-8 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-{1,4-dihydro-2-oxo-3[2H)-quinazoliny1}-1-piperidiny]-2-[[(2-ethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobuty]-(9CI) (CA INDEX MAME)

635712-13-9 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-2-[[(3-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dibydro-2-carb-3 (2H)-quinazolinyl)-1-piperidinyl}-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 22

JP2004\_018717\_2.trn

635712-16-2 CAPLOS
1,4'-Bipiperidine, 1'-[(2S)-2-[[[(4-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dinydro-2-oxo-3/2R)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl}-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-17-3 CAPLUS
1.4'-8lpiperidine, 1'-[(2S)-4-[4-(1.4-dihydro-2-oxo-3(2B)-quinazoliny1)-1-piperidiny1)-2-[[(4-fluoropheny1)amino]carbony1]amino]-1,4-dioxobuty1)-(9CI) (CA INDEX NAME)

RN 635712-19-5 CAPLUS
CN 1,4'=Bipiperidine, 1'-[(2S)-4-[4-{1,4-dihydro-2-oxo-3(2B)-quinazoliny1]-1piperidiny1)-2-[[(4-methoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl)(9CI) (CA INDEX NAME)

## Absolute stereochemistry.

RN 635712-20-8 CAPLUS

Benzoic acid, 4-[[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-di)ydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl] amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

Page 25

## JP2004\_018717\_2.trn

## Absolute stereochemistry

RN 635712-25-3 CAPLUS
CM 1.4-Bipiperidine, 1'-[(25)-2-[[[(5-chloro-2-methoxyphenyl)amino]carbonyl]
amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinaxolinyl)-1-piperidinyl]-1,4dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635712-22-0 CAPLUS

(N 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,5-difluorophenyl)amino]carbonyl]amino]
4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]
(9CI) (CA INDEX NAME)

### Absolute stereochemistry

RN 635712-23-1 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2R)-quinazolinyl)-1-piperidinyl]-2-[([(2,4-dimethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 26

## JP2004\_018717\_2.trn

RN 635712-26-4 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(2S)-2-[[[[4-chloro-2-[trifluoromethyl]phenyl]amino | captonyl]amino | captonyl]amino | captonyl]amino | captonyl]amino | captonyl]amino | captonyl]amino | captonyl]-1,4-dioxobutyl | captonyl capton

## Absolute stereochemistry.

RN 635712-27-5 CAPLUS
CN 1.4'-Bipiperidine, 1'-[{2S}-4-{4-(1.4-dihydro-2-oxo-3{2H}-quineroliny1}-1-piperidiny1}-2-[[{4-ethoxypheny1}amino]carbony1]amino]-1.4-dioxobuty1]-(9C1) (CA INDEX HAME)

635712-28-6 CAPLUS
1,4'-8ipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinezoliny1)-1-piperidiny1)-2-[[(4-ethylpheny1)amino]carbony1]amino]-1,4-dioxobuty1]-(9C1) (CA INDEX NAME)

Absolute stereochemistry.

635712-29-7 CAPLUS
1,4'-Bipiperidine, 1'-[[25]-2-[[[(4-chloro-2-methylphenyl)amino] carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3[2B]-quinazolinyl]-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 29

JP2004\_018717\_2.trn

635712-32-2 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-2-[[((4-bromo-2-methylphenyl)amino|carbonyl)amino|-d-(4-(1,4-dihydro-2-oxo-3(2B)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-33-3 CAPLUS
1.4'-Bipiperidine, 1'-[(25)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[([5-fluoro-2-methylphenyl)amino)carbonyl]amino]-1.4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-30-0 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-2-methylphenyl)amino]cerbonyl]a
mino]-4-[4-[1,4-dihydro-2-oxo-3(2R)-quinazolinyl)-1-piperidinyl]-1,4dioxobutyl]- (9CI) (CA INDEX NAME)

635712-31-1 CAPLUS
1.4'-Bipiperidine, 1'-[(25)-2-[[(3-chloro-4-fluorophenyl)amino]carbonyl)amino]-4-[4-(1.4-dhloydro-2-oxo-3(2B)-quinaxolinyl)-1-piperidinyl]-1.4-dioxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 30

JP2004\_018717 2.trn

635712-34-4 CAPLUS
Benzoic acid, 3-[[[[15]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(28)-quinasolinyl)-1-piperidinyl]-3oxopropyl]amino]carbonyl]amino]-, methyl ester [9CI] (CA INDEX NAME)

Absolute stereochemistry.

635712-35-5 CAPLUS
1,4'-Bipiperidine, 1'-{{25}-2-{{{{1,1'-biphenyl}-2-ylamino}carbonyl}amino}-4-{4-{1,4-dibydro-2-oxo-3(28)-quinazolinyl}-1-piperidinyl}-1,4-dioxobutyl}-(SCI) (CA INDEX MAME)

635712-38-8 CAPLUS
1.4'-Bipiperidine, 1'-[(25)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinezoliny1)-1-piperidiny1]-1.4-dioxo-2-[[[[2-(trifluoromethoxy)pheny1]amino]carbony1]amino]buty1]- (9C1) (CA INDEX NAME)

## Absolute stereochemistry.

- ANSMER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2003:991516 CAPLUS 140:42208 140:42208 Preparation of diszaheterocycles as calcitonin gene related peptide receptor antagonists Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Vig, Shikha Bristol-Myers Squibb Company, USA IN

### Page 33

## JP2004\_018717\_2.trn

635711-75-0 CAPLUS
1.4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-1,4-dioxo-2-[([(2,4,5-trimethylphenyl)amino]carbonyl]amino]buty1}-(9C1) (CA INDEX NAME)

## Absolute stereochemistry.

635711-76-1 CAPLUS
1.4'-Bipiperidine, 1'-[(2S)-2-[[((4-chlorophenyl)amino]carbonyl]amino]-4-(4-(1,4-dibydro-2-oxo-3(2B)-quinarolinyl)-1-piperidinyl]-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

## Absolute stereochemistry.

## JP2004\_018717\_2.trn

SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIN

KIND DATE APPLICATION NO. DATE WO 2003104236 20031218 MO 2003-US16576 2003-0151576 20030527
BG, BR, BN, BZ, CA, CH, CM,
EE, ES, FI, GB, GD, GE, GB,
KG, RP, KR, KZ, LC, LK, LR,
HM, HX, NI, NO, NZ, OH,
SK, SL, TJ, TM, TN, TR, TT,
ZM, ZM
TT, UG, ZM, ZM, AM, AZ, BY,
CR, CY, CZ, DE, DK, EZ, ES,
NI, PT, RO, SE, SI, SK, TR,
GM, ML, NR, NE, SN, TD, TG
1003-454826 20030604 20030527 EC. RE. MN. SG. ZA. SZ. BG. MC. GQ. DZ. JP. MK. SE. YU. SL. BE. LU. GN.

NUMBER OF STREET STREET

es; (preparation of diazaheterocycles as calcitonin gene related peptide

[preparation or distance:rocycles as calcitonin gene related peptide receptor antagonists] 635731-72-7 CAPLUS [ .4.-Glpiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinaxolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2-phenoxyphenyl)amino]carbonyl]amino]butyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 34

635711-77-2 CAPLUS
1.4'-Blpiperidine, l'-[{25}-4-{4-{1,4-dihydro-2-oxo-3{2H}-quinazoliny1}piperidiny1}-2-[[(2-methylphenyl)amino]carbonyl]amino}-1,4-dioxobutyl]
(SCI) (CA INDEX NAME)

## Absolute stereochemistry.

635711-78-3 CAPLUS
1,4'-8ipiperidine, 1'-{(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1]-2-[[(3-ethylphenyl)amino]carbonyl)amino]-1,4-dioxobuty1]-(9CI) (CA INDEX NAME)

RN 635711-79-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[{2S}-4-{4-{1,4-dihydro-2-oxo-3(2B}-quinazoliny}}-1piperidiny]-1,4-dioxo-2-[{{phenylamino}carbony}]amino]buty}- {9C1} (CA
INDEX NAME)

Absolute stereochemistry.

RN 635711-80-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[{[1,1'-bipheny1]-4-ylamino}carbonyl}amino]4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 37

JP2004\_018717\_2.trn

RN 635711-84-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]4-[4-[1,4-dibydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-86-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-{(25)-4-{4-(1,4-dihydro-2-oxo-3(28)-quinazoliny1)-1piperidiny1}-2-{[{(2-methoxyphenyl)amino}carbonyl]amino}-1,4-dioxobuty1}-.
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-82-9 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-4-[4-{1,4-dihydro-2-oxo-3(2B)-quinezoliny1)-1piperidiny1]-1.4-dioxo-2-[[[(4-phenoxypheny1)amino]carbony1]amino]buty1)(9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-83-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-acetylphenyl)amino]carbonyl]amino]-4[4-(1,4-dihydro-2-xox-3|2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](9Cl) (CA INDEX NAME)

Absolute stereochemistry.

Page 38

JP2004\_018717\_2.trn

RN 635711-87-4 CAPLUS

N 1.4'-Bipiperidine, 1'-[{2S}-4-[4-(1,4-dihydro-2-oxo-3{2R})-quinazolinyl}-1-piperidinyl}-2-[[{[3-methoxyphenyl}amino]carbonyl}amino]-1,4-dioxobutyl][9C1] (CA IMDEX NAME)

Absolute stereochemistry.

RM 635711-88-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-{(2\$)-4-{4-(1,4-dihydro-2-oxo-3(2B)-quinazoliny1)-1-piperidiny1}-2-[{{2,3-dinethylpheny1}amino|carbony1}amino|-1,4-dioxobuty1}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-90-9 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinasoliny1)-1piperidiny1)-1.4-dioxo-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amin
o|butyl|- (9CI) CA INDEX NAME)

Absolute stereochemistry."

Page 41

JP2004\_018717\_2.trn

RN 635711-94-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1piperidinyl)-2-[[(2C,5-dimethylphenyl)amino]carbonyl]amino]-1,4dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-95-4 CAPLUS
CN 1.4'-Bipiperidine, 1'-{(25)-4-{4-(1.4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1}-2-[{(3,4-dimethylphenyl)amino}carbonyi}amino]-1,4-dioxobuty1}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-92-1 CAPLUS
CN 1.4'-Bipiperidine, 1'-[[2S]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny])-1piperidiny1)-2-[[[(2,4-dimethoxypheny1)amino]carbony1]amino]-1,4dioxobuty1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-93-2 CAPLUS
CN 1.4\*-Blpiperidine, 1\*-[(2s)-2-[[[(2.4-difluorophenyl)amino]carbonyl)amino]-4-[(4-(1.4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1.4-dioxobutyl}-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 42

JP2004\_018717\_2.trn

RN 635711-96-5 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-2-[[[(3,5-dichlorophenyl)amino]carbonyl)amino]
4-[4-[1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]
(9Cl) (CA INDEX NAME)

Absolute stereochemistry.

N 635711-97-6 CAPLUS
N 1,4'-Bipiperidine, l'-[{25}-4-[4-{1,4-dihydro-2-oxo-3{2B}-quinaxolinyl}-1-piperidinyl}-1,4-dioxo-2-[{[{4-{trifluoromethyl}phenyl}amino]carbonyl}amino]btyl]- [9C1] (CA INDEX MAME)

RN 635711-98-7 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-2-[[(2,4-dichlorophenyl)amino]carbonyl]amino]4-[4-(1,4-dibydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl][9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 635711-99-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[{2S}-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-2-[[{4-(1-methylethyl)phenyl]amino}carbonyl]amino}-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 45

JP2004\_018717\_2.trn

RN 635712-02-6 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-4-[4-(1.4-dihydro-2-oxo-3(2B)-quinazolinyl)-1piperidinyl)-2-[[(3,5-dimethoxyphenyl)amino]carbonyl)amino]-1,4dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

83 635712-04-8 CAPLUS

1'-{(25)-2-[[[2-chloro-5-[trifluoromethy1]phenyl]amino | carbonyl]mino|-4-[4-[1,4-dihydro-2-oxo-3(28)-quinaxoliny1)-1- piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX MAME)

Absolute stereochemistry.

RN 635712-00-4 CAPLUS
CN 1.4'-Bipiperidine, 1'-[{25}-2-[{[(2,5-difluorophenyl)amino}carbonyl]amino}4-[4-(1,4-dihydro-2-oxo-3{2H}-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](9CI) (CA INDEX NAME)

Absolute stereochemistry

RN 635712-01-5 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-2-[[[(2,6-dichloro-4-pyridinyl)amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinasolinyl)-1-piperidinyl}-1.4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 46

JP2004\_018717\_2.trn

RN 635712-05-9 CAPLUS

CN 1.4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinaroliny1)-1-piperidiny1)-1,4-dioxo-2-[[[(2,3,4-trifluoropheny1)amino]carbony1]amino]buty1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry

RN 635712-08-2 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2B)-quinezoliny1)-1-piperidiny1]-2-[[(2-fluoropheny1) amino) carbony1] amino]-1,4-dioxobuty1]-(9C1) (CA INDEX NAMZ)

635712-09-3 CAPLUS
1,4'-Bipiperidine, 1'-[{25}-2-[[{2-chlorophenyl}amino}carbonyl]amino]-4[4-{1,4-dihydro-2-oxo-3(2H)-quinazolinyl}-1-piperidinyl}-1,4-dioxobutyl](9CI) (CA INDEX NAME)

635712-10-6 CAPLUS
1,4'-Bipiperidine, 1'-[{2\$}-2-{[[{2,5-dichlorophenyl}amino}carbonyl}amino}4-[4-(1,4-dihydro-2-oxo-3{2H})-quinatolinyl}-1-piperidinyl}-1,4-dioxobutyl](9C1) (CA INDEX NAME)

Absolute stereochemistry.

Page 49

JP2004\_018717\_2.trn

635712-13-9 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-2-[[(3-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2R)-quinazolinyl)-1-piperidinyl}-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-14-0 CAPLUS
1,4'-Bipiperidine, 1'-[{25}-4-[4-(1,4-dihydro-2-oxo-3(2B)-quinazoliny1)-1-piperidiny1]-2-[[(3-fluoropheny1)amino)carbony1]amino]-1,4-dioxobuty1]-(9CI) (CA INDEX NAME)

· Absolute stereochemistry.

635712-11-7 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2B)-quinazoliny1)-1-piperidiny1]-2-[[(2,5-dimethoxypheny1) amino]carbony1)amino)-1,4-dioxobuty1)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-12-8 CAPLUS
1.4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[[(2-ethoxypheny1) amino]carbony1]amino]-1,4-dioxobuty1]-(9CI) (CA INDEX NAME)

Page 50

JP2004\_018717\_2.trn

635712-15-1 CAPLUS
1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

635712-16-2 CAPLUS
1.4'-Bipiperidine. l'-[(2S)-2-[[(4-bromophenyl)amino]carbonyl]amino]-4-[4-(1.4-dibydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

N 635712-17-3 CAPLUS
N 1,4'-Bipiperidine, 1'-[{25}-4-]4-[1,4-dihydro-2-oxo-3{2H}-quinazoliny1}-1-piperidiny1}-2-[[{4-fluorophenyl}amino]carbony1}amino]-1,4-dioxobuty1}-(SCI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635712-19-5 CAPLUS

N 1,4'-Bipiperidine, 1'-[{25}-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(4-methoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 53

JP2004\_018717\_2.trn

RN 635712-23-1 CAPLUS

'CN 1,4'-Bipjeridine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[(2,4-dimethylpheny1)amino]carbony1]amino]-1,4-dioxobuty1)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635712-24-2 CAPLUS
CN 1.4'-Bipiperidine, 1'-[(25)-2-[[[(3-chloro-4-methylphenyl)amino]carbonyl]a
mino]-4-[4-(1.4-dihydro-2-oxo-3(2R)-quinazolinyl)-1-piperidinyl]-1.4dioxobutyl]-(9CI) (CA INDEX HAME)

Absolute stereochemistry.

JP2004\_018717\_2.trn

RN 635712-20-8 CAPLUS

Sensoic acid, 4-[[[(1s)-1-{[1,4'-bipiperidin}-1'-ylcarbonyl)-3-[4-{1,4-dihydro-2-oxo-3(2R)-quinazolinyl)-1-piperidinyl}-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635712-22-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(25)-2-[[[(2,5-difluorophenyl)amino]carbonyl)amino]4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl)(9C1) (CA INDEX NAME)

Absolute stereochemistry.

Page 54

JP2004\_018717\_2.trn

RN 635712-25-3 CAPLUS
CN 1,4'-Bipjeridine, 1'-[(25)-2-[[[(5-chloro-2-methoxyphenyl)amino]carbonyl]
amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 635712-26-4 CAPLUS
CM 1.4'-Bipiperidine, 1'-{{25}-2-{{[[{4-chloro-2-{trifluoromethyl}phenyl}amino}
|carbonyl|amino|-4-{4-{1,4-dibydro-2-oxo-3{2B}-quinasolinyl}-1piperidinyl]-1,4-dioxobutyl}- (9CI) (CA INDEX MAME)

RN 635712-27-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-[[(4-ethoxyphenyl)amino]carbonyljamino]-1,4-dioxobutyl]-(9CI) (CA INDEX NAME)

## Absolute stereochemistry.

RN 635712-28-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1}-2-[[(4-ethylpheny1)amino)carbony1]amino]-1,4-dioxobuty1]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 57

JP2004\_018717\_2.trn

RN 635712-31-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]a
mino]-4-[4-[1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4dioxobutyl]- (9C1) (CA INDEX NAME)

## Absolute stereochemistry.

RM 635712-32-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(25)-2-[[[(4-bromo-2-methylphenyl)amino]carbonyl)amino]-4-[4-(1,4-dihydro-2-oxo-3[(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

JP2004\_018717\_2.trn

RN 635712-29-7 CAPLUS
CN 1.4'-Bipiperidine. 1'-[(2S)-2-[[[(4-chloro-2-methylphenyl)amino|carbonyl]a
mino]-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4dioxobutyl)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

RN 635712-30-0 CAPLUS
CN 1,4'-Bipjperidine, 1'-[(2S)-2-[[[(3-chloro-2-methylphenyl)amino]carbonyl)a
mino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4dioxobutyl)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

Page 58

JP2004\_018717\_2.trn

RN 635712-33-3 CAPLUS
CN 1,4'-Bipliperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny])-2-[[([5-fluoro-2-methylpheny1)amino]carbony1)amino]-1,4-dioxobuty1]- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-{[[[(1s)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dibydro-2-cxx-3-[2B]-quinarolinyl)-1-piperidinyl]-3-oxopropyl)amino]carbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

635712-35-5 CAPLUS
1,4'-Bipiperidine, 1'-{{25}-2-{[{{1,1'-biphenyl}-2-ylamino}carbonyl}amino}-4-{4-(1,4-dihydro-2-oxo-3{2H})-quinazolinyl}-1-piperidinyl}-1,4-dioxobutyl}-(SC1) (CA INDEX NAME)

### Absolute stereochemistry

635712-38-8 CAPLUS
1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxo-2-[[(2-(trifluoromethoxy)phenyl)amino]carbonyl]aminobutyl)- (9Cl) (CA INDEX NAME)

JP2004 018717\_2.trn

ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STM 2002:6377 CAPLUS 136:69695 Preparation of β-lactam compounds as inhibitors of tryptase Bisacchi, Gregory S.; Sluserchyk, William A.; Treuner, Uwe; Sutton, James C.; Zahler, Robert; Seiler, Stewen; Kronenthal, David R.; Randazzo, Michael E.; Schwinden, Mark D.; Xu, Zhongmin; Shi, Zhongping Bristol-Hyers Squibb Co., USA U.S., 171 pp., Cont.-in-part of U. S. Ser. Number 336,253, abandoned. CODEN: USXXAM Patent English Cart 2 PATENT NO. KIND DATE APPLICATION NO. DATE

DT LA FAN

KIND

Absolute stereochemistry

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STR 2001:507689 CAPLUS

JP2004\_018717\_2.trn

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2003:76556 CAPLUS 138:131125 Fat accumulation-modulating compounds Stevenson, Michael John; Leighton, Harry Jefferson Adipoganix, Inc., USA PCT Int. Appl., 96 pp. CODEN: PIXXD2 Patent
 L4
AN
DN
TI
IN
PA
SO
 DŦ
                             Patent
 LA English
FAN.CNT'1
PATENT NO.
                                                                                                                                         KIND
                                                                                                                                                                              DATE
                                                                                                                                                                                                                                                  APPLICATION NO.
                                                                                                                                    A2 2
A3 2
A4, AT,
CZ, DE,
ID, IL,
LV, MA,
SD, SE,
YU, ZA,
LS, MN,
RU, TJ,
GR, IE,
GA, GR,
P 2
                                                                                                                                                                              20030130
20031127
                             WO 2003007888
WO 2003007888
                                                                                                                                                                                                                                                                                                                                                                                20020722
                                                                                                                                                                                                                                                    WO 2002-US23295
  PI
PI NO 2003007888 A2 200301317

Wi AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CB, CN, CO, CR, CL, CZ, DE, DK, DM, DZ, EC, EC, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, NM, MK, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, AZ, AM, ZW

RW: GB, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KX, ND, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NIL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GG, GM, ML, MR, NE, SN, TO, TG

US 2003144350 A1 20030731 US 2002-201588 20020722

OS MARRAT 138:131125

IT 491868-44-1 CAPLUS B101 (Biological study); USES (Uses) (fat accumunation—modulating compds.)

RN 491868-44-1 CAPLUS CN
```

Page 62

```
JP2004_018717_2.trn
```

-------

```
115:92860
Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders
Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander; Muller, Stephan Georg; Doods, Henris; Bauer, Eckhart
Boehringer Ingelheim Pharma K.-G., Germany
PCT int. Appl., 153 pp.
CODEN: PIXXD2
IN
DT Patent
LA German
FAN.CNT 1
                          PATENT NO.
                                                                                                                                KIND
                                                                                                                                                                   DATE
                                                                                                                                                                                                                                   APPLICATION NO.
                                                                                                                                                                                                                                                                                                                                                         DATE
                                                                                                                                                                                                                                    WO 2000-EP13236
                                                                                                                                                                                                                                                                                                                                                         20001222
                      WO 2001049676

W: AE, AG, AL,
CR, CU, CZ,
HU, ID, IL,
LV, AN,
SD, SE, SG,
YU, ZA, ZM,
RM: GR, GK, KE,
DE, DK, ES,
BJ, CF, CG,
DE 19963868
CA 2395541
BR 2000017063
EP 1252153
R: AT BE, CR
                                                                                                                                    Al
                                                                                                                                                                   20010712
                           WO 2001049676
                                                                                                                           A1 20010712 MO 2000-EP13236 20001222

AM, AT, AU, AZ, BA, BB, BB, BR, BY, BZ, CA, CH, CM, DE, DK, DM, DI, EE, ES, FI, GB, GD, GE, GH, GM, HR, MN, HS, HZ, MC, HZ, LC, LK, LR, LS, LT, MD, HG, HK, MN, HM, HK, HZ, NO, NZ, FL, FT, RO, RU, SI, SK, SL, TJ, TM, TR, TT, TI, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, LS, MM, MZ, BS, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, EFI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CI, CM, GA, GN, GW, MM, MR, NE, SN, TD, TG
A1 20010712 CA 2000-2395541 20001222

A1 20021022 BR 2000-17063 20001222

A1 20021023 BR 2000-17063 20001222

A1 20021023 BR 2000-17063 20001222

DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SS, MC, FT,
                                          1252153 A1
R: AT, BE, CH, DE, DK,
IE, SI, LT, LV, FI,
2003519222 T2
                                                                                                                                                                    20021030

ES, FR,

RO, MK,

20030617

20031015

20021229

20030930

20020628

20031113

19991230

20001222
                                                                                                                                                                                                                  EP 2000-991806
GB, GR, IT, LI, LU,
CY, AL, TR
JP 2001-50216
EE 2002-369
BG 2002-106848
2A 2002-5181
NO 2002-3161
US 2002-169009
                           JP 2003519222
EE 200200369
BG 106848
ZA 2002005181
NO 2002003161
US 2003212057
DE 1999-19963868
NO 2000-EP13236
MARPAT 135:92860
349535-73-59
                                                                                                                                                                                                                                                                                                                                                           20001222
20020620
20020627
   PRAI
                                                                                                                                                                      20001222
```

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of piperidine-substituted amino-acids for use in treatment of

CGRP-mediated disorders)
349535-73-5 CAPLUS
Piperidine, 1-(4-(4-amino-3.5-dibromophenyl)-1,4-dioxo-2-{[(2-pyridinylamino)carbonyl]amino]butyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiszepin-3-yl)- (9CI) (CA INDEX NAM2)

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT RE.CNT

```
ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 2000:133714 CAPLUS 132:180871 Preparation of hepatitis C inhibitory tripeptides Linas-Brunet, Montoe; Bailey, Murray D.; Cameron, Dale; Faucher, Anne-Marie; Ghiro, Elias; Goudreau, Nathalie; Halmos, Teddy; Poupart, Marc-Andre; Rancourt, Jean; Tsantrizos, Youla S.; Wernic, Dominik M.; Simpneau, Bruno
                  Simoneau, Bruno
Boehringer Ingelheim (Canada) Ltd., Can.
PCT Int. Appl., 168 pp.
CODEN: PIXXD2
PA
SO
                   Patent
English
```

FAN.	CNT 1													
		NO.		D DATE	:					10.			ATE	
PÍ	WO 2000	009543	A2	2000		W							990	109
	N:			AU, AZ, FI, GB,										
		JP, KE,	KG, KP,	KR, K2,	LC,	LK,	LR,	LS,	LT,	LU.	LV,	HD,	MG,	MK.
		TM, TR,	TT, UA,	NZ, PL, UG, US,										
	RW:		TJ, TM KE, LS,	MW, SD,	SL,	SZ,	UG ,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,
				GR, IE, GW, ML.						SE,	BF,	BJ,	CF.	CG,
	US 6323		В1		1127					56		19	990	805
		946	A.P	2000	0224									
	CA 2445	938	A.A	2000	0224	С	A 19	99-2	445	38		1	990	809
				2000			U 19	99-5	273	ι		1	990	309
	AU 7697			2004										
	BR 9913			2001										
	EP 1105		λ2		0613									
	R:			DK, ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PI,
			LT, LV,											
		00432			0921									
				2002										
	JP 2002	522554	. 72	2002	0723	J	P 20	00-5	6499	93				
	EE 2001	00081	A	2002	0815	Ε	E 20	01-6	11			15	990	309

Page 65

## JP2004\_018717\_2.trn

L4	ANSWER 8 OF	13 CAPLUS	COPYRIGHT	2005	ACS	on STN	
AN	1997:542334	CAPLUS					

DN TI

1997:54234 CAPLUS
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:223293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:233293
127:23329
127:23329
127:23329
127:23329
127:23329
127:23329
127:23329

18 PA

so

DT LA

	PATE	77	ю.										NOI1				ATE	
PΙ																		
	1	#:	AL,	AU,	BA,	BB,	BG,	BR.	CA,	CN,	CU	, cz	EE.	GE,	HU,	IL.	15,	JP,
			KP.	KR,	LC.	LK.	LR.	LT,	LV.	MG,	MK	, MIN	, MX,	NO.	NZ,	PL,	RO,	SG,
			SI,	SK.	TR,	II.	UA,	US,	UZ,	VN,	YU	. AM	AZ,	BY,	KG.	KZ,	MD,	RÜ,
			TJ,	TM														
		ROM :	KE,	LS.	MW.	SD.	SZ,	VG.	AT.	BE.	CH	. DE	DK,	ES.	FI.	FR.	GB,	GR,
			IE.	IT.	LU.	MC.	NL.	PT.	SE.	BF.	BJ	CF	. CG.	CI.	CH.	GA.	GN.	HL.
						TD.						•						
	FR 2	744						1997	8080		FR	1996	-1482			1:	9960	207
	FR 2	744	162			B1		1998	0227									
	AU 9										RΩ	1997	-1727	3		11	9970	203
PRAI	FR 1													•				
	WO 1							1997										
os	MARP					-			0203									
IT	1751					44-0	105	.002_	46-1									
	1950					••••		- 200										
						act												

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Uses)
(pharmaceutical compns. containing pyrrolidine derivs. for treatment of drug abose)
175153-959-4 CAPLUS
Prolins, 1-[H-{[(3-carboxypheny]) amino]carbonyl]qlycyl]-5-{2-fluorophenyl}-4-(4-morpholinylsulfonyl)-, 2-(1,1-dimethylethyl) ester,
(2a, 4β.5a)- (9CI) (CA INDEX NAME).

Relative stereochemistry.

JP2004\_018717\_2.trn

	NZ 510396	A	20040227	NZ 1999-510396	19990809
	US 6268207	B1	20010731	US 2000-660030	20000912
	US 6329379	B1	20011211	US 2000-675398	20000929
	US 6329417	Bl	20011211	US 2000-703751	20001101
	BG 105232	λ	20011130	BG 2001-105232	20010208
	HR 2001000102	A1	20020228	HR 2001-102	20010208
	NO 2001000683	λ	20010402	NO 2001-683	20010209
	US 2002016442	A1	20020207	US 2001-827976	20010406
	US 6420380	B2	20020716		
	US 2002037998	A1	20020328	US 2001-849057	20010504
	US 6410531	B2	20020625		*******
	US 6534523	B1	20030318	US 2002-91293	20020305
PRAI	US 1998-95931P	P	19980810		
	US 1999-132386	P P	19990504		
	US 1998-132386	P P	19980810		
	US 1999-368866	A3	19990805		•
	CA 1999-233894	6 A3	19990809		
	WO 1999-CA736	w	19990809		
	US 2001-849057	A1	20010504		
os	MARPAT 132:180	871			

MARRAT 132:180871

Z59216-26-7P Z59216-43-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Usea) (preparation of hepatitis C inhibitory tripeptides)

Z59216-26-7 CAPLUS

Cyclopropanecarboxylic acid, 3-methyl-N-{ (phenylamino) carbonyl]-L-valyl-(4R)-4-(17-methoxy-2-phenyl-4-quinolinyl) oxyl-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

259216-43-8 CAPLUS
Cyclopropanecarboxylic acid, N-[[(2,6-dimethylphenyl)amino]carbonyl}-3methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1amino-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

## JP2004\_018717\_2.trn

195002-44-9 CAPLUS Benzoic acid.  $3-[[[2-[5-[(3,3-dimethyl-1-piperidinyl)carbonyl]-2-(2-fluorophenyl)-3-(phenylsulfonyl)-1-pyrrolidinyl)-2-oxoethyl]amino]carbonyl]amino}-, <math>(2\alpha,3\beta,5\alpha)-(9CI)$  (CA INDEX NAME)

Relative stereochemistry.

195002-46-1 CAPLUS
D-Proline, N-{[(3-carboxyphenyl)amino}carbonyl]glycyl-5-phenyl-4-{l-pyrrolidinylcarbonyl}-, 2-{l,l-dimethylethyl} ester, (45.55)-rel- (9CI) (CA INDEX MARE)

Relative stereochemistry.

195002-52-9 CAPLUS
D-Proline, N-[([3-carboxyphenyl)amino]carbonyl]glycyl-5-(2-fluorophenyl)-4-(4-morpholinylcarbonyl)-, 2-(1,1-dimethylethyl) ester, (4S,5S)-rel- (9CI) (CA INDEX NAME)

### Relative stereochemistry.

IN PA SO

ANSMER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
1996:211766 CAPLUS
124:250823
Preparation of pyrrolidine derivatives as cholecystokinin and gastrin
receptor ligands
Capet, Marc; Dubroeucq, Marie-Christine
Rhone-Foulenc Rorer S.A., Fr.
PCT Int. Appl., 77 pp.
CODEN: PIXXD2
PATENT NO. KIND DATE APPLICATION NO. DATE NO 9535310 Al 19951228 NO 1995-PR796 1995061 N: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU,

## Page 69

## JP2004\_018717\_2.trn

175154-29-7P 175154-31-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidine derivs. as cholecystokinin and gastrin

receptor

ptor ligands) 175154-29-7 CAPLUS Prolime, 5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-1-[N-[[[3-[(phenylmethoxy)carbonyl]phenyl)amino[carbonyl]glycyl]-, 1,1-dimethylethyl ester, (2a,4ß,5a)- (9CI) (CA INDEX NAME)

## Relative stereochemistry.

## 175154-31-1 CAPLUS

## JP2004\_018717\_2.trn

SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN
RM: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IZ, IT,
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, ME,
SN, TD, TG FR 2721314 A1 1996.
FR 2721314 B1 19960719
AU 9527966 A1 19960115 AU 1995-2796
EP 766695 A1 19970409 EP 1995-923397
EP 766695 B1 19980722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, JP 105018020 T2 19980217 JP 1995-501747
AT 168697 E 19980815 AT 1995-923397
AT 19454 T3 19981001 ES 1995-923397
A 19960209 2A 1995-5052
19980210 US 1996-750653 19940620 . PT, SE 19950616 19950616 19950616 ES 2119454 T3 19981001 ES 1995-923397 19950616

LA 9505052 A 19960209 ZA 1995-5052 19950619

US 5716936 A 19980210 US 1996-750653 19950619

WO 1995-FR796 A 19980210

WO 1995-FR796 W 19950616

OS MARPAT 124:260823 W 19950616

FAL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidine derivs. as cholecystokinin and gastrin receptor)

ptor
ligands)
175153-95-4 CAPLUS
Proline, 1-[N-[[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(2-fluorophenyl)4-(4-morpholinylaulfonyl)-, 2-(1,1-dimethylethyl) ester,
(2a,4β,5a)- (9Cl) (CA INDEX NAME)

175153-96-5 CAPLUS Prolinamide, N-[[(3-carboxyphenyl)amino]carbonyl]glycyl-N-(3,3-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-,  $(2\alpha,4\beta,5\alpha)$ - (9CI) (CA INDEX NAME)

## Page 70

## JP2004\_018717\_2.trn

Prolinamide, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-N-(3,3-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-,  $(2\alpha,4\beta,5\alpha)$ - (9CI) (CA INDEX NAME)

ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS On STN 1994:217658 CAPLUS 120:217658

L4 An Dn Tj

120:217658

Preparation and formulation of 2- aryl-3-(ureidoacetyl)thiazolidine-4-carboxylates and snalogs as CCK receptor and gastrin receptor ligands Capet, Marc: Cotrel. Claude; Guyon, Claude; Joannic, Hichel; Manfre, Franco; Roussel, Gerard; Dubroeucq, Marie Christine; Cheve, Michel; Dutruc-Rosset, Gilles Rhone-Poulenc Rorer SA, Fr. PCT Int. Appl., 186 pp.

COGEN: PIXXD2

Patent
French

PA SO

FAN.	.CNT 1		
	PATENT NO.	KIND DATE	APPLICATION NO. DATE
PI	WO 9301167 W: AU, CA, CS, RW: AT, BE, CH.	FI, HU, JP, KR,	MO 1992-FR626 19920703 MO, PL, RU, US GB, GR, IT, LU, MC, NL, SE
	FR 2678938 FR 2678938	A1 19930115 B1 19931008	FR 1991-8675 19910710
	EP 527069 R: PT AU 9223275	A1 19930210	
	AU 662345 EP 593639	A1 19930211 B2 19950831 A1 19940427	AU 1992-23275 19920703
	EP 593639	B1 19950405	EP 1992-915456 19920703 GB, GR, IT, LI, LU, NL, SE
	JP 06509331 JP 3034043	72 19941020 B2 20000417	JP 1992-502018 19920703
	AT 120732	E 19950415	AT 1992-915456 19920703

	ES 2071510	Т3	19950616	ES 1992-915456	19920703
	HU 70403	A2	19951030	HU 1994-61	19920703
	PL 171054	B1	19970228	PL 1992-313380	19920703
	PL 171094	Bl	19970328	PL 1992-313379	19920703
	PL 171112	В1	19970328	PL 1992-313381	19920703
	PL 171095	B1	19970328	PL 1992-313382	19920703
	PL 171333	B1	19970430	PL 1992-302029	19920703
	CZ 283602	B6	19980513	CZ 1994-49	19920703
	RU 2118316	Cl	19980827	RU 1994-15258	19920703
	CA 2102697	C	20030930	CA 1992-2102697	19920703
	ZA 9205128	Ā	19930428	ZA 1992-5128	19920709
	NO 9304300	A	19931126	NO 1993-4300	19931126
	NO 180166	В	19961118		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	NO 180166	č	19970226		
	FI 105190	B1	20000630	FI 1994-72	19940107
	US 5610144	A	19970311	US 1994-175381	19940627
PRAI	FR 1991-8675	Ä	19910710		13340027
	WO 1992-FR626	Ä	19920703		
05	MARPAT 120:217658		-22-0703		

OS IT

## Absolute stereochemistry.

153243-31-3 CAPLUS L-Proline, 5-[lH-indol-3-yl]-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, cis- [5Cl] (CAINDEX NAME)

## Absolute stereochemistry.

### Page 73

# JP2004\_018717\_2.trn .

IT

## Absolute stereochemistry

153241-76-0 CAPLUS
Ouinoline, 1.2,3.4-tetrahydro-1-[[1-{[[[(3-methylphenyl)amino]carbonyl]amino]acetyl]-5-phenyl-2-pyrrolidinyl)carbonyl]-, cis- (9CI) (CA INDEX HAME)

## Relative stereochemistry.

153241-77-1 CAPLUS
Piperidine, 3,3-dimethyl-1-[{1-[{[[[3-methylphenyl]amino]carbonyl]amino]acetyl]-5-phenyl-2-pyrrolidinyl)carbonyl}-, cis- (9CI) (CA INDEX HAME)

Relative stereochemistry.

153243-32-4 CAPLUS L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsily1)ethoxy]carbonyl]phenyl]mino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, trans- [9CI] (CA INDEX NAME)

### Absolute stereochemistry.

153244-03-2 CAPLUS
D-Proline, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-5(2-pyridinyl)-, 1,1-dimethylethyl ester, (58)-rel- (9CI) (CA INDEX NAME)

## Relative stereochemistry.

## Page 74

## JP2004\_018717\_2.trn

153241-89-5 CAPLUS L-Proline, 1-[N-[[(3-carboxyphenyl)amino]carbonyl)glycyl]-5-(1E-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, cis- (9CI) (CA INDEX NAME)

# Absolute stereochemistry.

153241-90-8 CAPLUS L-Proline, 1-[N-[[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, trans- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

153242-19-4 CAPLUS

### Relative stereochemistry.

ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1992:256054 CAPLUS 116:256054 CAPLUS 116:256054 CAPLUS 116:256054 Captus Preparation of peptide-linked 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles and related compounds as inhibitors of cholecystokinin and gastrin Molino, Bruce F.; Darkes, Paul R.; Ewing, William R. Rozer International (Holdings), Inc., USA PCT Int. Appl., 94 pp. CODEN: PIXXD2

IN PA SO

Patent English

FAN.	CNT 1		
	PATENT NO.	KIND DATE APPLICATION NO.	DATE
PI	WO 9200295	Al 19920109 WO 1991-US4236	19910613
	W: AU, CA, JP,	OS	
	RW: AT, BE, CH,	DE, DK, ES, FR, GB, GR, IT, LU, NL, SE	
	US 5162336	A 19921110 US 1990-573514	19900824
	CA 2068887	AA 19911222 CA 1991-2068887	19910613
	AU 9186116 .	Al 19920123 AU 1991-86116	19910613
	AU 640277	B2 19930819	
	EP 491943	Al 19920701 EP 1991-916717	19910613
	R: AT, BE, CH,	DE, DK, ES, FR, GB, GR, IT, LI, LU, NL,	SE
PRAI	US 1990-542495	A 19900621	
	US 1990-573514	A2 19900824	
	WO 1991-US4236	A 19910613	
~~	**********		

WO 1991-US4236 A 19910613
MARRAT 116:226054
133985-57-2P 139985-59-4P 139985-60-7P
139986-68-B 139986-28-0P 140148-72-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); a cholecystokinin and gastrin antagonist)
139985-57-2 CAPLUS
3-Plperidinecarboxylic acid, 1-[[1-{[2-[[3,4-dichlorophenyl] maino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]- (SCI) (CA INDEX NAME)

Page 77

JP2004\_018717\_2.trn

139986-26-8 CAPLUS L-Proline,  $1-\{1-\{\{2-\{\{(3,4-dichlorophenyl\}amino\}carbonyl\}-2,3,4,9-tetrahydro-18-pyrido[3,4-b]indol-3-yl\}carbonyl]-L-prolyl]-, (R)- (9CI) (CA INDEX NAME)$ 

139986-28-0 CAPLOS
3.4-Pyrrolidinedicarboxylic acid, 1-[[1-[[2-[[3.4-dichlorophenyl)amino]carbonyl]-2.3.4.9-terrahydro-18-pyrido[3.4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

JP2004\_018717\_2.trn

139985-59-4 CAPLUS
3-Eyrrolidinecarboxylic acid, 1-[[1-[{2-[{3,4-dichlorophenyl}amino|carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yllcarbonyl]-2-pyrrolidinyl|carbonyl)-, [3s-[3R\*[R\*(S\*)]]]- (9CI) (CA INDEX NAME)

139985-60-7 CAPLUS
2-Pyrroliddineacetic acid, 1-[[1-[[2-[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indo[-3-yl]carbonyl]-2pyrroliddinyl]carbonyl]-; [3R-[3R\*[S\*(S\*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 7B

JP2004\_018717\_2.trn

140148-72-7 CAPLUS
3-Pyrrolidinecarboxylic acid, 1-[[1-[[2-[[3,4-dichlorophenyl)amino|carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, [3R-[3R\*[S\*(R\*)]]]- (9CI) (CA

139986-13-3 CAPLUS
3-Pyrrolidinecarboxylic acid, 1-[[1-[[2-[[(3,4-dichlorophenyl)]amino]carbonyl]-2-3,4.9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl](acrbonyl]-, phenylmethyl ester,
[3R-[3R\*[S\*(S\*)]]- (9CI) (CA INDEX NAME)

ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
1988:570130 CAPLUS
109:170130
Preparation and formulation of novel mitomycin derivatives as antitumor agents
Muto, Kenji; Kuroda, Tokuyuki; Morimoto, Makoto
Kyowa Hakko Kogyo Co., Ltd., Japan
Japan Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
Patent
Japanese
CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

.....

DÎ LA Fan

PI JP 63035575 A2 19880216 JF 1986-181012 19860731
PRAI JP 1986-181012 19860731
S MARPAT 109:170130
IT 116939-80-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

Page 81

JP2004\_018717\_2.trn

103126-82-5 CAPLUS L-Proline, 1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, compound with L-arginine (9CI) (CA INDEX NAME)

CN 1

CRN 103126-81-4 CMF C20 H26 N4 O5

Absolute stereochemistry.

CH 2

CRN 74-79-3 CMF C6 E14 N4 O2

Absolute stereochemistry.

=> LOG Y COST IN JAPANESE YEN

SINCE FILE ENTRY TOTAL SESSION JP2004\_018717\_2.trn

study); PREP (Preparation)
(preparation of, as antitumor agent)
16593-80-1 CAPLUS
Axirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8([(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl1-1-1(-N-((phenylamino)carbonyl)-L-alanyl]-L-prolyl]-. (la5(laa,8,8aa,8ba)]- (9CI) (CA INDEX NAME)

ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN 1986:443340 CAPLUS 105:43340

L4 AN DN TI IN PA SO 105:43340
Tripeptide derivatives for use as antihypertensive agents
Eguchi, Chikahiko; Kurauchi, Masahiko; Sakakibara, Shumpei
Ajinomoto Co., Inc., Japan
Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW

Patent English

FAN	PATENT NO.	RIND	DATE	APPLICATION NO.	DATE
PI	EP 173510	A2	19860305	EP 1985-305727	19850813
	EP 173510	A3	19870916		1,050015
	R: CH, DE, FR,	GB, 11	, LI		
	JP 61053298	A2	19860317	JP 1984-176355	19840824
	JP 06055758	B4	19940727		
	US 4719200	A	19880112	US 1985-769029 ·	19850826
	I JP 1984-176355	A	19840824	•	

103126-81-4P 103126-82-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antihypertensive)
103126-81-4 CAPLUS
L-Proline, 1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

JP2004\_018717 2.trn FULL ESTIMATED COST

5895 5996

STN INTERNATIONAL LOGOFF AT 11:05:17 ON 09 FEB 2005

Host Name: +++ OK

JP2004 018717\_2.trn で七叶叶化合物

hialing COMPUSERVE at 0070670488888

CONNECT 45333

Connecting through CompuServe

0019TEA

Host Name: STNT

Connected to 0004 CAA 0

Welcome to STN International! Enter x:x LOGINID:TKYBAJ74

TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2


Item Date Headline

STN, CAS FILES Workshop Schedule in Japan
KOREAPAT now available on STN
CUrrent-awareness elerts, saved answer sets, and
current search transcripts to be affected by CERAB,
COMPORAB, ELCOM, and SOLIDSTATE reloads
November 22, 2004 LISA new on STN
PHAR reloaded with additional data
12 databases to be removed from STN on 31, Dec., 2004
MEDLINE update schedule for December 2004
ELCOM reloaded; updating to resume; current-awareness
alerts(SDIs) affected
COMPURB reloaded; updating to resume;
CUrrent-awareness alerts(SDIs) affected
SOLIDSTATE reloaded; updating to resume;
CUrrent-awareness alerts(SDIs) affected
CERAB reloaded; updating to resume; current-awareness
alerts(SDIs)s affected'
Three new fields added to IFIPAT/IFIUDB/IFICDB
EFFULL:New patent full text database to be available
on STN
CAPLUS - PATENT COVERAGE EXPANDED NEWS 1 2 3 Oct 26 Nov 19 Nov 22 Dec 1 Dec 15 Dec 17 Dec 20 9 Dec 20 NEWS NEWS 10 Dec 20 NEWS 11 Dec 20 NEWS 12 Dec 20 NEWS 13 Dec 27 on STN
CAPLUS - PATENT COVERAGE EXPANDED
No connect-hour charges in EPFULL during January and
February 2005
Urgent announcement to STN customers accessing via
phone line WorldCom access points were changed
CA/CAPLUS - Expanded patent coverage to include the
Russian Agency for Patents and Trademarks (ROSPATENT) NEWS 14 Dec 31 NEWS 15 Jan 1 NEWS 16 Jan 5 NEWS 17 Jan 12 SIN operating Hours SIN Righ Speed Access via Worldcom INTERNET ACCSESS to SINT(SIN-Tokyo) NEWS HOURS NEWS WORLDCOM NEWS INTER

Page 1

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{2.3-dihydro-2-oxo-1B-benzimidazol-1-y1}-1-{{ethyl{|{4-ethylphenyl}amino|carbonyl}amino|acetyl}- (9C1) C25 H31 N5 O3

JP2004\_018717\_2.trn

STN Express 7.0 with Discover!

(Windows) Now available! STN Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:59:13 ON 08 FEB 2005

SINCE FILE TOTAL ENTRY

FULL ESTIMATED COST

SESSION 36

FILE 'REGISTRY' ENTERED AT 13:59:35 ON 08 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS) CHARGED TO COST-4PRD

Property values tagged with IC are from the SIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-DICTIONARY FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROF at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/ragistryss.html

=> ACT RD018717/A

L2 L3

STR

-> D SCAN

C34 H43 C12 N7 O4

MF

Absolute stereochemistry

Page 2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

REGISTRY COPYRIGHT 2005 ACS on STN
1-{2-{{|{2,4-difluorophenyl}amino}carbonyl}amino}-3-methyl-1-[3-(trifluoromethyl)-2-pyridinyl)- {9CI}

F5 N5 02

\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS Piperidine,

ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN ridine, 4-(18-benzimidazol-2-yl)-1-[3-[[[(3-ophenyl)amino]carbonyl)cyclohexylamino]-1-oxopropyl]- (9CI) bromophenyl)amin C28 H34 Br N5 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STB Piperidine, 4-{1R-benzimidazoi-2-yl}-1-{(2S)-3-methyl-2-{[[(2-methylphenyl)amino|carbonyl]amino]-1-oxobutyl]- (9C1) C25 H31 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[(4methylphenyl)amino)carbonyl](2-methylpropyl)amino)-1-oxopropyl)- (9CI)
C27 H35 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 3-Piperidinecarboxylic acid, 1-[[1-[[2-[[(],4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-lH-pyrido[3,4-b]indol-3-yl[carbonyl]-2-pyrrolidinyl]carbonyl]-, phenylmethyl ester (9CI) C37 H37 C12 N5 O5

Page 5


JP2004\_018717\_2.trn

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperazine, 1-[2-[[[(3-methoxyphenyl)amino]carbonyl] oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl)- [9CI) C23 H28 F3 N5 O3 nyl]amino]-3-methyl-1-

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[cyclohexyl[[(2,6-dimethylphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI) C30 H39 N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 AMSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimidazol-2-yl)-1-[3-[[[(3-chlorophenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl)- (9C1) C30 H32 C1 N5 O2

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1.4'-Bipiperidine, 1'-[(2S)-2-[[(2,6-dichloro-4pyridinyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)quinaxolinyl)-1-piperidinyl)-1.4-dioxobutyl}- (9CI)
C33 B42 C12 N8 04

Absolute stereochemistry.

\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidszol-1-yl)-1-[[(2-methylpropyl)[[(2-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]-

(9CI) C26 H30 F3 N5 O3

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dlhydro-2-oxo-1H-benzimidazol-1-y1)-1-[{ethyl[[{2-methylphenyl}amino}carbonyl]amino}acetyl]- (9CI)

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2.4-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl)- (9CI) C26 H31 C12 NS 02

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 4-Thiazolidinecarboxylic acid, 3-[{[[(3-carboxyphenyl)amino]carbonyl]am. | lacetyl]-2-(3-pyridinyl)-, 4-(1,1-dimethylethyl) ester, (2R-cis)- (9CI) C23 B26 N4 O6 S

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSHERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[{2,4-dichlorophenyl)amino|carbonyl]{2-methylpropyl)amino|acetyll\_n4-12\_3-dihydro-2-oxo-1H-benzimidazol-1-yl}-(9CI)
C25 H29 C12\*N5 O3 L3 IN


PROPERTY DATA AVAILABLE IN THE PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[(2,3-dichlorophenyl)amino]carbonyl]propylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- [9CI) C24 H27 C12 N5 O3 L3 IN

Page 9

\*PROPERTY DATA AVAILABLE THE THE PROP. FORMAT.

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benrimidazol-2-y1)-1-[3-[[[(2-methoxyphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl)- (9CI) C27 H35 M5 O3



\*\*PROPERTY DATA AVAIDABLE IN THE PROP FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN D-Proline, N-[[(3-carboxyphenyl)amino]carbonyl]glycyl-5-(2-pyridinyl)-, 22-(1,1-dimethylethyl) ester, (55)-rel- (9C1) C24 H28 M4 O6

Relative stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


JP2004\_018717\_2.trn

PROPERTY EDATA AVAILABLE IN THE PROPERTORNAL

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[methyl[(phenylamino)carbonyl]aminolacetyl]- (9CI) C22 H25 NS C3

PROPERTY DATAS AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl[[(4-mathoxyphenyl)amino|carbonyl)amino]-1-oxopropyl)- (9CI) C29 H37 N5 O3



\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(l#-benzimidazol-2-yl)-1-(3-[[(4bromophenyl)amino]carbonyl](l-phenylethyl)amino]-1-oxopropyl}- (9CI)
C30 H32 Br N5 O2

Page 10


JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-piperidinyl]-2-[[[(3-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-(9C1) C34 H44 F N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 AMSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{2,3-dihydro-2-oxo-1H-benrimidazol-1-yl}-1-[[[[{4-ethylphenyl}]amino]carbonyl][2-eethylpropyl)amino]acetyl]- [9CI] C27 E35 N5 O3



PROPERTY DATE AVAILABLE IN THE PROP FORMAT.

349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2-oxb-xyphenyl)amino]carbonyl]propylamino]acetyl]- (9CI) C25 H31 M5 O4

PROPLE FORMATO \*PROPERTY DATA-AVAILABLE IN THE

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[methyl[[[2-trifluoromethyl]phenyl]mino]carbonyl]mino]acetyl]- (9CI) C23 H24 F3 M5-03

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-benzoxazoly)-1-(3-[[(3-chlorophenyl)amino]carbonyl] (1c25 829 Cl N 03 L3 IN

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2-methylphenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI) C31 B35 N5 O2


JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Benzoic acid, 4-[[[(1S)-1-([1,4-bipiperidin]-1-y]carbonyl)-3-[4-(1,4-dihydro-2-cno-3(2H)-quinacolinyl)-1-plaeridinyl]-3-oxopropyl]amino|carbonyl)amino|-, ethyl ester (9CI) C37 H49 N7 O6

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dthydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2-methylphenyl)amino)acetyl)- (9CI) C26 H33 N5 03



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 1-[|butylf|[3-(trifluoromethyl)phenyl)amino}carbonyl)amino}ace tyl]-4-(2,3-dihydro-2-oxo-1H-benrimidaro1-1-yl)- (9C1) C26 B30 F3 N5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidezol-2-yl)-1-[3-[(2-methylpropyl)][[(4-(trifluoromethyl)phenyl]amino]carbonyl)amino]-1-oxopropyl]- (9CI) C27 H32 F3 N5 O2



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Proline, 1-(N-[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, 2-(1,1-dimethylethyl) ester, (2c,46,5a)- (9CI) (2c9 H35 F N4 09 S

Relative stereochemistry.

JP2004\_018717\_2.trn


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Page 14

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1={([[2,4-dich]orophenyl]amino]carbonyl]methylamino}acetyl}-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) L3 IN

PROPERTY DATA AVAILABLE IN THE 'PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazoly1)-1-[3-[[[(2,4-dichlorophenyl)amino]carbonyl](1-methylethyl)amino]-1-oxopropyl]- (9CI) C25 H28 C12 N4 O3



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2,4-dichlorophenyl)amino]carbonyl](1-methylethyl)amino]-1-exopropyl]- (9CI) C25 H29 C12 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-[[[(4-nitrophenyl)amino)carbonyl]propylamino)-1-oxopropyl]- (9CI) C25 H30 N6 O4

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN D-Proline, N-[([(3-carboxyphenyl)amino]carbonyl)glycyl-5-phenyl-4-(1-pyrrolidinylcarbonyl)-, 2-(1,1-dimethylethyl) ester, (45,55)-rel- (9CI) C30 H36 N4 O7

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
1,4'-Bipiperidine, 1'-[(25)-2-([(4-chloro-2-(trifluoromethy1)phenyl]amino
|carbonyl]amino|-4-(4-(1,4-di)ydro-2-oxo-3(2H)-quinazolinyl)-1-


Page 17

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[(2-bromophenyl)amino]carbonyl]butylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
C25 H30 Br M5 O3

PROPERTY DATA AVAILABLE IN THE PROP FORMAT.

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{2.3-dihydro-2-oxo-1H-benzimidazol-1-yl}-1-{{{{4-ethylphenyl}amino}carbonyl}methylamino}acetyl}- (9CI) C24 H29 N5 O3



JP2004\_018717\_2.trn

piperidinyl)-1,4-dioxobutyl)- (9CI) C35 H43 C1 F3 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-{(25)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-1,4-dioxo-2-{[[(2,4,5-trimethylpheny1)amino|carbony1]amino]buty1]- (9C1) C37 H51 N7 O4

Absolute stereochemistry.

Page 18

JP2004\_018717\_2.trn


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazolyl)-1-[3-[(1-methylethyl)[[(2-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI) C26 H32 N4 O3

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzokarolyl)-1-[3-[cyclohexyl[[(3-methylphenyl]amino]-1-oxopropyl]- (9CI) C29 H36 N4-03

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimidazol-2-yl)-1-{3-[[[3-cyanophenyl)amino]carbonyl]propylamino]-1-oxopropyl]- (9CI) C26 H30 N6 O2

-- - --



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..


349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
1,4'-Bipiperidine, 1'-[(25)-2-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
C34 H43 Cl F N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(2S)-2-[[([1,1'-biphenyl]-4-ylemino)carbonyl]amino]-

Page 21



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazoly))-1-[3-[buty][[[3-(trifluoromethyl)]phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) C27 H31 F3 N4 (3)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-benioxaiolyl)-1-[3-[[([2,6-bis(1-methylethyl)phenyl)sminolcarbonyl)cyclohexylaminol-1-oxopropyl)- (9CI)
C34 R46 N4 03

\* PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benrimidazol-2-y1)-1-[3-[[[(4-methoxyphenyllamino|carbonyl]propylamino|-1-oxopropyl)- (9CI) C26 H33 M5 03

JP2004\_018717\_2.trn

4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl] (9CI) C40 H49 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROF' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-14f(77f6-bfs/tz-methylethyl)phenyl)amino)carbonyl|butylamino)acetyl)-4-(7,3-dihydro-2-oxo-1H-ben7tamidazol-1-yl)- (9CI)
C31 H47 N5 O3

\*PROPERTY DATA AVAILABLE TH THE PROP

349 ANSMERS REGISTRY \*\*COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-lH-benzimidazol-1-yl)-1-[{methyl{{(2-methylphenyl)amino|carbonyl]amino|acetyl}- (9Cl)}

Page 22

JP2004\_018717\_2.trn

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT.

349 AMSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidezol-2-yl)-1-[3-[butyl][[(2,3-dichlorophenyl)amino]-izoxopropyl]- (9CI) C26 H31 C12-N5-02

D. PROPERTY DATA AVAILABLE IN THE PROPERFORMAT.

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM 1.4'-Bipiperidine, 1'-[(2S)-4-14-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2-(trifluoromethoxy)phenyl]amino]carbonyl]aminolbutyl]- (9CI)
C35 B44 F3 N7 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(25)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[[(3-methoxypheny1)amino]carbony1]amino]-1,4-dioxobuty1]-(9CI)
C35 H47 N7 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 AMSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[butyl][[4-(1-methylethyl)phenyl]amino]carbonyl]amino]acety

Page 25

JP2004 018717 2.trn

\*\*PROPERTY\_DATA\_AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1R-benzimidazol-2-yl)-1-[(25)-2-[[[(3-bromophenyl)amino]carbonyl)amino]-3-methyl-1-oxobutyl]- (9CI) C24 H28 Br N5 O2

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1R-benzimidszol-2-yl)-1-(3-[butyl[[(4-methoxyphenyl)amino]-1-oxopropyl]-(9CI) C27 HJ5 N5 03

\*\* PROPERTY COATA AVAILABLE IN THE 'PROP' FORMAT ..

JP2004\_018717\_2.trn


1]-4-(2,3-dihydro-2-0xo-1H-benzimTdazol-1-y1)- (9CI) C28 H37, N5\*03

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperiddine, 4-(2,3-dihydro-2-oxo-18-benzimidasol-1-y1)-1-[[ethyl[[(2-fluorophenyl]amino]acety]- (9CI) C23 H26 F.MS-03

PROPERTY DATA AVAILABLE IN-THE PROPERTY

349 ANSWERS REGISTRY COPYRIGHT 7005 ACS on STN
Piperidine, 4=(2-benzozazolyl)-1-(3-(butyl)[[12(methylthoiphenyl)amino)carbonyl)aminoj-1-oxopropyl(9CI)
C27\_H34 74 03 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4 (1H-benzimidazol-2-yl)-1-[3-[cyclohexyl[[(3,4-dichlorophenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI) C28 H33 C12 M5 O2

Page 26

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-2-[[4-(4,6-dimethyl-2-pyrimidinyl)-1-piperazinyl]carbonyl]-4-hydroxy-, (2R,4R)- (9CI) C22 H27 Cl N6 03

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-[(2S)-2-[({(2,4-difluorophenyl)amino]carbonyl]amino] 4-[(4-(1,4-dihydro-2-oxo-3(2B)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl}


(9CI) C34 H43 F2 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM

Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[(2-methylpropyl)[(phenylamino)carbonyl)amino]acetyl)- (9CI)
C25 H31 N5 03




ROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[12,6-bis(1-methylethyl])phenyl]amino] carbonyl]ethylamino] acetyl] -4 (2,3 dhlydroj2roxo\_1H-benzimidarol-1-yl) - (9CI) C29 H39 N5 03



\*\*PROPERTY DATA AVAILABLE IN THE PROP' FORMAT \*\*

349 ANSWERS TREGISTRY COPYRIGHT 2005 ACS on STN Piperazine, 1-[2-[[[3:5]comphenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3:5]therefore the state of the st



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[cyclohexyl][[(2-fluorophenyl)]mino]-carbonyl]lmino]-1-cxopropyl]- (9CI)

Page 29

JP2004\_018717\_2.trn

349 ANSWERS 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
3-Piperidinecarboxylic acid, 1-[i]-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tectrahydro-lH-pyrido[3,4-b]indol-3-yl]carbonyl]-2pyrrolidinyl]carbonyl]- (9CI)

230 H31 C12 N5 05

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-[{2S}-2-[{[{2,4-dichlorophenyl}amino}carbonyl]amino}-4-[4-(1,4-dihydro-2-oxo-3{2H}-quinazolinyl}-1-piperidinyl}-1,4-dioxobutyl}-(9CI) C34 H43 C12 N7 O4

\*\*PROPERTY DATA AVAILABLE IN THE 'PEOP' FORMAT'

C28 H34 PONS 02

JP2004\_018717\_2.trn


.. PROPERTINGATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-][[(2,6-dimethylphenyl)amino]carbonyl)amino]-3-methyl-1-oxobutyl]- (9CI) C26 H33 N5 O2

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benrimidezoi-2-y1)-1-[3-[([(3-chlorophenyl) amino/carbonyl) (2-methylpropyl) amino/carbonyl) (2-methylpropyl) amino/carbonyl (26 H32 CL M5 02 mino)-1-exopropyl}- (9CI)




Page 30

JP2004\_018717\_2.trn


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Benzolc acid, 4-[[[[2-]4-{2,3-dihydro-2-oxo-1H-benzimidszol-1-yl)-1piperidinyl]-2-oxoethyl (2-mothyl-propyl) mino) carbonyl) amino]-, ethyl
c28 H35:N5:05



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM
Piperidine, 4-(2.3-dihydro-2-oxio-18-ben;almidazol-1-y1)-1-[[ethy1][(2-methoxyphenyl)amino]acetyl)- (SCI)
C24 223 85 04



3.19 ANSWERS REGISTAT COPYRIGHT 2005 ACS on STM
Piperazine, 1-[2-[[[[2\_c-dimethylphenyl]amino]carbonyl]amino]-3-methyl-1oxobutyl]--[3]sttrffluoromethyll-2-pyridinyl]- (9CI)
C24 H3Lyr3-N5 02




\*\* PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STH Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-[[[(3-cyenophenyl)amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI) C29 H34 M6 O2

.. PROPERTY DATA AVAILABLE IN THE PROP. FORMAT.


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-methsyphenyl)amino] carbonyl] (1-methyl)thyl)amino]-1-oxopropyl}- (9CI) C26 H33 N5 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..


L3 IN

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benrimidazol-2-yl)-1-[3-[[[(2-bromphenyl) amino] carbonyl] (22machylpropyl) amino] -1-oxopropyl) - (9CI)
C26 H32 Br N5 02




349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN L-Proline, 1-[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-prolyl]-, (R)- (9CI) C29 H29 C12 N5 O5

Page 33



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Benzoic acid, 4-[[[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1piperidinyl]-2-oxoethyl)propylamino[carbonyl]amino]-, ethyl ester (9CI)
C27 H33 N5 O5



349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperazine, 1-[3-methyl-2-[[[(2-methylphenyl)amino]carbonyl]amino]-1oxobutyl]-4-[3-[trifluoromethyl]-2-pyridinyl](9CI)
C23 H28 E3-N5-02



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, (-{1B-benimidazol-2-y1)-1-[3-[cyclohexy1][(4-ethylphenyl)amino]carbonyl|amino]-1-oxopropyl]- (9CI) C30 E39 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*


349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-{(2S)-2-({[[2-chloro-5-(trifluoromethyl)phenyl]amino|carbonyl|amino|-4-[4-dlhydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dloxobutyl]- (9CI) C35 H43 C1 F3 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-[[[[3-bromophenyl)amino]carbonyl](2methylpropyl)amino]ecetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(9CI)
(25 H30 Br N5 O3

Page 34



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benrimidazol-2-yl)-1-(3-[[(3-methylphenyl)laminol]carbonyl-1[-] phenyletyl]nemnol-1-oxopropyl]- (9CI) C31 H35 N5 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidezol=2-y1)=1-(3-([(4-ethoxypbeny)] naminojcarbonyi] (2-methylprobyl) aminoj-1-oxopropyl)- (9CI)
CZ8 B37 N3\_03=

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 3,3-dimethyl-1-[[]-[[]([3-methylphenyl)amino)carbonyl]amino)ac etyl]-5-phenyl-2-pyrrolidinyl]carbonyl]-, cis- (9CI) C28 H36 M4 O3

Relative stereochemistry.

\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-[(2S)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1]-2-[([(2.5-dimethoxypheny1)amino]carbony1]amino]-1.4-dioxobuty1|- (9C1) C36 H49 M7 06

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{2,3-dihydro-2-oxo-1H-benzimidazol-1-yl}-1-[[[[{2,4-dimethoxyphenyl}amino]carbonyl](2-methylpropyl)amino]acetyl)- [9CI] C27 H35 N5 O5 L3 IN

Page 37



PROPERTY DATA AVAILABLE IN THE 'PROP'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{llh-benzimidazol-2-yl}-1-[3-[[[4-ethoxphenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl)- (9CI) C32 H37 N5 O3

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1R-benzimidazol-2-yl)-1-[3-[[[(4-copyrent))]]]] amino]-1-oxopropy1]- (9CI)


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM L-Proline, 5-(lH-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, cis- (9C1) C32 H42 M4 O6 S1

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PROPERTY DATA AVAILABLE IN THE PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005-ACS on STN
Benroic acid, 4-[[[2-[4-[2,3-dihydro-2-oxo-lH-benzimidazol-1-yl)-1piperidinyl]-2-oxoethyl]methylamino]carbonyl)amino]-, ethyl ester (9Cl)
C25 H29 N5 O5



\*\*PROPERTY DATA-AVAILABLE IN THE 'PROP' FORMAT

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[cyclohexyl][{2-methylphenyl)amino]carbonyl]amino]-1-oxopropyl}- (9CI) C29 H37 N5 O2

Page 38

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(2S)-2-[[(4-bromophenyl)amino]carbonyl)amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]-(9CI) C34 H44 Br N7 O4

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidatol-1-y1)-1-{{{{2-bethoxphenyl} amino|carbonyl}{2-bethylpropyl}amino|acetyl}- (9C1) C26 B33 M5.04

PROPERTY DATA-AVAILABLE IN THE 'PROPERTY

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2,3-dihydrp\_2coxc\_H-benzimidazol-1-yl)-1-[[[[4(methylthio)phenyl]hamino]cerbpnyl]propylamino]ecetyl- (9C1)
C25 H31 M5 O3 S

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[,[3]-bromopheny]]amino]carbonyl]methylamino]acetyl]-4-(2,3-di)dydro-2;0x6-[H-bentimidaro[-1-y]]-19C1]
C22\_H22\_Br NS 03 L3 IN

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxatoly), 1-(3-([(2-bromophenyl)amino)carbonyl)(1-cothyl)amino)=1-oxopropyl = 9ck

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[{2S}-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,4-dimethylphenyl)amino]carbonyl]amino]-1,4-dioxobuyl)- [9CI) C36 H49 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-bensimidazol-2-yl)-1-[3-[[[(2-bromophenyl) amino] carbonyl].1(2,methyl)ethyl) amino]-1-oxopropyl]- (9CI) C25 H30 Br NS.02

OPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-11-oxo-3-(propy)[[[3-(trifluoromethyl)phenyllamino]carbonyl]amino]propyl]- (9CI)
C26 H30 F3 N5 O2

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Proline, 5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-1-(N-[[[3[(phenylmethoxy) carbonyl]phenyl]amino)carbonyl]glycyl]-, 1,1-dimethylethyl
ester, (2a,48,5a)- (9CI)
C36 H41 F N4 O9 S

Relative stereochemistry.

JP2004 018717 2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 2-Axetidinecarboxylic acid, 3-[[1-{aminoiminomethyl}]-3-piperidinyl]methyl]-4-oxo-1-[[4-[[(|phenylamino) carbonyl]amino]acetyl]-1-piperazinyl]carbonyl]-, (25, 38)- (9C1) C25 H34 H8 O6 ME


Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Paperiding and (1907) [1007] [4-11 trophenyl) amino [carbonyl) amino [acetyl] -4-(2,3-dihydro-72 oxo-18-benzimidazol-1-yl) - (9CI) (225-830 N6 05


\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(2,3-dihydro-2-0xo-18-benzimidazol-1-y1)-1-[[[(2,4-disethoxyphenyl\*minfo]carbonylimethylemino]acety1|- (9CI) C24 #129.85 OS:



349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-{2-benzoxaroly1}-1-{3-{[[(4-ethylphenyl)amino}carbonyl](1-methylethyl)amino}-1-oxopropyl}- (9CI)

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazolyl)-1-{3-[cyclohexyl[((3,4-dichlorophenyl)amino]carbonyl]amino]-1-oxopropyl)- (9CI) C28 H32 C12 Ne O3



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperiddne, 4=(1H-benzimidazol-2-yl)-1-[3-[[[(2-bromophenyl)amino]carbonyl)propylamino]-1-oxopropyl]- (9CI) C25 H30 Br N5 O2

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Cyclopropanecarboxylic acid, 3-methyl-N-[(phenylamino)carbonyl]-L-velyl-

Page 45

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4-Bipiperidine, 1'-[(2S)-4-|4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[[(2-methylpheny1)amino]carbony1)amino]-1,4-dioxobuty1]-(9CI)
C35 B47 N7 O4

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl]butylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
C25 H30 B7 N5 O3

\*\* PROPERTY DATA AVAILABLE :IN THE PROP' FORMAT ..

349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-12,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[{2-oxb-0xyphenyl}]amino]carbonyl]methylamino]acetyl]- (9C1)
C23 H27 M5 04

JP2004\_018717\_2.trn


(4R)-4-((7-met (1R,2S)- (9CI) C40 H43 N5 O7 ethoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-,

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM 1,4'-Bipiperidine, 1'-[(25)-4-[4-(1),4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[([(4-ethylpheny1)amino]carbony1]amino]-1,4-dioxobuty1)-(9CI) C36 H49 N7 O4


Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxarolyl)-1-[3-[buryl[[4-chlorophenyl)amino]-acotopyl/Tamino]-l-boxopropyl]- (9CI) C26 H31 C1 N4-033

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[(3-bromophenyl)amino]carbonyl]cyclo hexylamino]-1-oxopropyl]- (9CI) C28 B33 Br N4 03 IN



PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(1R-benzimidazol-2-yl)-1-[3-[[[2,6-dimethylphenyl]emino]carbonyl]propylamino]-1-oxopropyl]- (9CI) C27 H35 M5 O2

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benrimidaro)-2-y1 - 10-(buty1[[(4-nitrophenyl)amino] carbonyl]amino]-1-oxopropyl) (9CI) C26 H22 N5004 L3 IN

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(5-fluoro-2-methylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- [9CI)
C35 H46 F N7 O4

Absolute stereochemistry.

Page 49

JP2004\_018717\_2.trn

(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1) - (9CI) C27 H35 N5 O34-\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-lH-benzimidazol-1-yl)-1-[[ethyl[[(3-methylphenyl] amino]carbonyl] amino]acetyl]- (9CI) C24 H29 N5 03

\*\* PROPERTY DATA AVAILABLE IN THE PROP FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazolyl)-1-[3-[butyl][(2,4-dichlorophenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI) C26 H3D C12 Ne O3

\* PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benroxazoly1)-1-[3-[cyclohexyl[{[3-methoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) C29 H36 N4 O4

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-[(25)-2-[[(3-acetylphenyl)amino)carbonyl)amino]-4-[4-(1,4-dihydro-2-oxo-3 (2H)-quinszolinyl)-1-piperidinyl]-1,4-dioxobutyl]-(9C1) C36 H47 N7 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-{{butyl[{(2,6-dimethylphenyl)amino}carbonyl]amino}acetyl]-4-


Page 50

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(25)-3-methyl-1-oxo-2-[([chenylamino]carbonyl]amino]butyl]- (9CI) C24 H29 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimida<u>zol-2-yll-d-[3-dburyl</u>][(2,4-dimethoxyphenyl)aminolcarbonyljamino)-1-oxopropyr]-(9C1) C28 H37 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STW 1-Pyrroidinecarboxanide, N-(4-chlorophenyl)-4-hydroxy-2-[14-(4-pyridinyl)-1-piperazinyl]carbonyl]-, (2R,4R)- (9CI)

MF C21 H24 C1 N5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(2S)-2-[([(4-chloro-3-(trifluoromethyl)phenyl)amino)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl)- (9CI) C35 H43 Cl F3 N7 O4

lute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[butyl[[(3-methoxyphenyl)amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) C26 H33 N5 O4

Page 53

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(25)-2-[[(2,4-difluorophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI) C24 H27 F2 N5 O2 MF

Absolute stereochemistry

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[butyl([4(trifluoromethyl)phenyl]amino[Carbonyl]amino[-1-oxopropyl](27 H32 F3 N5 02


PROPERTY DATA AVAILABLE IN THE TIPROP FORMA

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM L-Proline, 1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]- (9C1) C20 H26 N4 O5


JP2004\_018717\_2.trn

DATA AVAILABLE IN THE 'PRO

REGISTRY COPYRIGHT 2005 ACS on STN
1-[[[(2-bromopheny) amino]carbonyl]ethylamino]acetyl]-4-(2,3-xo-1B-benzimidazol-1-yl)- (9CI) 349 ANSWERS L3 IN Piperidine, 1-[] dihydro-2-oxo-1H C23 H26 Br N5 O3



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-benzoxazolyll\_1]-[3-[butyl[[[4-(trifluoromethyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
C27 H31 F3 N4703



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(3-chlorophenyl)amino]carbonyl]cyclohexylamino]-1-oxopropyl)- {9CI} C26 H34 Cl N5 O2

JP2004\_018717\_2.trn

CI COM

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4-Bipiperidine, 1'-[25]-4-[4-(1,4-dihydro-2-oxo-3(28)-quinazoliny1)-1-piperidiny1]-2-[[(],4-dimethylpheny1) amino|carbony1]amino|-1,4-dioxobuty1|- (9C1) C36 H49 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(2,3-dihydro-2-oxo-lH-benzimidazol-1-yl)-1-[[(2-methylpropyl)][[[3-(trifluoromethyl)phenyl]amino]carbonyl]emino]acetyl]-(9CI)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT"

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS ON STN Piperidine, 4-(2,3-dihydro-2-oxo-18-benfinidazoi-1-y1)-1-{{{[[[2,6-dimethylphenyl)amino|carbonyl]ethylamino|acetyl]- (9CI) C25 H31 M5 03

PROPERTY DATA AVAILABLE IN THE 'PROP'

349 ANSNERS REGISTRY\_CORYRIGHT 2005 ACS on STN Piperszine 1-72-[[[2.4-dichlorophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl-4-[3-[trifluoromethyl]-2-pyridinyl]- (9CI) C22-H24 C12 F3 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2-bromophenyl)amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
C28 H34 Br N5 O2

Page 57

JP2004 018717 2.trn

2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolldinyl]carbonyl}-, [3R-[3R\*[s\*(5\*)]]- (9CI) C30 H31 C12 M5 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4 -Bipiperidine, 1'-[(25)-2-([(2.6-dift)urophenyl)amino]carbonyl)amino]-4-[4-(1.4-dibytor-2-oxo-3(28)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-C34 H43 F2 N7 O4

\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

JP2004\_018717\_2.trn PERTY-DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{1H-benzimidazol-2-yl}-1-[(2S)-2-[[(4-methoxyphenyl)amino)carbonyl)amino]-3-methyl-1-oxobutyl}- (9CI) C25 H31 N5 O3

Absolute stereochemistry.




349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[{[3-methylpenopyl]amino]-1-oxopropyl]- (9CI)
C27 H35 N5 022 mol\_carbonyl]\*(2 methylpropyl)amino]-1-oxopropyl]- (9CI)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 2-Pyrrolidineacetic acid, 1-[[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-ddhydro-2-oxo-1H-benzimidarol-1-y1)-1-[[[[(3-floor-opheny)] amino]acety1)- (9CI) C25 H30 F N5-03




FORMAT \*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benrimidarol-1-y1)-1-[[ethyl[[[4-(methylthio)phenyl]amino]carbonyl]amino]acatyl]- (9CI) C24 H29 N5 O3 S

\*PROPERTY DATA AVAILABLE IN THE 'PROP'

OPERTY DATA AVAILABLE IN THE 'PROP' FORMAT.

319 ANSWERS REGISTRY COPYRIGHT TO ACT ON STN
Piperatine, 1-[2-[[[(2-methoxyphenyl)amino]carbonyl]amino]-3-methyl-1oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
C23 H28 F3 NS.O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-[{[[2,6-bis(1-bethylethyl]phenyl]amino]carbonyl]cyclohexylemino]-1-oxopropyl}- (9CI) CJ4 H47 M5 O2

PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimidazol\_2\_yll\_tl\_[3-[[[[3-(yanophenyl) amino] carbonyl] [2\_methylpropyl] amino[-1-oxopropyl] - (9CI) C27 H32 N6 O2

PROPERTY DATA AVAILABLE IN THE PROPERTY

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
3-Pyrrolidinecarboxylic acid. 1-[[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl[carbonyl]-2-pyrrolidinyl]carbonyl]-, [3R-[3R\*[5\*(R\*)]]]- (9CI)
C29 H29 C12 NS 05

JP2004 D18717 2.trn

peridine, 1-[[[[(2,3-dichlorophenyl)amino]carbonyl](2-thylpropyl)amino}acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-

PROPERTY DATA AVAILABLE IN THE 'PROP'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl]propylamino]acetyl]-4-[2,3-dihydro-2-oxo-1H-benzimidezol-1-yl)- (9C1)
C24 H28 Br. N5.03

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[+[4-\frac{1}{2}]Enlorepheny|]amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yi)=(901)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-|cyclohexyl[|(3-methoxyphenyl)amino)carbonyl)amino]-1-oxopropyl]- (9CI) C29 H37 H5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[[(2-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobuty1]-(9C1)

C34 H44 F N7 04 ME

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

Page 62

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-y1)-1-[3-[[[3-bromophenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
C30 H32 Br M5 O2

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[[4-(1methylethyl)phenyl)aminolcarbonyl]TZ-methylpropyl)amino]-1-oxopropyl)(ST)

-- PROPERTY DATA AVAILABLE IN THE 'PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STH L-Proline, 1-[M-[[(3-carboxyphenyl)amino[carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-[1,1-dimethylethyl) ester, trans- (9CI) C27 B30 M4 O6

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSHERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-[(25)-2-[{{(3-bromophenyl)amino}carbonyl]amino}-4-{4-(1.4-dihydro-2-oxo-3(2H)-quinazolinyl}-1-piperidinyl}-1,4-dioxobutyl}-L3 IN (9CI) C34 H44 Br N7 O4

Absolute stereochemistry.


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[[[[(4-ethoxyphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9C1) C27 H35 N5 O4

Page 65

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FOR

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benximidaxo1-2-y1)-1-[3-[[[4-methoxyphenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI) C31 H35 N5 O3 L3 IN



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP FORMAT.

349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[(2-methylphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI) C27 B35 N5 O2



\* PROPERTY DATA AVAILABLE IN THE PROP' FORMAT


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
D-Proline, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-5(2-pyridinyl)-, 1,1-dimethylethyl ester, (55)-rel- (9CI)
C31 H34 H4 O6

Relative stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidezol-1-yl)-1-[[[[4-(1-methylethyl)phenyl]amino|cartonyl]propylamino|acetyl]- (9CI) C27 H35 N3 O3

349 ANSWERS REGISTRIC COPYRIGHT 2005 ACS on STN Piperidine, 4-(2.3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(3-fluorophenyl)amino]carbonyl]methylamino]acetyl]- (9CI) C22 H24 F N5 O3



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazolyt) 1-[3-[[[(4-chlorophenyl)amino]carbonyl] (1-methylethyl)amino]-1-oxopropyl) (9C1) (25 H29 C1 N4 O3

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(25)-4-|4-(1,4-dihydro-2-oxo-3(2B)-quinazoliny1)-1-piperidiny1)-2-[[(4-methoxypheny1)amino]carbony1)amino]-1,4-dioxobuty1)-(9CI) (9CI) C35 H47 N7 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM
Piperidine, 4-{2,3-dihydro-2-oxo-1H-benzimidasol-1-y1}-1-{{2-cethylpropyl}{{[4-(methylthio)phenyl]amino)carbonyl]amino|acetyl}- (9C1)

349 ANSMERS REGISTRY COPYRIGHT 1005 ACS on STN Piperidine, 1-[[butyl[[(4-chlorophenyl)amino]carbonyl]amino]acetyl]-4-(2,3-dinydro-2-oxoglih-benžimidžiol\*]-ylla [3C1] L3 IN

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REGISTRY COPYRIGHT 2005 ACS on STN
1-[[[[(2,3-dichlorophenyl) amino|carbonyl]methylamino]acetyl]-40-2-0xo-1H=benFilmiMazol-1cyl)- (9CI)
(9CI)

\*\*PROPERTY DATA AVAILABLE IN THE

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazoly1)-1-[3-[[[(2,3-dichlorophenyl)amino]carbonyl] (1-methylethyl)amino]-1-oxopropyl] - (9CI) C25 H28 C12 N4 O3

Page 69

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-[(25)-2-[[(5-chloro-2-methoxyphenyl)amino]carbonyl]amino]-d-dioxobutyl]- (3C1) dioxobutyl]- (9C1) C35 H46 C1 N7 O5

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinaroliny]]-1-piperidiny]]-1,4-dioxo-2-[{[(2-phenoxyphenyl)amino]carbonyl]amino]buty]-


JP2004\_018717\_2.trn

PROPERTY DATA AVAILABLE IN THE 'PROP'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-[[(4-bromophenyl)amino]carbonyl)(1-methylethyl)amino]-1-oxopropyl)- (9CI)
C25 H30 Br N5 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{lh-benzimidazol-2-yl}-l-{3-{[[(4-mathylphenyl)amino]carbonyl]propylamino]-l-oxopropyl]- (9CI) C26 H33 N5 O2 IN



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Benzoic acid, 3-[[[[2-[5-[(3,3-dimethyl-1-piperidinyl)carbonyl]-2-(2-fluorophenyl)-3-(phenylsulfonyl)-1-pyrolidinyl]-2-oxoethyl]amino|carbonyl]amino|-,  $(2\alpha,3\beta,5\alpha)$ - (9CI) C34 H37 F N8 07 S MP

Relative stereochemistry.

Page 70

JP2004\_018717\_2.trn

(9CI) MF C40 H49 N7 O5

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[butyl[[[2-[trif]uoromethyl]phenyl]amino]carbonyl]amino]acetyl]-[-[2,]-dihydro-[2-0x0-]H-benz[midazol-]-yl)- (9CI) C26 H30 F3-H3 03


PROPERTY DATA AVAILABLE IN THE

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dthydro-2-oxo-14-benzimidazol-1-y1)-1-[[[[4-ethoxyphenyl]amino]cerbonyl]methylamino]certyl]- (9C1) C24 H29 H5 04

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzosazolyl)-1-(3-([(4-methoxyphenyl)amino]carbonyl)(1-methyl-thyl)amino]-1-oxopropyll-(9C1)
C26 H32 N4 04

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-benzoxaző]y]-1-[3-[cyclohexy][[[3-(trifluoromethyl)phenyl]Amino]-carbonyl]amino]-1-oxopropyl]- (9CI)
C29 H33 F3 N4 O3 L3 IN



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine diff-Denzimidazol-2-yll-1-da\_[[[(4-bromopheny1)amino]carbony1]propylamino]-1-oxopropyl]- (9CI) C25-830 Br N5 02

Page 73

JP2004\_018717\_2.trn


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[buty1[[(2,4-dichlorophenyl)amino]carbonyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) C25 H29 C12 N5 O3 L3 IN



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT"

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[methyl[[[4-(methylthio)phenyl]amino]carbonyl]amino]acetyl)- (9C1) C23 H27 N5 O3 S L3 IN



100

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{2-benzoxatoly1}-1-{3-[buty1][(3-

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperiding -[1H-benzimidezol-2-y1]-1-[3-[butÿ1-[[4-chloropheny]]amino]carbonyl]amino]-1-oxopropyl]- [9C1] C26 B32 C1 NS 02 L3 LN

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACs on STN

1.4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-2-methylphenyl)amino]carbonyl]a
mino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4dioxobutyl]- (9CI)

MF: C35 H46 C1 N7 04


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-{(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxo-2-{((phenylamino)carbonyl)amino)butyl}- (9CI) C34 H45 N7 O4


Absolute stereochemistry

Page 74

JP2004\_018717\_2.trn




349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazolyl)-1-[3-[cyclohexyl[[(2,4dfluorophenyl)amino]carbonyl]amino]-1-oxopropyl]- (9 H32 F2 N4-03-(9CI)



AVAILABLE INTHE PROPERTORMAT.

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-(1-methylathyl)phenyllamino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
C28 H37 M5 02



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(18-benzimidazol-2-yl)-1-[3-[[(3-bromophenyl)amino]carbonyl]butylamino]-1-exopropyl]- (9C1) C26 H32 Br N5 O2

349 ANSWERS REGISTRY COPYRIGHT 2005.ACS on STM 1,4'-Bipiperidine, 1'-[(2S)-2-[(([1;1'-biphenyl]-2-ylamino)carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-(9CI)
C40 H49 N7 O4

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipliperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1]-2-[[[(2-methoxypheny1)amino]carbony1]amino]-1,4-dioxobuty1]-(9CI) C35 847 M7 05

Absolute stereochemistry.

Page 77


JP2004\_018717.2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STH Piperidine, 4-(2-benzoxezolyl)=1=[3-[butyl][(4-methoxyphenyl)amino]-acopyropyl]=C27 H34 N4 O4

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-bengoxazoly1)-1-f3-(cyclohexy1([(2-methylphenyl]mino]=1-oxopropy1]- (9CI) C29 B36 N3-03



\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimidazol-2-y1)-1-[(2S)-2-[[[(2-bromophenyl)amino)carbonyl)amino]-3-methyl-1-oxobutyl)- (9CI) C24 H28 B7 M5 O2

Absolute stereochemistry.


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[|butyl[|(4-ethylphenyl)amino|carbonyl]amino|acetyl]-4-(2,3-dhydro-2-oxo-]H-benzimidazol-1-yl)--(9CI)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Benroic acid, 4-[[[2-[4-[2.3-dihydro-2-oxo-lH-benrimidatol-1-yl]-1piperidinyl]-2-oxoethyl]ethylamino]carbonyl]amino]-, ethyl ester (9CI)
C26 H31 N5 O5



JP2004\_018717\_2.trn



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yt)-lei3-[butyl[[(3-mathoxyphenyl)amino]carbonyl)amino]elsgxppropyl]- (9C1) C27 H35 N5\_03

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 AMSWERS REGISTRY COSYRIGHT 2005 ACS on STN
1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-2-[(4-(4-ethyl-1-piperazinyl)-1-piperidinyl)carbonyl)-4-hydroxy-, (2R,4R)- (9CI)
C23 B34 C1 N5 O3 MF

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 1,4'-Bipiperidine, 1'-{(2S)-4-|4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-2-[[(2,4-dimethoxyphenyl)amino]carbonyl]amino}-1,4-dioxobutyl- (9CI)

MF C36 H49 N7 O6


Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*




L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl]ethylamino]acetyl]-4-(2,3-dhydro-2-oxo-lH-benzimidazol-1-yl)- (9CI)
MF C23 H26 Br N5 03

Page Bl



L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(IH-benzimidazol-2-yl)-1-[3-[(2-mathylpropyl)] (phenylamino) carbonyl]amino)-1-oxopropyl]- (9CI)
MF C26 H33 N5 02



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Azirino[2',3':3,4]pyrrolo[1,2'-a]indole-4,7-dione, 6-amino-8[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-bexahydro-8a-methoxy-5-methyl1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, [laS(lac,8,8a,8ba,8bc)]- (9CI)

MY C30 H35 N7 O8

BE C CH2-N-C-NH

JP2004\_018717\_2.trn

SPROPERTY DATA AVAILABLE IN THE, 'PROP' PORMAT

L3 349-AMSMERS REGISTRY COPYRIGHT 2005-ACS on STN
1N Piperazine, 1-[2-[[[3-fluorophenyl]mino]carbonyl]amino]-3-methyl-1oxobutyl]-4-[3-(trifduoromethyl)-2-pyridinyl)- (9CI)
HF C22 H25-F4-N5 02

PROPERTY DATA AVAILABLE IN THE PROP FORMAT

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-(cyclohexyl)[(4methylphenyl)amino)carbonyl)smino)-1-oxopropyl)- (9CI)
MF C29 H37 N5 O2


\*\*PROPERTY: DATA-AVAILABLE IN THE PROP EGRMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(25)-2-[[(2,4-dimethoxyphenyl)amino]carbonyl)amino]-3-methyl-1-oxobutyl]- (9CI)
MF C26 H33 N5 04

Absolute stereochemistry

Page 82

JP2004\_018717\_2.trn



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1.4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1]-1,4-dioxo-2-[[[(4-(trifluoromethy1)pheny1]amino]carbony1]amin olbuty1]- (9CI)
MF C35 844 F3 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACs on STN

IM Piperidine, 4-[2,3-dihydro-2-oxo-1H-benzimidaro]-1-yl)-1-[[[[4-exthylphenyl)amino]carbonyl](2-exthylphenyl)amino]acetyl]- (9CI)

MF C26 H33 M5 O3

\*\*PROPERTY-DATA AVAILABLE IN THE 'PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-{2,3-dihydro-2-oxo-1H-bentimidatol-1-yl)-1-{[ethyl][[4-{1-machylethyl]phenyl]amino]acetyl]- (9CI) C26 H33 N5 01

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

DATA AVAILABLE IN THE 'PROP' FORMAT ..

- 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, (-(lH-benzimidazol-2-yl)-1-[3-[{[(4-bcnomphenyl)amino]carbonyl]cyclohexylamino]-1-oxopropyl}- (9C1) C28 B34 B7 N5 02

Page 85

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(2S)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[(13,5-dimethoxypheny1)amino]carbony1)amino]-1,4-dioxobuty1]- (9C1) C36 H49 M7 O6

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STR Piperidine, 1-[[[[(2-bromophenyl)amino|carbonyl](2-methylpropyl)amino|acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(9C1)

JP2004\_018717\_2.trn

\*\*PROPERTY DATABAVALLABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimidarol-2-y1)-1-(3-([[(3-bethylehephyl)amino|carbonyl]/(1-bethylethylkamino|-1-oxopropyl)- (9CI) C26 H33 N5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-fluorophenyl] amino]carbonyl] (2-methylpropyl) amino]-1-oxopropyl]- (9CI) C26 H32 F N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
3-Pyrrolidinecarboxylic acid, 1-[1-[2-[3.4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3.4-b]indol-3-yllcarboxyl]-2-pyrrolidinyl]carboxyl]-, phenylmethyl eater,
[3R-[3R-[3R-[3R-[3R-5]]]- (9CI)
C36 H35 Cl2 N5 O5

Page. 86

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(2,3-dihydro-2-2585-18-benzimidazol-1-yl)-1-[[[[4-nitrophenyl)amino|carbonyl]propylamino|acetyl- (9CI) C24 R23\_M6-05

PROPE FORMATOO PROPERTY DATA AVAILABLE IN THE


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperarine, 1-[3-methy1=2-[T[[4-(methy1thio)phenyl]amino]carbonyl]amino]-1oxobutyl]-4-[3-[trifluoromethyl)-2-pyridinyl]- (901)
C23 R2BSF3 N5-02 S

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 AMSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(IH-benzimidazol-2-yl)-1-[3-[cyclohaxyl][(4-ethoxyphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9C1) C30 H39 M5 O3

\*\*PROPERTY DATA AVAILABLE IN THE PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(lH-benzimidazol-2-yl)-1-[1-oxo-3-[(1-phenylethyl)[[[3-trifluoromethyl)phenyl]amino]carbonyl]amino]propyl]- (9CI) C31 H32 F3 M5 O2




349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benrimidazol-2-yl)-1-13-[[[(2,4difluorophenyl]amino]Tarbonyl[(2-methylpropyl) amino]-1-oxopropyl]- (9CI)
C26 H31 [2-N5 02

PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Owinoline, 1,2,3,4-tetrahydro-1-[[1-{[[(3-methylphenyl)amino]carbonyl}amino]acetyl]-5-phenyl-2-pyrrolidinyl}carbonyl]-, cis- (9CI) C30 H32 N4 O3

Relative stermochemistry.

Page 89



THE 'PROP' FORMAT

COPYRIGHT 2005 ACS ON STN

dichlorophenyl] amino] carbonyl] propylamino] acetyl]-4
[midazo]-1-yl]-(9C1) 349 ANSWERS REGISTRY COPYRIGHT 2005 AC Piperidine, 1-[[[[(2,4-dichlorophenyl)am], 2,3-dihydro-2-oxo-1H-benzimidaiol-1-jTy-C24 H27 C12 M5.03

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidacol-1-y1)-1-[[methyl[[(3-methylphenyl)lamino]carbonyl]amino]acetyl]- (9C1)
C23 H27 N5 03

PROPERTY DATA AVAILABLE IN THE 'PROP FORMAT'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STH Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-{cyclohexyl[{{4-(methyltholophenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) C29 H37 N5 O2 S

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-{(2S)-2-[[[(2,5-dichlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl)-4001 (9CI) C34 H43 C12 N7 O4 .

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(3C1) H43 N5 O3

Page 90

\*PROPERTY-DATA-AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[{2.4-dichlorophenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
C30 H31 C12 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACs on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[{[(3-methoxyphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
C27 H35 N5 03

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 4-Thiazolidinecarboxylic acid, 2-(3-pyridinyl)-3-|{[[]3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino|carbonyl]amino|acetyl]-, 1.1-dimethylethyl ester, (2R-cis)- (9Cl) C28 H38 N4 06 S S1

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSHERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1.4'-Bipiperidine, 1'-{(2S)-2-{{(3-chlorophenyl)amino}-4-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-1,4-dioxobutyl}-(9CI)
MF C34 H44 Cl N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[4-(1-methylethyl)phenyl)amino)carbonyl](2-methylpropyl)amino)acetyl)- (9CI)

Page 93


JP2004\_018717\_2.trn

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(18-benzimidaxols2-ylln-1;-[(1-methylethyl)([(4-methylphenyl)amino[carbonyl-mino)-3-oxopropyl--(9C1)

MF C26 H33 N3 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN |
IN Piperidine, 4-(18-bentimidazol-2-yl)-1-[3-[[[3,4-dichlorophenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
MF C25 M29 C12 N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

Prolinanide, N-[[(3-carboxyphanyl)anino]carbonyl]qlycyl-M-(3,3-dimethylbutyl)-5-(2-fluorophanyl)-4-(4-morpholinylaulfonyl)-,
(20,4B,5a)- (9C1)


MF C31 H40 F N5 08 S

JP2004\_018717\_2.trn

NF C28 H37-N5 03

L3 349 ANSNERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidexol-1-y1)-1-[[[[(3-methoxyphenyl) amino]carbonyl]propylamino]acety1]- (9CI)
NF C25 H31 N5 04

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(2-bromophenyl)amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidarol-1-yl)- (9CI)
MF C22 H24 Br N5 O3



L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[(1-methylethyl) [[(3-methylphenyl)amino]carbonyl)amino]-1-oxopropyl]- (9CI)
MF C26 H32 N4 O3

Page 94

JP2004\_018717\_2.trn

Relative stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1N 1,4'=Bipperidine, 1'-[(25)-2-[([(2,5-difluorophenyl)amino]carbonyl]amino]4-[4-(1,4-dihydro-2-oxo-3(2B)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl](9C1)
WF C34 H43 F2 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

J3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-[4-(4-amino-3,5-dibromophenyl)-1,4-dioxo-2-[[(2-pyridinylamino)carbonyl]amino]butyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI)
FC C30 H31 Br2 N7 O4

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

\*\*PROPERTY DATA AVAILABLE IN THE PROP' FORMAT\*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) MF C28 H37 N5 O3

Page 97

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAL'

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
D-Proline, N-[[(3-carboxyphenyl)amino|carbonyl]glycyl-5-(2-fluorophenyl)-4-(4-morpholinyl6arbonyl)-, 2-(1,1-dimethylethyl) eater, (45,58)-rel-(9CI)
MF C30 H35 F N4 08

Relative stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 1.4'-Bipiperidine, 1'-[(25)-4-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-[[[(4-ethoxyphenyl)amino]carbonyl;amino]-1,4-dioxobutyl]-(9C1)

MF C36 H49 M7 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE PROPE TORNAT ..

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1N Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[(2,6-dimethylphenyl)amino]carbonyl]
(1-methylethyl)amino]-1-oxopropyl}- (9CI)
MF C27 H34 H4 O3

\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT\*

L3 349 ANSWERS REGISTRY COPYRIGHT-2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-{{[[2,6-bis(1-methyl)phenyl]amino]carbonyl}(1-methylethyl)amino|-1-oxopropyl}-(9C1)
MF C31 H43 N5 02

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(18-benzimidezol-2-yl)-1-[1-oxo-3-[propyl[[(2-(trifluoromethyl)phenyl]amino]carbonyl]amino]propyl]- (9CI)
MF C26 H30 F3 N5 02

Page 98

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN

1.4 -Bipiperidine, 1'-[(2S)-2-[[(4-chlorophenyl)amino]carbonyl]amino]-4[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl](9C1)

MF C34 H44 C1 N7 04

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[(3-bromophenyl)amino]carbonyl]butylamino]acetyl]-4-[2,3-dihydro-2-oxo-]H-benzimidatola\_[]]- (9C1)
C25 B3\_Bonn5-03

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dthydro-2-oxo-1H-benzimidezol-1-y1)-1-[[methyl[[[4-(1-methyl]phenyl]benino|carbonyl]amino|acetyl]- [9C1) C25 H31-M5\*03

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FOR

(trifluoromet) C26 H29 F3 N4 ME

\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazoly1)-1-(3-[[[[3,5-bia(trifluoromethy1)pheny1]amino]carbony1]eyclohexylamino]-1-oxopropy1]- (9CI) C30 H32 F6 N4 O3 L3 IN

Page 101

JP2004\_018717\_2.trn

Absolute stereochemistry.

.. PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1.4'-Bipiperidine, 1'-[(23)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny])-1-piperidiny]-1,4-dioxo-2-[[[(4-phenoxypheny1)amino]carbony1]amino]buty1]-(9CI)
(9CI)

Absolute stereochemistry.

.. PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*

349 ANSWERS REGISTRY COPYRIGHT 2005, ACS on STN Piperidine, 4-(18-benzimidazol-2-yl)-1-[3-[[[(2,4-difluoropheny)|amino]carbonyl]propylaminol\_1-oxopropyl]- (9CI) C25 H29 F2 N5:02

\*\*PROPERTY DATE AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-Z-yl)-1-[3-[butyl]([(4-methylphenyl]amino]carbonyl)amino]-carpropyl)- (9C1) (27 H35 N5-02

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4-Bipiperidine, 1'-[(2S)-2-[[[(A-Eromo-2-methylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3 (2R)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
C35 H46 Br N7 O4

MF

Page 102

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[butyl][(2,4-dimethoxyphenyl)amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-]H-benzimidago[-1-yl) - (9CI)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[[[(4-chlorophenyl]amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidarol-1-yl)- (9C1)
C23 H26 C1 N5 O3


\* PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT"

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoszolyl)-1-[3-[butyli([2-fluorophenyl)amino]-lawopropyl]- (9CI) C26 H31 F N4\_03

PROPERTY FORTA AVAILABLE IN THE 'PROP' FORMAT ..


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxarolyl)-1-[3-[cyclonexyl[[4-ethoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1R-benzimidazol-2-y1)-1-[(2S)-2-[[[(4-chlorophenyl)amino)carbonyl)amino]-3-methyl-1-oxobutyl}- (9CI) C24 H28 C1 N5 O2



\*\*PROPERTY-DATA AVAILABLE IN THE 'PROP' FORMAT


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H:benzimi@azol-2-yl)-1-[3=tbutyl[[2.4] dichlorophenyllamino] carbonyllamino] 1-5xopropyll (2.6) H31\_C12 N5 02



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Page 105

JP2004\_018717\_2.tro



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2,3-dihydro-2-oxo-18-benzimidazol-1-yl)-1-[[ethyl[[[2-(triflooromethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
C24 B26 F3 N5 O3

Et O <sup>F3C</sup>. | || -N-C-NH-

349 ANSHERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4(2-benzoxazoly)1-1-(3-buty)[[(2-methyl)amino]-1-oxopropyl]- [9CI) C27 R34 M4 03



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benzimidazol-2-yl)-1-[3-[cyclohexyl](phenylamino)carbony l]amino]-1-exopropyl]- (9CI) C28 B35 M5 02

JP2004\_018717\_2.trn

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperazine, 1-[3-methyl-1-oxo-2-[[[]-(trifluoromethyl)phenyl]amino]carbon ylamino|butyl]-f\_2[3a(trifluoromethyl)-2-pyridinyl]- (9CI) C23 H25 E6-NN 02-

\*\*PROPERTY DATA AVAILABLE IN THE 'PROPERTY FORMAT\*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 1,4'-Bipiperidine, 1'-[(25)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[((2,3-dimethylphenyl)amino)carbonyl]amino]-1,4-dioxobutyl]- (9CI)

MF C36 H49 N7 O4


Absolute stereochemistry.

The same of the sa \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[|butylf([(2-methoxyphenyl)amino|carbonyl)amino|acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) C26 H33 N5 O4

Page 106

JP2004 018717 2.trn



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-y1)-1-[(2S)-2-[[(4-bromophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI) C24 H28 Br M5 02

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT.

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, (-(18-benzimidazol-2-yl)-1-(3-(butyl)((2-methylphenyl)lamino)larbonyl]aminolal-poxpropyl)- (9C1) C27 H35 H5-02

n-Bu O

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STH 1-Pyrrolidinecarboxamide, B-(4-chlorophenyl)-4-hydroxy-2-[[4-(1-methyl-4-

piperidinyl)-1-piperazinyl)carbonyl)-, (2R,4R)- (9CI) HF C22 H32 Cl N5 O3

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-2-[[(2,5-dimethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)

MF C36 H49 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(3-chlorophenyl)amino|carbonyl](2-methylpropyl)amino|acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(9CI)
MF C25 H30 C1 N5 O3

Page 109

PROPERTY DATA AVAILABLE IN THE 'PROP FORMAT'

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-{1H-benzimidazol-2-yl}-1-{(25)-3-methyl-2-{[[[4-{1-methylethyl)phenyl}amino]carbonyl}amino]-1-oxobutyl}- (9CI)
MF C27 H35 N5 02


Absolute stereochemistry



l3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STM

IN Piperidine, 4-(1H-benimidazol-2-y1)-1-(3-((2-bethylpropyl))([(3-(trifluoromethyl)phenyl)minol-1-exopropyl)- (9CI)


MF C27 #43 P1 NS 02



L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM
IN 3-Pyrrolidinecarboxylic acid, 1-[[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-

O 1-BU O C-CH2-N-C-NH- C1

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS\_on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2,4-dimethoxyphenyl)amino)carbonyl]ethylamino]acetyl]- (9CI)
NF C25 H31 N5 05



L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperszine, 1-[2-[[[(4-bromophenyl)amino]carbonyl]amino]-3-methyl-1oxobutyl)-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C22 H25 Br F3 N5 O2

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-y1)-1-[3-[cyclohexyl{[{3-fluorophenyl}amino}carbonyl]amino]-1-oxopropyl]- (9CI)
MF C28 H34 F N5 O2

Page 110

JP2004\_018717\_2.trn

yl)carbonyl)-2-pyrrolidinyl)carbonyl]-, (35-[3R\*[R\*(S\*)])]- (9CI)
MF C29 H29 Cl2 N5 O5


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STH
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-exo-3(2H)-quinazoliny1)-1piperidiny1]-2-[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-1,4dioxobuty1|- [9C1]
MF C37 H51 M7 O6

Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM




\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-[2\_3\_dihydro\_2-oxo-1H-benzimidazol-1-yl]-1-[[ethyl[[(3-methoxyphemyl]amino].carbonyl]Tahtnolacetyl]- (9CI) C24\_H29\_H5-04

PROPERTY DATA AVAILABLE IN THE PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperarine legariff(4=ethylphenyl)amino|carbonyl)amino|-3-methyl-1oxobutyliff(3=|crifluoromethyl)-2=pyridinyl)- (9C1)
CZE/R3D 73 N5 02



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[cyclohexyl][(2,4-dichlorophenyl)amino)carbonyl]amino)-1-oxopropyl]- (9CI) C28 H33 C12 N5 O2

Page 113

JP2004\_018717\_2.trn

N092100295

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Bipiperidine, 1'-{(2S)-4-[4-(1.4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-1.4-dioxo-2-{{{(2,3,4-trifluoropheny1)amino}carbony1}amino}buty11-{9CI} C34 H42 F3 N7 O4

olute stereochemistry.

\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

JP2004\_018717\_2.trn PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-yl)/-1-[3-[[(4-chlorophenyl)amino]carbonyl) (1-phenylethyl)amino]-1-oxopropyl}- (9CI) C30 H32 C1 N5 O2

FORMAT\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(lH-bensimidazol-2-yl)-1-[3-[[(4-brompheneyl) amine]carbonyl] (2-msthylpropyl) amine)-1-exepropyl)- (9CI) C26 H32 B2-N5 02



\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 3.4-Pyrrolidinedicarboxylic acid, 1-[[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2.3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrolidinyl]carbonyl]- (9CI) C30 H29 C12 N5 07

Page 114

JP2004\_018717 2.trn

Piperidine, 1-[[[{4-bromophenyl}amino]carbonyl]{2-methylpropyl}amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl) (9CI) C25 H30 Br N5 03

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dthydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-fluorophenyl)amino]carbbnyl]propylamino]acetyl]- (9CI) C24 H28-F-N5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperazine, 1-[3-methyl-1-exo-2-[[[[4-(trifluoromethyl)phenyl]amino]carbon yl]amino]butyl]-4\_lJaitrifluoromethyl)-2-pyridinyl]- (9C1) C23 B25\_E6+NS-02

PROPERTY-DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1B-benzimidarol-2-yl)-1-[3-[cyclohexyl][(2-methoxyphenyl)amino)carbonyl]amino]-1-oxopropyl]- (9CI) C29 B37 N5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-{\text{H}-benrimidazol-2-y1}-1-{3-\[[{2-\text{Clucrophenyl}}amino]carbonyl}{1-phenylethyl}amino]-1-oxopropyl}- (9CI)
C30 H32 f N5 02

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(lR-benzimidazol-2-yl)-1-[3-[[[4-ethylphenyl)amino]carbonyll/[2-mathylpropyl)amino]-1-exepropyl}- (9CI) C28 H37 N5 02

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN L-Proline, 1-(N-[[(3-carboxyphenyl)amino|carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, cis- (9C1) C27 H30 N4 O6

Absolute stereochemistry.

Page 117

JP2004\_018717\_2.trn PROPERTY DATA AVAILABLE IN THE PROP FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(4-ethylphenyl)amino]acetyl]- (9CI) C26 H33 N5 03

PROPERTY DATA AVAILABLE IN THE PROP

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2-fluorophenyl)amino]carbonyl)methylamino]acetyl]- (9CI)
C22 H21\_F-NS 03

\*\*PROPERTY DATA AVAILABLE IN THE 'PROPE-FORMAT ..

349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(18-benrimidazoi-2-yl)-1-[3-[cyclohexyl[[4-(trifluoromethyl)phenyl]amino]carbonyl)amino]-1-exopropyl]- (9CI) C29 H34 F3 N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM
1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[[[(2-ethoxypheny1)amino]carbony1]amino]-1,4-dioxobuty1]-(9CI)
C36 R49 N7 O5

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4 (2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2,6-dimethylphenyl)amino]carbonyl](2-methylphenyl)amino]acetyl]- (9CI) C27 H35 N5 O3

Page 118


JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1B-bensimidazol-2-yl)-1-[3-[[[4-(1-methyl-phenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]-(9C1)
(33 H39 N5 02

PROPERTY BATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-y1)-1-[3-((2-methylpropyl)([4-(methylthio)phenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI) C27 H35 N5 O2 S



\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STM L-Proline, 5-(H=indol-3-yl)-1-[N-[[[3-[[2-(trimethylsily])ethoxy]carbonyl]phenyl]mino[carbonyl]glycyl]-, 1,1-dimethylethyl ester, trans- (9C1) C32 B42 B4 06 Si

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN 1,4'-Bipiperidine, 1'-[(ZS)-4-(4-(1,4-dihydro-2-oxo-2(2H)-quinatoliny1)-1-piperidiny1)-7-[([(4-fluoropheny1) amino]carbony1]amino]-1,4-dioxobuty1]-(9CI) (34 R44 F N7 O4

MF

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

Page 121

JP2004\_018717\_2.trn

\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

L3 IN



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

J49 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(lH-bensimidazol-2-yl)-1-[3-[[{(3-methylhenyl)amino}carbonyl]propylamino}-1-oxopropyl]- (9CI) C26 HJ3 N5 O2

\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Prolinamide, H-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-H-[3,3-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, (2a,4B,5a)- (9CI)
C38 B46 F M5 O8 S

Relative stereochemistry.

. - -

JP2004\_018717\_2.trn

Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[{{(3-methoxyphenyl)aminolcarbonyl1(2-methylpropyl)aminolacetyl}-(9CI) C26 H33 N5-04\*\*\*

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT"

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-1[[{(2-methylphenyl)amino|carbonyl]propylamino|acetyl]- (9CI) C25 H31 N5 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-{{[[(4-bromophenyl)amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yI)- (9CI) C72 H74 R7 N5 03 L3 IN C22 H24 Br N5 O3

349 ANSWERS REGISTRY COPYRIGHT 2005, ACS on STN Piperidine, 4-{2-benzoxazolyl}-1-[3-[[[(4-bromophenyl)amino]carbonyl](1-methylathyl)amino]-1-oxopropyl}- (9CI) C25 H29 Br N4 O3

Page 122


JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*


Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-([[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl][9CI)
C30 H33 F6 N5 O2



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[butylft]3=fluorophanyblamino]carbonyl]amino]acetyl]-4-(2,3-dinydro-2-oxo-ll-benzimiderof=1-yl)--(9C]1



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, (=(2,3-ddhydro-2-oxo-lh-benzimidazol-1-y1)-1-[[[[(2,6-dimethyl-pheny1)amino]carbonyl]methylamino]acetyl]- (9CI) C24 H29 N5 03



Page 125

JP2004\_018717\_2.trn

Cyclopropanecarboxylic acid, N-[[(2,6-dimethylphenyl)amino]carbonyl]-3-methyl-L-valyl-[4R]-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- (9CI)
C42 H47 N5 O7

olute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN 1.4'-Biplepridine, 1'-[(2S)-2-[([(4-chloro-2-methylphenyl)amino)carbonyl)amino]-d-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1.4-dioxobutyl)- (9CI) C35 H46 C1 N7 04

. . .


Absolute stereochemistry

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-[2-benroxazoly1)-1-[3-[[[(2-methoxypheny1)amino]carbony1](1-methylylamino]-1-oxopropy1]- (9CI)
C26 H3Z N4 O4

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(2-benzoxazoly1)-1-[3-[[[(3-chlorophenyl)amino]carbonyl]cycl ohexylamino]-1-oxopropyl)- (9CI) C28 H33 Cl N4 O3



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-bensimidazol-2-y1)-1-[3-[[(3-bromophenyl)amino]carbonyl]propylamino]-1-oxopropyl]- (9CI) C25 H30 Br N5 O2



REGISTRY COPYRIGHT 2005 ACS on STN

Page 126

JP2004\_018717\_2.trn

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny1)-1-piperidiny1)-2-[((3-ethylpheny1)amino)carbony1)amino]-1,4-dioxobuty1)-(9CI)

(9CI) C36 H49 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-[[butyl][[2,3-dich]orophenyl]amino]carbonyl]amino]acetyl]-4[2,3-dihydro-2-oxo-tH-benylmidarol=1-yl], [9CI]

C25 H29 C12-W5 03.



PROPERTY DATA AVAILABLE IN THE PROP FORMAT.


349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STM Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[[[(3-methoxyphenyl)mino)carbonyl)methylamino]acetyl)- (9CI) C23 B27 M5 O4

\*\*PROPERTY DATA AVAILABLE IN THE PROPERTY FORMAT ..

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-(butyl[(3,4dichlorophenyl)aminojcatbonyl)aminoj-1-oxogropyl]- (9CI)
MF C26 H30 C12 N4 03

\*\*PROPERTY DATA AVAILABLE IN THE PROP' FORMAT \*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-benzoxazőlýl)215[cyclohexyl[[(2,3dichlorophenyl;amino]carbonyl]amino]-1-oxoprobyl]- (9CI)
MF C28 H32\_C12 N4 03



\*\*PROPERTY DATA\_AVAILABLE IN THE 'PROP' FORMAT \*\*

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(18-benzimidezol-2-yl)-1-[3-[[[(4-ethylphenyl)amino]carbonyl)propylamino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O2

Page 129

JP2004\_018717\_2.trn

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[(2,3-dichlorophenyl)amino]-d-[d-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-(SCI)

HF C34 H3 C12 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 349 ANSHERS REGISTRY COPYRIGHT 2005 ACS on STM
IN Piperidine, 1-[(butyl[[(4-ethoxyphenyl)amino]carbonyl)amino]acetyl]-4-(2,3-

N-Pr 0 Et

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2-bromophenyl)amino]carbonyl]butylamino]-1-oxopropyl]- (9CI)
MF C26 H32 Br N5 O2

\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT ..

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 3-[[[[[1S]-1-([1,4-b]piperidin]-1'-ylcarbonyl)-3-[4-(1,4-d)piperidinyl)-3oxopropyl]amino]carbonyl]amino]-, methyl ester [9CI)
HF C36 H47 N7 O6

Absolute stereochemistry.

JP2004\_018717\_2.trn

Page 130

JP2004\_018717\_2.trn

L3 349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[ethyl][[(4-methylphenyl)amino]acronyl]amino]acctyl]- (9CI)
MF C24 H29 NS 03

N C-CH<sub>2</sub>-N-C-NH

. PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-(2-benzoxazoly1)-1-(3-buty1[[(2,6dimethylphenyl)amino}carbonyl)amino|-1-oxopropyl)HF C28 H36 N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 AMSWERS REGISTRY COPYRIGHT 2005 ACS on STM

IN Piperidine, 4-(2-benzoxazoly1)-1-[3-[cyclohexy1[[4(methylthio]pheny1]amino]carbony1]amino]-1-oxopropy1]- (9CI)


MF C29 H36 N4 03 S

Dana 131

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1R-benzimidazo1-2-y1)-1-[(2S)-2-[[(3-fluorophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI) C24 H28 F M5 O2

Absolute stereochemistry,

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT"




\*\*PROPERTY DATA AVAILABLE IN THE PROP FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-{[4-(2-pyridinyl)-

Page 133

.... 135



349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 1-[[[(3-bromophenyl)amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
C23 H26 Br NS 03

AVAILABLE THE 'PROP' FORMAT

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperazine, 1-[2-[[(2-fluoropheny]) amino] carbonyl] amino] -3-methyl-1coxobutyl] -4-[3-[trifloromethyl) -2 pyridinyl] - (9C1)
C22 H25 F4 M5:00

.. PROPERTY DATA AVAILABLE IN THE PROP. FORMAT.

J49 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STH Piperidine, 4-(1H-benzimidazol-2-y1)-1-[3-[cycloheryl][[3-methylphenyl]amino]carbonyl]amino]-1-exopropyl]- [9CI] C29 B37 N5 O2

JP2004\_018717\_2.trn

1-piperazinyl)carbonyl)-, (2R,4R)- (9CI) C21 H24 CI N5 O3

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'\*


349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
1,4'-Bipiperidine, 1'-[(28)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]butyl]-(9CI)
C35 H44 F3 N7 O4

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 1-[[butyl[[(2-methylphenyl)amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-lH-benzimidazol-1-yl)- (9C1) 
C26 H33 N5 O3

Page 134




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT ..

349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN Piperidine, 4-(1H-benzimidazol-2-y1)-1-[(25)-2-[[[2,6-bis(1-methylethyl)phenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI) C30 H41 N5 O2

PROPERTY DATA AVAILABLE IN THE PROP FORMAT

349 ANSMERS REGISTRY COPYRIGHT 2005 ACS on STN
Piperidine, 4-{1R-benzimidazoi-2-y1}-1-|3-{[[(3,4-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl)- (9CI)
C26 H31 C12 M5 O2



PROPERTY DATA-AVAILABLE IN THE 'PROP' FORMAT ..

349 AMSMERS REGISTRY COPYRIGHT 2005 ACS on STW L-Proline, l-[1-[#-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, compound with L-arginine (9C1)

JP2004\_018717\_2.trn

MF C20 H26 N4 O5 . x C6 H14 N4 O2

CM

Absolute stereochemistry.

A61-53298

Absolute stereochemistry

ALL ANSWERS HAVE BEEN SCANNED

-> LOG Y COST IN JAPANESE YEN

INCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

ESSION 231

STN INTERNATIONAL LOGOFF AT 14:01:27 ON 08 FEB 2005

DK Name: +++

OR

Page 137

CONNECT 46667

Connecting through CompuServe

0029TEA

Connected to 0002 CAA 0

Welcome to STN International! Enter x:x LOGINID:TKYBAJ74 TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2

Item Date

NEWS 1 NEWS 2 Oct 26 NEWS 3 Nov 19

Headline

STM, CAS FILES Morkshop Schedule in Japan

KOREAPAT now available on STM

Current-awareness alerts, saved answer sets, and

current search transcripts to be affected by CERAB,

COMPUAB, ELCOM, and SOLIDSTATE reloads

November 22, 2004 LISA new on STM

PHAR reloaded with additional data

12 databases to be removed from STM on 31,Dec.,2004

HEDLINE update schedule for December 2004

ELCOM reloaded; updating to resume; current-awareness

alerts(SDLS) affected

COMPUAB reloaded; updating to resume;

current-awareness alerts(SDIs) affected

SOLIDSTATE reloaded; updating to resume;

current-awareness alerts(SDIs) affected

ERAB reloaded; updating to resume;

current-awareness alerts(SDIs) affected

ERAB reloaded; updating to resume; current-awareness

alerts(SDLS)s affected

Three new fields added to IFIPAT/IFIUDB/IFICDB

EFFULL:New patent full text database to be available

on STM

CAPLUS - PATENT COMPURCE EVANATION. NEWS NEWS

4 Nov 22 5 Dec 1 6 Dec 15 7 Dec 17 8 Dec 20 NEWS

NEWS 9 Dec 20

NEWS 11 Dec 20

NEWS 14 Dec 31 NEWS 15 Jan 1

NEWS 16 Jan 5

on STN
CAPLUS - PATENT COVERAGE EXPANDED
No connect-hour charges in EPFULL during January and
February 2005
Urgent announcement to STN customers accessing via
phone line WorldCom access points were changed
CA/CAPLUS - Expanded patent coverage to include the
Russian Agency for Patents and Trademarks (ROSPATENT) NEWS 17 Jan 12

NEWS HOURS NEWS WORLDCOM NEWS INTER STN operating Hours STN High Speed Access via Worldcom INTERNET ACCSESS to STNT(STN-Tokyo)

JP2004\_018717\_4.trn

NEWS 10 Dec 20

FILE LAST UPDATED 05 FEBRUARY 2005 (20050205/UP)

For datails on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPAC, HELP SPOR, HELP SPOR, HELP SPOR, HELP SPOR, HELP SPOR, HELP CTOR, HELP CTOR,

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 8 million records. See HELP CONTENT and NEWS FILE for details.

-> S L5

-> D BIB ABS HITSTR
'BIB' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
'ABS' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
YOU HAVE RECEIVED THIS ERROR MESSAGE 3 CONSECUTIVE TIMES

The following are valid formats:

The default display format is IDE.

The default display format is IDE.

ALL ---- AN, CO, PD, CN, CN, RM, ST, Purity, Impurity, product identifiers, product notes, STR, product text (properties, regulatory information, references, prices, warnings, miscellaneous fields), CO, CA, CY, TX (products, terms, and conditions; products and services; packaging and shipping; safety and handling; other supplier information)

COMP --- AN, CO, PD, CO, TX
IDE --- AN, CO, PD, CO, TX
IDE --- AN, CO, PD, CM, RN, LSF, ST, STR
MISC --- AN, miscellaneous product information fields
PINFO -- AN, pricing information text
PRICE --- AN, pricas, quantities
PROD --- AN, product text
PROP --- AN, product text
PROP --- AN, properties
REF --- AN, references
REFS --- AN, references
REGS --- AN, references
SINFO --- AN, safety text
HIT ---- All fields containing hit terms
KMIC --- All hit terms plus 20 words on either side
OCC ---- List of display fields containing hit terms
Hit terms will be highlighted in all displayable fields.

Hit terms will be highlighted in all displayable fields.

To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'BELP DFIELDS' at an arrow prompt (=>). Examples include: 'KMIC'; 'CN RN'; 'IDE CO'. You may specify the formats and fields in any order, and the

JP2004 018717 4.tin

NEWS EXPRESS

STN Express 7.0 with Discover! (Windows) Now available! STN Tokyo Norld Wide Web Site

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:45:50 ON 09 FEB 2005

-> FILE REG COS-4PRD COST IN JAPANESE YEN

FULL ESTIMATED COST

TOTAL SESSION 36

FILE 'REGISTRY' ENTERED AT 16:46:06 ON 09 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS) CHARGED TO COST-4PRD

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0 DICTIONARY FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROF at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

ACT RD018717A/A STR STR 349)SEA FILE-REGISTRY SSS FUL L1 AND L2 STR 257 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

FULL ESTIMATED COST

FILE 'CHEMCATS' ENTERED AT 16:46:27 ON 09 FEB 2005 USE IS SUBJECT TO THE TERMS OF YOUR STM CUSTOMER AGREEMENT FLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS) CHARGED TO COST-4

Page 2

JP2004\_018717\_4.trn

information will be displayed in the same order as the format specification.

The same formats (except for HIT, KWIC, and OCC) may be used with the DISPLAY ACC command to display the record for a specified Accession Number.

IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK ENTER DISPLAY FORMAT (IDE): END

-> D ALL HITSTR
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
ENTER DISPLAY FORMAT (IDE):END

L6 ANSWER 1 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number
(AN): 2004:1764846 CHEMCATS
(CC): Comdenex Product List
Publication Date (FD): 25 Jun 2003
Order Number (GN): CGX-0562707
(Chemical Name (CN): Piperarine, 1-[3-methyl-1-oxo-2-[[[3-(trifluoromethyl) phenyl]amino]carbonyl]amino]butyl]-4
CAS Registry Number
CAS Registry Number (RN): 684277-53-0
Supplementary Term Structure

Structure

PRICES Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-{732} 438-8001 Fax: +1-{732} 438-8004 E-mail: info@compenex.com Meb: http://www.compenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

```
JP2004_018717_4.trn
```

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.

=> D ALL 2-10

L6 ANSMER 2 OF 256
Accession Number
Catalog Name
Chemical Name
Chemical Name
CAS Registry Number
Structure
CAS Registry Number

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@commenex.com
Web: http://www.commyenex.com -ax: E-mail: Web:

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

ANSWER 3 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN saion Number (AN): 2001:903161 CHEMCATS (100) Name (CO): ComeGenex Product List (PD): 26 Jun 2003 Accession Number Catalog Name Publication Date

Page 5

JP2004\_018717\_4.trn

-----

?RICES

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 formouth, NJ, 08852

!elephone: +1-(732) 438-8001 \*ax: +1-(732) 438-8004 :-mail: info@comgenex.com leb: http://www.comgenex.com

ComGenex Inc. Sem rakpart 33/34 Sudapest, H-1027 Sungary

'elephone: +36-1-214-2306 'ax: +36-1-214-2310 :-mail: info@comgenex.hu

6 ANSWER 5 OF 256
CCEBSION Number
atalog Name
ublication Date
rder Number
(AM): 2001:903159 CHEMCATS
(CO): Commence Product List
(PD): 2 d Jun 2003
(CM): CGK-0593613
(CM): CGK-0593613
(CM): CGK-0593613
(CM): Piperidine, 4-[2,3-dihydro-2-oxo-1B-benzimidazol-1-yll-1-[[[(2-methoxypheny1) amino]carbony1](2-methylpropyl) amino]carbony1](2-methylpropyl) amino]carbony1](2-methoxypheny1) amino]carbony1](2-methoxypheny2) (CM): 336624-91-0
(ST): CHEMICAL LIBRARY

RICES

Dentity

: milligram quantities, Price: contact supplier

CHPANY INFORMATION

JP2004\_018717\_4.trn

Order Number
Chemical Name
(CN): CGX-0593616
(CN): Piperidine, 4-[2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[((2-methylpropyl)[([4-(methylthio)phenyl]amino]carbonyl]amino]acetyl](RN): 336824-93-2
Structure
(ST): CHEMICAL LIBRARY

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGanex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Pax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER ( OF 256
Accession Number (AN): 2001:903160 CHEMCATS
Catalog Name (CD): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (CN): CGX-0593614
(CN): Pieridine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[[[(3-methoxyphenyl)amino]carbonyl](2-chemical Name (RN): 316824-92-1
Supplementary Term (ST): CHEMICAL LIBRARY

Page 6

JP2004\_018717\_4.trn

ComGenex International Inc Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth; NJ, 08852 USA

Telephone: +1-{732} 438-8001 Fax: +1-{732} 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

Accession Number Catalog Name Publication Date Order Number Chemical Name

ANSWER 6 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
ssion Number (AN): 2001:903158 CHEMCATS
log Name (CO): Condenex Product List
leation Date (PD): 26 Jun 2003
r Number (ON): CGX-0593512
leal Name (CN): Piperidine, 4-[2,3-dihydro-2-oxo-1H-benzimidazol-1yl)-1-[[[[[4-(1-methylethyl]phenyl]amino]carbonyl][2methylpropyl)amino]acetyl]Registry Number (RN): 336824-90-9
lementary Term (ST): CHEMICAL LIREARY

CAS Registry Number (RN): 336824-90-9
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@compens.com Web: http://www.comgenex.com

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSMER 7 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number
Catalog Name Publication Date
Chemical Name (PD): 26 Jun 2003
Commission Commission

PRICES

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Sta. 210 Monmouth, NJ, 08852 USA.

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com .ax: E-mail: Web:

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

-----

ANSMER 8 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN ssion Number (AN): 2001:903155 CHEMCATS log Name (CO): ComGenex Product List Accession Number Catalog Name

Page 9

JP2004\_018717\_4.trn

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852

Telephone: +1-{732} 438-8001 fax: +1-{732} 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 10 OF 256 CHEMICATS COPYRIGHT 2005 ACS on STN
Accession Number
Cetalog Name (AN): 2001:903153 CHEMICATS
(CO): Commenex Product List
(PD): 26 Jun 2003
(CN): CGX-0593607
(CN): Piperidine, 4-(2,3-dihydro-2-oxo-18-benzimidazol-1-yl)-1-[[[(2,4-dimethoxyphenyl)amino]carbonyl](2-methylpropyl)lamino]acetyl]CAS Registry Number
Supplementary Term (ST): CHEMICAL LIBRARY

JP2004\_018717\_4.trn

Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593609
Chemical Name (CN): Piperidine, 4-[2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[[[[(4-ethoxypbeny])amino]carbonyl](2-methylpropyl)amino] acetyl]CAS Registry Number (Supplementary Term Structure (ST): CHEMICAL LIBRARY

PRICES

: milligram quantities, Price: contact suppli

COMPANY INFORMATION

Commonex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 9 OF 256
ACCESSION Number
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 2 Jun 2003
Chemical Name (CN): CGX-0593608
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[[[(2,6-dimethylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl)(RN): 336824-86-3
Supplementary Term (ST): CHEMICAL LIBRARY

Page 10

: milligram quantities, Price: contact supplier

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-16:7 Hungary

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

-> D ALL 11-20

L6 ANSMER 11 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STM
Accession Number
Catalog Name (AN): 2001:903152 CHEMCATS
Crubication Date (PD): 26 Jun 2003
Crder Number (CN): ComGenex Product List
(PD): 26 Jun 2003
Comment (PD): 26 Jun

PRICES Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

CommGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Honmouth, NJ, D8852

USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Meb: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

> Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 12 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN

Accession Number
Catalog Name (AN): 2001:903151 CHEMCATS
Crowdian Company Product List
(PD): 25 Jun 2003
COM: CGX-0593604
(CN): Piperidine, 1-[[[[(2,4-dichlorophenyl)amino]carbonyl]
(2-methylpropyl)amino]acetyl]-4-(2,3-dibydro-2-oxo-1HCAS Registry Number
Supplementary Term Structure
(ST): CHEMICAL LIBRARY

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

Princeton Corporate Plaza IV 11 Deer Perk Drive, Ste. 210 Monmouth, NJ, 08852 USA ComGenex International Inc.

felephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@compenex.com Web: http://www.compenex.com

ComGenex Inc.

Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306

JP2004\_018717\_4.trn

Structure

?RICES )uantity

: milligram quantities, Price: contact supplier

OMPANY INFORMATION

omGenex International Inc. rinceton Corporate Plaza IV 1 Deer Park Drive, Ste. 210 ionmouth, NJ, 08852

elephone: +1-{732} 438-8001 ax: +1-{732} 438-8004 :-mail: info@comgenex.com 'eb: http://www.comgenex.com

omGenex Inc. em rakpart 33/34 udapest, H-1027 ungary

elephone: +36-1-214-2306 ax: +36-1-214-2310 -mail: info@comgenex.hu

ANSWER 15 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN ssion Number (AN): 2001:903148 CHEMCATS (CO): ComGenex Product List ication Date (PD): 26 Jun 2003 (CM): CGK-0593600

ccession Number atalog Name ublication Date

(ON): CGX-0593600
hemical Name (CN: Piperidine, 1-[{[([(3-bromophenyl)amino)carbonyl](2-methylpropyl)amino)acetyl)-4-(2,3-dihydro-2-oxo-1H-benrimidazol-1-yl)AS Registry Number upplementary Term tructure (ST): CHEMICAL LIBRARY

RICES

JP2004\_018717\_4.trn

Fax: +36-1-214-2310 E-mail: info@comgen

L6 ANSMER 13 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number
Catalog American
Publication Date
Order Number
Chemical Name

CAS Registry Number
Supplementary Term
Structure

CAS Registry Number
Supplementary Term
Structure

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 14 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903149 CHEMCATS
Catalog Name (PD): 26 Jun 2003
Order Number (CD): ComGenex Product List
Order Number (CD): CGK-0593601
(CN): CGK-0593601
(CN): Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-ben/midasol-1-yl)CAS Registry Number (RN): 336824-618
SUPPlementary Term (ST): CHEMICAL LIBRARY

Page 14

Quantity

: milligram quantities, Price: contact supplier

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSHER 16 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AM): 2001:903147 CHEMCATS .

(CO): Commence Product List
(PD): 26 Jun 2003

(CM): CGX-0593599

Chemical Name (CN): Piperidine, 1-[[[{{2-bromophenyl}}amino]carbonyl]{2-methylpropyl}amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-bensimidazol-1-yl)
CAS Registry Number (ST): CHEMICAL LIBRARY
Structure (ST): CHEMICAL LIBRARY

PRICES

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852

Telephone: +1-(732) 438-8001

+1-(732) 438-8004 info@comgenex.com http://www.comgenex.com E-mail: Web:

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Fax; +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 17 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903144 CHEMCATS
Catalog Name (CD): Commonsx Product List
(PD): 25 Jun 2003
(ON): CGX-0593594
(CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[([2-methyllpropyl)[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]CAS Registry Number (RN): 336624-76-1
Structure (ST): CHEMICAL LIBRARY

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 18 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN

Page 17

JP2004\_018717\_4.trn

......

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

relephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info-4info@comgenex.hu

L6 ANSMER 20 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STR
Accession Number
(AN): 2001:903141 CHEMCATS
Catalog Name (CO): ComGenes Product List
(PD): 26 Jun 2003
(CN): CGX-0593551
(CN): Bancoic acid, 4-[{[[2-|4-{2,3-dihydro-2-oxo-1H-benzimidazol-1-y1]-1-piperidiny1]-2-oxoethy1] (2-methylpropyl) mainojcarbony1] aminoj-. ethyl ester
CAS Registry Number
CAS Registry Number
Structure
(ST): CHEMICAL LIBRARY

1-Bu 0 c-oet

PRICES

JP2004\_018717\_4.trn

Publication Date (FD): 26 Jun 2003
Order Number (CN): Econogene X-Product lliar RACHE
Chemical Name (CN): Piperidine, 4-{2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[3-fluorophenyl]amino]carbonyl]](2-methylpropyl)amino]acetyl)
CAS Registry Number (RN): 336824-75-0
Structure (ST): CHEMICAL LIBRARY

PRICES

Quantity

: milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852 USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Fax: +36-1-214-2310 E-mail: info@comgenex.hu

L6 ANSWER 19 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903142 CHEMCATS
Catalog Name (CD): Commons Froduct List
(PD): 25 Jun 2003
Order Number (CN): CgX-0593592
Chemical Name (CN): Pleridine, 4-{2,3-dihydro-2-oxo-1H-benzimidazol-1-y1)-1-[[[(2-fluorophenyl)amino]carbonyl](2-methylpropyl)amino]acstyl)CAS Registry Number (Sumplementary Term (ST): CHEMICAL LIBRARY

CAS Registry Number (RN): 336824-74-9
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :

Page 18

JP2004\_018717\_4.trn

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc. Princeton Corporate Plaza IV 11 Deer Park Drive, Ste. 210 Monmouth, NJ, 08852

Telephone: +1-(732) 438-8001 Fax: +1-(732) 438-8004 E-mail: info@comgenex.com Meb: http://www.comgenex.com

ComGenex Inc. Bem rakpart 33/34 Budapest, H-1027 Hungary

Telephone: +36-1-214-2306 Pax: +36-1-214-2310 E-mail: info@comgenex.hu E-mail:

-> LOG Y COST IN JAPANESE YEN FULL ESTIMATED COST

SINCE FILE ENTRY 10461

STN INTERNATIONAL LOGOFF AT 16:50:28 ON 09 FEB 2005

Host Name: +++

OK

## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

□ OTHER: \_\_\_\_\_

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.